	submission_name	submission_date	time to curate	spot_check	template_name	tissue_type	tissue_type_term_id	response_component_original	response_component_standardized	response_behavior_type	response_behavior	subgroup	time_point	time_point_units	baseline_time	first_exposure_process	first_disease_name	first_disease_stage	target_pathogen	target_pathogen_taxonid	vaccine_year	exposure_material_text	exposure_material	additional_exposure_material	Group1	addntl_time_point_units	Group0	target_pathogen_taxonid	comparison	number_subjects	cohort	Geographic Location	adjuvant	route	scheduling	publication_reference	publication_year	signature_source	signature_source_url	comments	is_model	short_comment	process_note	publication_reference_url	age_group	age_min	age_max	age_units	extra_comments
subject	submission_name	submission_date	time to curate	spot_check		cell_subset	Cell Ontology ID	response_component_original	response_component_standardized	response_behavior_type	response_behavior	subgroup	time_point	time_point_units	baseline_time	first_exposure_process	first_disease_name	first_disease_stage	target_pathogen			exposure_material_text	vaccine						comparison	number_subjects	cohort					publication_reference	publication_year	signature_source	signature_source_url	comments				publication_reference_url					
evidence										label	label	label	label	label	label	label	label	label			label	label		label	label	label	label		label	label	label		label	label	label	label	label	label	label	label	label	label	label	url	label	label	label	label	label
role						tissue		gene_biomarker	gene_biomarker	background	measured	background	observed	observed	background	background	background	background	pathogen		background	background	vaccine	background	observed	observed	observed		background	observed	observed		background	background	background	background	background	background	background	background	background	background	background	reference	observed	observed	observed	observed	observed
mime_type																																																	
numeric_units																																																	
display_text	submission name	submission date	time to curate	spot check		tissue type	Cell Ontology ID	response component_original	response component_standardized	response behavior type	response behavior	subgroup	time point	time point units	baseline time	first_exposure_process	first_disease_name	first_disease_stage	target pathogen	NCBI TaxonID (non-influenza)	vaccine year (influenza only)	exposure material (name)	exposure material (VO)	exposure material - additional	Group1	addntl time point units	Group0	NCBI TaxonID	comparison	number of subjects	cohort	Geographic Location	adjuvant	route	scheduling	publication reference (PMID)	publication year	signature source figure, table or text section 	signature source URL	comments and additional details	gene signature is a model	short comment for mSigDB standard name	internal use only	publication URL	age group	age min.	age max.	age units	will not appear in Dashboard
	Amani	14/2/2021	total: 3hrs 45min			peripheral blood mononuclear cells		Natural Killer cells, CD56dim Natural Killer cells		cell type frequency	down		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs healthy patients 	27	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		Natural Killer cells, CD56bright Natural Killer cells, CD56dim Natural Killer cells		cell type frequency	down		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs healthy patients 	33	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		Ki-67+ CD56bright Natural Killer cells; HLA-DR+ CD56bright Natural Killer cells; CD69+ CD56bright Natural Killer cells		cell activation state	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients vs healthy	43	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 1D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		Ki-67+ CD56dim Natural Killer cells; CD69+ CD56dim Natural Killer cells		cell activation state	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate patients vs healthy patients	27	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 1F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		Ki-67+ CD56dim Natural Killer cells; HLA-DR+ CD56dim Natural Killer cells; CD69+ CD56dim Natural Killer cells		cell activation state	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe patients vs healthy patients	33	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 1F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		Ki-67+ NKG2A+ CD56dim Natural Killer cells; HLA-DR+ NKG2A+ CD56dim Natural Killer cells; CD69+ NKG2A+ CD56dim Natural Killer cells		cell activation state	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	NKG2A+ CD56dim NK cells vs NKG2A- CD56dim NK cells	26	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 1H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		HLA-DR+ CD57- CD56dim Natural Killer cells		cell activation state	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CD57- CD56dim NK cells vs CD57+ CD56dim NK cells	26	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 1H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		Ki-67+ CD62L+ CD56dim Natural Killer cells; HLA-DR+ CD62L+ CD56dim Natural Killer cells		cell activation state	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CD62L+ CD56dim NK cells vs CD62L- CD56dim NK cells	26	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 1H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		CD69+ CD62L- CD56dim Natural Killer cells		cell activation state	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CD62L- CD56dim NK cells vs CD62L+ CD56dim NK cells	26	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 1H	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F1/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		perofrin CD56bright Natural Killer cells; MIP-1beta CD56bright Natural Killer cells; CD98 CD56bright Natural Killer cells; Tim-3 CD56bright Natural Killer cells; Granzyme B CD56bright Natural Killer cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate patients vs healthy patients	27	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		perofrin CD56bright Natural Killer Cells; MIP-1beta CD56bright Natural Killer cells; CD98 CD56bright Natural Killer cells; Tim-3 CD56bright Natural Killer cells; Granzyme B CD56bright Natural Killer cells; Ksp37 CD56bright Natural Killer cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe patients vs healthy patients	32	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		CD98 CD56dim natural killer cells, Tim-3 CD56dim natural killer cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate patients vs healthy patients	27	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients classified as having moderate COVID-19 disease had oxygen saturation of 90 to 94% or were receiving 0.5 to 3 liters/min of oxygen at inclusion."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				peripheral blood mononuclear cells		CD98 CD56dim natural killer cells, Tim-3 CD56dim natural killer cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe patients vs healthy patients	33	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	"COVID-19 patients were sampled 5 to 24 days after symptom debut and 0 to 8 days after being admitted to the hospital. Patients with severe COVID-19 disease were treated in an ICU or a high dependency unit, requiring either noninvasive or mechanical ventilation."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.	30min total			NK Cells		translation/RNA metabolism, mitochondrial activity		pathway enrichment	enriched		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy vs moderate	6	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	-Annotation system: GO 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.				NK Cells		interferon response, activation/proliferation		pathway enrichment	enriched		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs healthy	6	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2I. First paragraph under Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	-Annotation system: GO 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.				NK Cells		effector function		pathway enrichment	enriched		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs healthy 	9	Adults (18-78)	Stockholm, Sweden				32826343	2020	First paragraph under Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	-Annotation system: GO 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.				NK Cells		effector function		pathway enrichment	enriched		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs moderate	9	Adults (18-78)	Stockholm, Sweden				32826343	2020	First paragraph under Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	-Annotation system: GO 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.				NK Cells		translation/RNA metabolism, mitochondrial activity, activation/proliferation		pathway enrichment	enriched		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy vs severe	9	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	-Annotation system: GO 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.				BAL NK Cells		cytoxicity, chemotaxis		pathway enrichment	enriched		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs healthy	9	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2I. Discussion 3rd paragraph	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	-Annotation system: GO 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.				BAL NK Cells		interferon response, activation/proliferation, translation/RNA metabolism		pathway enrichment	enriched		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs severe 	9	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2I. Discussion 3rd paragraph	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	-Annotation system: GO 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.				NK Cells		effector function/chemotaxis, metabolism/degranulation, mitochondrional activity		pathway enrichment	enriched		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs moderate 	9	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2I. Discussion 3rd paragraph	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	-Annotation system: GO 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.				NK Cells		effector functions/chemotaxis, activation/proliferation, interferon response		pathway enrichment	enriched		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate & severe vs healthy	12	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/	-Annotation system: GO. Also in 2nd sentence after Fig 2				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				NK Cells		GZMA, GZMB, PRF1, HAVCR2, CCL3, CCL4, CCL5		gene expression	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049		12	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				NK Cells		LAG3		gene expression	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate & severe vs healthy	12	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 2K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F2/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		NKG2C+ CD57+ CD56dim Natural Killer cells		cell type frequency	up		0 to 5	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs moderate	9	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 3B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		NKG2C- CD57- CD56dim Natural Killer cells		cell type frequency	down		0 to 5	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs healthy	6	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		NKG2C- CD57- CD56dim Natural Killer cells		cell type frequency	down		0 to 5	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs healthy	9	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 3C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		NKG2C- CD57- CD56dim Natural Killer cells		cytokines/protein levels	up		0 to 5	days	time of admission	Occurrence of infectious disease	COVID-19.	none	SARS-CoV-2 (COVID-19)									2697049	NKG2C- CD57- CD56dim NK cells vs NKG2C+ CD57+CD56dim NK cells	17	Healthy Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 3I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		NKG2C- CD57- CD56dim Natural Killer cells		cytokines/protein levels	up		0 to 5	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	NKG2C- CD57- CD56dim NK cells vs NKG2C+ CD57+CD56dim NK cells	26	SARS-CoV-2 patients (18-78)	Stockholm, Sweden				32826343	2020	Fig 3I	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		HLA-E Natural Killer cells, HLA-E B cells, HLA-E epithelial cells, HLA-E mDCs, HLA-E T cells, HLA-E macrophages		cytokines/protein levels	up		0 to 5	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs healthy	27	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 3K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		HLA-E Natural Killer cells, HLA-E B cells, HLA-E epithelial cells, HLA-E T cells, HLA-E macrophages		cytokines/protein levels	up		0 to 5	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs moderate	17	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 3K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		HLA-E Natural Killer cells, HLA-E B cells, HLA-E epithelial cells, HLA-E mDCs, HLA-E T cells, HLA-E macrophages		cytokines/protein levels	up		0 to 5	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs healthy	27	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig 3K	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F3/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		perforin CD56bright natural killer Cells; Granzyme B CD56bright natural killer Cells		cytokines/protein levels	positively correlated		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	IL-6 (NPX) levels	24	SARS-CoV-2 patients (18-78)	Stockholm, Sweden				32826343	2020	Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		granzyme B CD56bright natural killer Cells; CD25 CD56bright natural killer Cells; CD25 CD56bright natural killer Cells; perforin CD56bright natural killer Cells		cytokines/protein levels	positively correlated		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	perforin (MFI) expression on CD56bright NK cells	25	SARS-CoV-2 patients (18-78)	Stockholm, Sweden				32826343	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/	Clarify: Perforin expression measured as MFI positively correlated with CD25 MFI and % expression and perforin expression measured as %. 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		CD56bright natural killer cells		cell type frequency	positively correlated		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	granzyme B (MFI) expression on CD56bright NK cells	25	SARS-CoV-2 patients (18-78)	Stockholm, Sweden				32826343	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		peforin CD56bright natural killer Cells; CD25 CD56bright natural killer Cells; Ksp37 CD56bright natural killer Cells; CD25 CD56bright natural killer Cells; Granzyme B CD56bright natural killer Cells		cytokines/protein levels	positively correlated		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	granzyme B (MFI) expression on CD56bright NK cells	25	SARS-CoV-2 patients (moderate & severe) (18-78)	Stockholm, Sweden				32826343	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/	Clarify: Granzyme B expression measured as MFI positively correlated with CD25 MFI and % expression and granzyme B expression measured as %. 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		perforin CD56dim natural killer Cells		cytokines/protein levels	positively correlated		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	perforin (MFI) expression on CD56bright NK cells	25	SARS-CoV-2 patients (moderate & severe) (18-78)	Stockholm, Sweden				32826343	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/	Clarify: Perforin expression (MFI) on CD56bright NK cells positively correlated with perforin expression (MFI) on CD56dim NK cells. 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		granzyme B CD56dim natural killer cells, CD25 CD56dim natural killer cells		cytokines/protein levels	positively correlated		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	granzyme B (MFI) expression on CD56bright NK cells	25	SARS-CoV-2 patients (moderate & severe) (18-78)	Stockholm, Sweden				32826343	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/	Clarify: Granzyme B expression (MFI) on CD56bright NK cells positively correlated with granzyme B expression (MFI) & CD25 (%) expression on CD56dim NK cells. 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		TIGIT CD56dim natural killer Cells		cytokines/protein levels	negatively correlated		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	perforin (MFI) expression on CD56bright NK cells	25	SARS-CoV-2 patients (moderate & severe) (18-78)	Stockholm, Sweden				32826343	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/figure/F5/	Clarify: Perforin expression (MFI) on CD56bright NK cells negatively correlated with TIGIT expression (MFI) on CD56dim NK cells. 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		TIGIT CD56bright natural killer Cells; CD38 CD56bright natural killer Cells; CD25 CD56bright natural killer Cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs healthy	27	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig S2C	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		TIGIT CD56bright natural killer Cells; CD38 CD56bright natural killer Cells; CD25 CD56bright natural killer Cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs healthy	32	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig S2C	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		KIR2DL1 CD56dim natural killer Cells		cytokines/protein levels	down		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs healthy	27	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig S2D	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		CD38 CD56dim natural killer cells; MIP-1beta CD56dim natural killer cells; CD62L CD56dim natural killer cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs healthy	27	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig S2D	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		CD38 CD56dim natural killer cells; MIP-1beta CD56dim natural killer cells; CD62L CD56dim natural killer cells; NKG2C CD56dim natural killer cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs healthy	33	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig S2D	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		NKG2C CD56dim natural killer cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs moderate	26	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig S2D	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		Ki67+ NKG2C+ CD57+ CD56dim natural killer cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs healthy	33	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig S4H & J	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1	Measurements in % (S4H) & absolute (from NK cell counts/mL) (S4J).				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				Peripheral Blood Mononuclear Cells (PBMCs)		Ki67+ NKG2C+ CD57+ CD56dim natural killer cells		cytokines/protein levels	up		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs moderate	26	Adults (18-78)	Stockholm, Sweden				32826343	2020	Fig S4H	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				NK cells		positive regulation of natural killer cell chemotaxis, regulation of natural killer cell chemotaxis, regulation of lymphocyte chemotaxis, regulation of lymphocyte migration, regulation of leukocyte migration, regulation of cell migration, regulation of cell motility, regulation of locomotion, regulation of biological process, biological regulation, regulation of cellular component movement, regulation of localization, regulation of cellular process, regulation of immune system process, regulation of leukocyte chemotaxis, regulation of chemotaxis, regulation of response to external stimulus, regulation of response to stimulus, positive regulation of lymphocyte chemotaxis, positive regulation of lymphocyte migration, positive regulation of leukocyte migration, positive regulation of cell migration, positive regulation of cell motility, positive regulation of cellular component movement, positive regulation of cellular process, positive regulation of biological process, positive regulation of locomotion, positive regulation of immune system process, positive regulation of chemotaxis, positive regulation of response to external stimulus, positive regulation of response to stimulus, granzyme-mediated apoptotic signaling pathway, apoptotic signaling pathway, apoptotic process, programmed cell death, cell death, cellular process, signal transduction, signaling, cell communication, cellular response to stimulus, response to stimulus, regulation of peptidyl-serine dephosphorylation, regulation of phosphate metabolic process, regulation of phosphorus metabolic process, regulation of cellular metabolic process,, regulation of metabolic process, regulation of protein modification process, regulation of cellular protein metabolic process, regulation of protein metabolic process, regulation of, primary metabolic process, regulation of macromolecule metabolic process, regulation of nitrogen compound metabolic process, astrocyte cell migration, cell migration, cell motility, movement of cell or subcellular component, localization of cell, localization, locomotion, T cell mediated cytotoxicity, leukocyte mediated cytotoxicity, cell killing, leukocyte mediated immunity, immune effector process, immune system process, T cell mediated immunity, lymphocyte mediated immunity, adaptive immune response, immune response, negative regulation by host of viral transcription, modulation by host of symbiont process, modulation of process of other organism involved in symbiotic interaction, modulation of, process of other organism, interspecies interaction between organisms, interaction with symbiont, symbiotic process, negative regulation of viral transcription, negative regulation of viral process, negative regulation of biological process, regulation of viral process, regulation of symbiosis, encompassing mutualism through parasitism, regulation of viral transcription, positive regulation of NMDA glutamate receptor activity, regulation of molecular function, regulation of transport, regulation of signal transduction, regulation of cell communication, regulation of signaling, positive regulation of molecular function, positive regulation of signal transduction, positive regulation of signaling, positive regulation of cell communication, positive regulation of transport, positive regulation of ion transport, positive regulation of microglial cell activation, positive regulation of macrophage activation, positive regulation of leukocyte activation, positive regulation of cell activation, regulation of cell activation, regulation of leukocyte activation, regulation of macrophage activation, positive regulation of neuroinflammatory response, positive regulation of inflammatory response, regulation of inflammatory response, regulation of defense response, regulation of response to stress, positive regulation of defense response, T cell extravasation, leukocyte migration, T cell migration, lymphocyte migration, regulation of chronic inflammatory response, macrophage chemotaxis, leukocyte chemotaxis, cell chemotaxis, chemotaxis, taxis, response to external stimulus, response to chemical, cellular response to chemical stimulus, macrophage migration, myeloid leukocyte migration, eosinophil chemotaxis, granulocyte chemotaxis, granulocyte migration, eosinophil migration, regulation of vascular wound healing, regulation of developmental process, regulation of multicellular organismal development, regulation of multicellular organismal process, positive regulation of killing of cells of other organism, regulation of killing of cells of other organism, regulation of cell killing, positive regulation of cell killing, tolerance induction, regulation of tau-protein kinase activity, regulation of phosphorylation, regulation of catalytic activity, regulation of protein phosphorylation, monocyte chemotaxis, mononuclear cell migration, macrophage activation involved in immune response, macrophage activation, myeloid leukocyte activation, leukocyte activation, cell activation, myeloid cell activation involved in immune response, leukocyte activation involved in immune response, cell activation involved in immune response, positive regulation of nitric-oxide synthase biosynthetic process, positive regulation of metabolic process, positive regulation of macromolecule metabolic process, positive regulation of exosomal secretion, regulation of exosomal secretion, regulation of secretion by cell, regulation of secretion, positive regulation of secretion by cell, positive regulation of secretion, negative regulation of interleukin-2 production, regulation of interleukin-2 production, regulation of cytokine production, negative regulation of cytokine production, negative regulation of multicellular organismal process, negative regulation of natural killer cell mediated cytotoxicity, regulation of natural killer cell mediated cytotoxicity, regulation of natural killer cell mediated immunity, regulation of innate immune response, regulation of immune response, regulation of response to biotic stimulus, negative regulation of immune system process, negative regulation of cellular process, negative regulation of innate immune response, negative regulation of response to external stimulus, negative regulation of response to stimulus, negative regulation of immune response, negative regulation of defense response, lymphocyte chemotaxis, natural killer cell mediated immunity, innate immune response, defense response to other organism response to other organism, response to external biotic stimulus, response to biotic stimulus, defense response, response to stress, cytolysis, chemokine-mediated signaling pathway, cytokine-mediated signaling pathway, cell surface receptor signaling pathway, cellular response to cytokine stimulus, cellular response to organic substance, response to organic substance, response to cytokine, cellular response to chemokine, response to chemokine, lipopolysaccharide-mediated signaling pathway, cellular response to lipopolysaccharide, response to oxygen-containing compound, response to lipopolysaccharide, response to lipid, response to molecule of bacterial origin, response to bacterium, cellular response to lipid, cellular response to molecule of bacterial origin, cellular response to biotic stimulus, neutrophil chemotaxis, neutrophil migration, protein kinase B signaling, intracellular signal transduction, regulation of endothelial cell apoptotic process, regulation of apoptotic process, regulation of programmed cell death, regulation of cell death, establishment of protein localization to vacuole, protein localization to organelle, protein localization to vacuole, negative regulation of cytokine secretion, negative regulation of protein secretion, regulation of protein secretion, regulation of peptide secretion, regulation of peptide transport, regulation of protein transport, regulation of establishment of protein localization, regulation of protein localization, negative regulation of peptide secretion, regulation of cytokine secretion, positive regulation of reactive oxygen species biosynthetic process, positive regulation of cellular metabolic process, regulation of monooxygenase activity, positive regulation of dephosphorylation, positive regulation of phosphate metabolic process, positive regulation of phosphorus metabolic process, positive regulation of myeloid leukocyte differentiation, regulation of cell differentiation, positive regulation of multicellular organismal process, regulation of hemopoiesis, regulation of leukocyte differentiation, regulation of myeloid leukocyte differentiation, regulation of myeloid cell differentiation, T cell activation involved in immune response, positive regulation of interleukin-1 production, regulation of interleukin-1 production, cellular response to interleukin-1, response to interleukin-1, positive regulation of phagocytosis, regulation of osteoclast differentiation, interferon-gamma-mediated signaling pathway, cellular response to interferon-gamma, response to interferon-gamma, positive regulation of neuron death, positive regulation of cell death, regulation of neuron death, positive regulation of cytokine secretion, positive regulation of protein secretion, positive regulation of protein transport, positive regulation of establishment of protein localization, positive regulation of peptide secretion, response to cAMP, response to organophosphorus, response to purine-containing compound, response to organic cyclic compound, positive regulation of ERK1 and ERK2 cascade, regulation of ERK1 and ERK2 cascade, regulation of MAPK cascade, regulation of intracellular signal transduction, positive regulation of MAPK cascade, positive regulation of intracellular signal transduction, positive regulation of protein phosphorylation, positive regulation of phosphorylation, positive regulation of protein modification process, positive regulation of cellular protein metabolic process, positive regulation of protein metabolic process, positive regulation of nitrogen compound metabolic process, response to hydrogen peroxide, response to reactive oxygen species, response to toxic substance, cellular response to tumor necrosis factor, response to tumor necrosis factor, positive regulation of calcium ion transport, regulation of calcium ion transport, regulation of metal ion transport, regulation of endothelial cell proliferation, regulation of epithelial cell proliferation, regulation of cell population proliferation, regulation of smooth muscle cell proliferation, inflammatory response, regulation of interleukin-6 production, regulation of tumor necrosis factor production, regulation of tumor necrosis factor superfamily cytokine production, negative regulation of lymphocyte activation, regulation of lymphocyte activation, positive regulation of epithelial cell proliferation, regulation of cytokine-mediated signaling pathway, positive regulation of T cell activation, positive regulation of leukocyte cell-cell adhesion, regulation of leukocyte cell-cell adhesion, regulation of cell-cell adhesion, regulation of cell adhesion, positive regulation of cell-cell adhesion, regulation of T cell activation, Fc receptor signaling pathway, positive regulation of GTPase activity, positive regulation of hydrolase activity, regulation of hydrolase activity, positive regulation of catalytic activity, regulation of GTPase activity, MAPK cascade, signal transduction by protein phosphorylation, response to virus, positive regulation of apoptotic process, positive regulation of programmed cell death, neutrophil degranulation, neutrophil mediated immunity, myeloid leukocyte mediated immunity, neutrophil activation involved in immune response, neutrophil activation, granulocyte activation, leukocyte degranulation, regulated exocytosis, exocytosis, secretion by cell, export from cell, secretion, vesicle-mediated transport, positive regulation of protein kinase activity, positive regulation of immune response, G protein-coupled receptor signaling pathway, negative regulation of developmental process, negative regulation of protein metabolic process		pathway enrichment	positive		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients' GO cluster 1	44	Adults (18-78)	Stockholm, Sweden				32826343	2020	Table S4	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1	Annotation system: GO				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				NK cells		positive regulation of CD8-positive, alpha-beta T cell proliferation, positive regulation of alpha-beta T cell proliferation, regulation of alpha-beta T cell proliferation, regulation of T cell proliferation, regulation of lymphocyte proliferation, regulation of mononuclear cell proliferation, regulation of leukocyte proliferation, regulation of cell population proliferation, regulation of biological process, biological regulation, regulation of lymphocyte activation, regulation of leukocyte activation, regulation of immune system process, regulation of cell activation, regulation of T cell activation, positive regulation of T cell activation, positive regulation of leukocyte cell-cell adhesion, regulation of leukocyte cell-cell adhesion, regulation of cell-cell adhesion, regulation of cell adhesion, positive regulation of cell-cell adhesion, positive regulation of cell adhesion, positive regulation of cellular process, positive regulation of biological process, positive regulation of lymphocyte activation, positive regulation of leukocyte activation, positive regulation of immune system process, positive regulation of CD4-positive, alpha-beta T cell proliferation, antigen processing and presentation of exogenous peptide antigen via MHC class I TAP-independent, immune system process, antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway TAP-independent, antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, antigen processing and presentation of endogenous peptide antigen via MHC class I, antigen processing and presentation of endogenous peptide antigen, antigen processing and presentation of endogenous antigen, antigen processing and presentation of endogenous peptide antigen via MHC class Ib, antigen processing and presentation of peptide antigen via MHC class Ib, antigen processing and presentation via MHC class Ib, positive regulation of T cell cytokine production, positive regulation of cytokine production involved in immune response, regulation of cytokine production, regulation of immune effector process, regulation of immune response, positive regulation of immune effector process, regulation of T cell cytokine production, regulation of T cell mediated immunity, regulation of leukocyte mediated immunity, positive regulation of T cell mediated immunity, positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains, positive regulation of adaptive immune response, positive regulation of lymphocyte mediated immunity, positive regulation of leukocyte mediated immunity, nuclear migration, nucleus localization, cellular localization, establishment of localization in cell, positive regulation of T cell mediated cytotoxicity, regulation of T cell mediated cytotoxicity, regulation of leukocyte mediated cytotoxicity, positive regulation of leukocyte mediated cytotoxicity, positive regulation of cell killing, positive regulation of neutrophil chemotaxis, positive regulation of neutrophil migration, regulation of leukocyte migration, regulation of cell migration, regulation of cell motility, regulation of locomotion, regulation of cellular component movement, positive regulation of leukocyte migration, positive regulation of cell migration, positive regulation of cell motility, positive regulation of cellular component movement, positive regulation of locomotion, positive regulation of granulocyte chemotaxis, positive regulation of leukocyte chemotaxis, positive regulation of chemotaxis, positive regulation of response to external stimulus, regulation of leukocyte chemotaxis, regulation of neutrophil chemotaxis leukocyte mediated cytotoxicity, cell killing, leukocyte mediated immunity, immune effector process, positive regulation of T cell migration, regulation of T cell migration, regulation of lymphocyte migration, negative regulation of leukocyte mediated immunity, negative regulation of biological process, type I interferon signaling pathway, response to stimulus, cellular response to cytokine stimulus, cellular response to organic substance, cellular response to chemical stimulus, response to chemical, response to organic substance, response to cytokine, cellular response to type I interferon, response to type I interferon, innate immune response, defense response to other organism, response to other organism, interspecies interaction between organisms, response to external biotic stimulus, response to biotic stimulus, response to external stimulus, defense response, response to stress, immune response, interferon-gamma-mediated signaling pathway, cellular response to interferon-gamma, response to interferon-gamma, regulation of RNA splicing, regulation of gene expression, regulation of macromolecule metabolic process, regulation of metabolic process, regulation of nucleobase-containing compound metabolic process, regulation of cell shape, translational initiation, lymphocyte mediated immunity, lymphocyte activation, leukocyte activation, cell activation, cellular response to growth factor stimulus, response to growth factor, viral process, symbiotic process, mRNA metabolic process, protein localization to organelle, positive regulation of cell death, regulation of cell death, cellular response to endogenous stimulus, response to endogenous stimulus, negative regulation of nucleobase-containing compound metabolic process, negative regulation of metabolic process, negative regulation of gene expression, negative regulation of macromolecule metabolic process		pathway enrichment	positive		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients' GO cluster 2	44	adults (18-78)	Stockholm, Sweden				32826343	2020	Table S4	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1	Annotation system: GO				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				NK cells		negative regulation of low-density lipoprotein particle receptor catabolic process, membrane raft assembly, cellular process, mitochondrial electron transport cytochrome c to oxygen, mitochondrial ATP synthesis coupled electron transport, ATP synthesis coupled electron transport, respiratory electron transport chain, electron transport chain, generation of precursor metabolites and energy, oxidative phosphorylation, ATP metabolic process, aerobic electron transport chain, aerobic respiration, collagen catabolic process, inner mitochondrial membrane organization, proton transmembrane transport, transport, establishment of localization, localization, transmembrane transport, neutrophil degranulation, neutrophil mediated immunity, myeloid leukocyte mediated immunity, immune effector process, immune system process, neutrophil activation involved in immune response, neutrophil activation, granulocyte activation, myeloid leukocyte activation, leukocyte activation, cell activation, myeloid cell activation involved in immune response, leukocyte activation involved in immune response, cell activation involved in immune response, immune response, leukocyte degranulation, regulated exocytosis, secretion by cell, export from cell, secretion, establishment of localization in cell, cellular localization, regulation of endopeptidase activity, symbiotic process, cellular response to chemical stimulus, response to organic substance		pathway enrichment	positive		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients' GO cluster 3	44	adults (18-78)	Stockholm, Sweden				32826343	2020	Table S4	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1	Annotation system: GO				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				NK cells		regulation by virus of viral protein levels in host cell, regulation of viral process, regulation of symbiosis, encompassing mutualism through parasitism, type I interferon signaling pathway, cytokine-mediated signaling pathway, cell surface receptor signaling pathway, signal transduction, signaling, cell communication, cellular response to stimulus, response to stimulus, cellular response to cytokine stimulus, cellular response to organic substance, cellular response to chemical stimulus, response to chemical, response to organic substance, response to cytokine, cellular response to type I interferon, response to type I interferon, innate immune response, defense response to other organism, response to other organism, interspecies interaction between organisms, response to external biotic stimulus, response to biotic stimulus, response to external stimulus, defense response, response to stress, immune response, immune system process, response to interferon-alpha, negative regulation of viral genome replication, regulation of viral genome replication, regulation of viral life cycle, negative regulation of viral life cycle, negative regulation of viral process, negative regulation of biological process, negative regulation of viral entry into host cell, regulation of viral entry into host cell, modulation by symbiont of entry into host, response to interferon-beta, interferon-gamma-mediated signaling pathway, cellular response to interferon-gamma, response to interferon-gamma, defense response to virus, response to virus, immune effector process, viral process, symbiotic process		pathway enrichment	positive		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients' GO cluster 4	44	adults (18-78)	Stockholm, Sweden				32826343	2020	Table S4	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1	Annotation system: GO				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				NK cells		electron transport coupled proton transport, energy coupled proton transmembrane transport, against electrochemical gradient, proton transmembrane transport, monovalent inorganic cation transport, cation transport, ion transport, inorganic cation transmembrane transport, cation transmembrane transport, ion transmembrane transport, transmembrane transport, inorganic ion transmembrane transport, mitochondrial electron transport cytochrome c to oxygen, mitochondrial ATP synthesis coupled electron transport, ATP synthesis coupled electron transport, respiratory electron transport chain, electron transport chain, oxidation-reduction process, metabolic process, generation of precursor metabolites and energy, cellular metabolic process, cellular respiration, energy derivation by oxidation of organic compounds, oxidative phosphorylation, phosphorylation, phosphate-containing compound metabolic process, phosphorus metabolic process, ATP metabolic process, aerobic electron transport chain, aerobic respiration, mitochondrial electron transport NADH to ubiquinone, mitochondrial ATP synthesis coupled proton transport, ATP synthesis coupled proton transport, energy coupled proton transport down electrochemical gradient, response to hyperoxia, response to increased oxygen levels, response to abiotic stimulus, mitochondrial respiratory chain complex I assembly, NADH dehydrogenase complex assembly, cellular protein-containing complex assembly, mitochondrial respiratory chain complex assembly, mitochondrion organization		pathway enrichment	positive		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients' GO cluster 5	44	adults (18-78)	Stockholm, Sweden				32826343	2020	Table S4	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1	Annotation system: GO				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				NK cells		SRP-dependent cotranslational protein targeting to membrane, protein targeting to ER, protein targeting, intracellular protein transport, cellular protein localization, cellular macromolecule localization, cellular localization, cellular process, localization, macromolecule localization, protein localization, intracellular transport, establishment of localization in cell, establishment of localization, transport, protein transport, establishment of protein localization, peptide transport, amide transport, nitrogen compound transport, organic substance transport, establishment of protein localization to endoplasmic reticulum, protein localization to endoplasmic reticulum, protein localization to organelle, establishment of protein localization to organelle, cotranslational protein targeting to membrane, protein targeting to membrane, establishment of protein localization to membrane, protein localization to membrane, viral transcription, viral process, symbiotic process, interspecies interaction between organisms, viral gene expression, nuclear-transcribed mRNA catabolic process nonsense-mediated decay, nuclear-transcribed mRNA catabolic process, mRNA catabolic process, negative regulation of gene expression, negative regulation of macromolecule metabolic process, negative regulation of metabolic process, negative regulation of biological process, regulation of biological process, biological regulation, regulation of metabolic process, regulation of macromolecule metabolic process, regulation of gene expression, RNA catabolic process, RNA metabolic process, nucleic acid metabolic process, nucleobase-containing compound metabolic process, heterocycle metabolic process, cellular metabolic process, metabolic process, primary metabolic process, cellular aromatic compound metabolic process, cellular nitrogen compound metabolic process, nitrogen compound metabolic process, organic cyclic compound metabolic process, organic substance metabolic process, macromolecule metabolic process, cellular macromolecule catabolic process, macromolecule catabolic process, organic substance catabolic process, catabolic process, cellular macromolecule metabolic process, cellular catabolic process, nucleobase-containing compound catabolic process, cellular nitrogen compound catabolic process, heterocycle catabolic process, aromatic compound catabolic process, organic cyclic compound catabolic process, mRNA metabolic process, translational initiation, translation, gene expression, cellular macromolecule biosynthetic process, cellular biosynthetic process, biosynthetic process, macromolecule biosynthetic process, organic substance biosynthetic process, cellular protein metabolic process, protein metabolic process, organonitrogen compound metabolic process, peptide biosynthetic process, peptide metabolic process, cellular amide metabolic process, amide biosynthetic process, cellular nitrogen compound biosynthetic process, organonitrogen compound biosynthetic process, cytoplasmic translation, ribosomal small subunit assembly, ribosome assembly, cellular component organization or biogenesis, cellular component biogenesis, ribosome biogenesis, ribonucleoprotein complex biogenesis, ribosomal small subunit biogenesis, ribonucleoprotein complex assembly, ribonucleoprotein complex subunit organization, ribosomal large subunit assembly, ribosomal large subunit biogenesis, maturation of LSU-rRNA, rRNA processing, ncRNA processing, RNA processing, ncRNA metabolic process, rRNA metabolic process, positive regulation of translation, regulation of cellular amide metabolic process, regulation of translation, posttranscriptional regulation of gene expression		pathway enrichment	positive		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients' GO cluster 6	44	adults (18-78)	Stockholm, Sweden				32826343	2020	Table S4	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1	Annotation system: GO				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	14/2/2021				NK cells		Hepatitis B Apoptosis, Epstein-Barr virus infection, TNF signaling pathway, Hepatitis C, NF-kappa B signaling pathway, Pathways in cancer, Kaposi's sarcoma-associated herpesvirus infection, NOD-like receptor signaling pathway, Measles, Focal adhesion, Osteoclast differentiation, Influenza A, Necroptosis, Toxoplasmosis, Chronic myeloid leukemia, IL-17 signaling pathway, Small cell lung cancer, Chemokine signaling pathway, Viral carcinogenesis, Toll-like receptor signaling pathway, Fluid shear stress and atherosclerosis, T cell receptor signaling pathway, Pancreatic cancer, Prostate cancer, Chagas disease (American trypanosomiasis), Proteoglycans in cancer, MAPK signaling pathway, HTLV-I infection, AGE-RAGE signaling pathway in diabetic complications, Th17 cell differentiation, RIG-I-like receptor signaling pathway, Colorectal cancer, Apoptosis - multiple species, PI3K-Akt signaling pathway, FoxO signaling pathway, Endometrial cancer, Cytokine-cytokine receptor interaction, Protein processing in endoplasmic reticulum, Tuberculosis, B cell receptor signaling pathway, Ubiquitin mediated proteolysis, Adherens junction, Neurotrophin signaling pathway, Transcriptional misregulation in cancer, Platinum drug resistance, Signaling pathways regulating pluripotency of stem cells, Pertussis, Shigellosis, Legionellosis, Jak-STAT signaling pathway, EGFR tyrosine kinase inhibitor resistance, Cell cycle, Bacterial invasion of epithelial cells, Cytosolic DNA-sensing pathway, Ribosome, Prolactin signaling pathway, Acute myeloid leukemia, Non-small cell lung cancer, Pathogenic Escherichia coli infection, Endocrine resistance, Th1 and Th2 cell differentiation, Amyotrophic lateral sclerosis (ALS), Cellular senescence, TGF-beta signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Fc epsilon RI signaling pathway, Thyroid hormone signaling pathway, Natural killer cell mediated cytotoxicity, Breast cancer, Epithelial cell signaling in Helicobacter pylori infection, Adipocytokine signaling pathway, Renal cell carcinoma, Endocytosis, Inflammatory bowel disease (IBD), ErbB signaling pathway, Melanoma, GnRH signaling pathway, Estrogen signaling pathway, Platelet activation, Malaria, Glioma, Sphingolipid signaling pathway, HIF-1 signaling pathway, Salmonella infection, Leishmaniasis, ECM-receptor interaction, Leukocyte transendothelial migration, Fc gamma R-mediated phagocytosis, Herpes simplex infection, MicroRNAs in cancer, Insulin resistance, Mitophagy - animal, Huntington's disease, Prion diseases, Hippo signaling pathway, Regulation of actin cytoskeleton, Thyroid cancer, Antifolate resistance, Central carbon metabolism in cancer, Amoebiasis, VEGF signaling pathway, Rap1 signaling pathway, Type II diabetes mellitus, Bladder cancer, p53 signaling pathway, Gap junction, Vasopressin-regulated water reabsorption, Ras signaling pathway, Autophagy - animal, Insulin signaling pathway, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Intestinal immune network for IgA production, Tight junction, African trypanosomiasis, Hypertrophic cardiomyopathy (HCM), Proteasome, Choline metabolism in cancer, Dilated cardiomyopathy, Viral myocarditis		pathway enrichment	positive		0 to 8	days	time of admission	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049		44	SARS-CoV-2 patients (moderate & severe) (18-78)	Stockholm, Sweden				32826343	2020	Table S11	https://immunology.sciencemag.org/content/suppl/2020/08/20/5.50.eabd6832.DC1	-Annotation system: KEGG				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.	1.5hrs total					response to type I interferon, type I interferon signaling pathway, cellular response to type I interferon, defense response to virus, defense response to other organism, response to virus, regulation of viral genome replication, regulation of viral life cycle, negative regulation of viral genome replication, negative regulation of viral life cycle, negative regulation of viral process, proteolysis involved in cellular protein catabolic process, regulation of viral process, viral genome replication, negative regulation of multi-organism process		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 autopsy vs healthy	26	Adults (53-104)	Basal & Liestal, Switzerland				33033248	2020	Table 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/table/Tab2/?report=objectonly	-Annotation system: GO 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665314/					
	Amani	19th Feb 2021.						DMBT1, TDO2, IFI6, KIAA0101, MELK, BUB1, ISG15, IFI27, PSMB9, OAS3, CDK1, HLA-G, SLAMF8, CDKN3, OAS1, OAS2, CXCL11, IDO1, FOXM1, LAMP3, IFIT3, MAD2L1, CD38, CCR1, GZMB, LAG3, IFI44L, TOP2A, MX1, CXCL9, CD276, STAT1, IFI35, IFIH1, CCL18, GBP1, IFIT2, PDCD1LG2, CXCL10, IFIT1, C1QB, CXCL13, CCNB2, BRCA2, MKI67, DDX58, SNAI2, POU2AF1, XAGE1B, C1QA, CCR5, HERC6, BST2, CMKLR1, ISG20, TNFSF18, CD163, CYBB, IFITM1, IRF4, IL21, FCGR1A, SLAMF7, GZMA, IL10, TNFRSF17, KRT5, KRT7		gene expression	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 autopsy vs healthy	26	Adults (53-104)	Basal & Liestal, Switzerland				33033248	2020	Suppl Table 3.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/#__sec1title	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani	19th Feb 2021.						JAML, IRS1, MLANA, IGF1R, TCF7, KLF2, KLRB1, CXCR4, CEACAM8, BCL6, CD69, PTGS2, CD226, BCL2, KLRG1, PTPRC, CCL17, CD1C, MPO, CD83, CRTAM, HLA-DQB2, RORC, TNFRSF9, IL2, CCR6, ARG1, MAGEC2, CXCR5, GAGE10		gene expression	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 autopsy vs healthy	26	Adults (53-104)	Basal & Liestal, Switzerland				33033248	2020	Suppl Table 3.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/#__sec1title	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani	19th Feb 2021.						Interferon-stimulated genes (ISG)		gene expression	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 1 vs cluster 2	14	Adults (53-96)	Basal, Switzerland				33033248	2020	Fig 1e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig1/	-2 distinct clusters based on diagnosis & viral load, done by k-means clustering of COVID-19 and healthy lung samples by gene expression levels. "Clusters 1 (50% of samples) and 2 (41%) contained COVID-19 samples". "Cluster 1 or 2 were assigned ISG activation label ISGhigh and ISGlow, respectively"				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani	19th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		CD3+ T cells, CD68+ monocytes, CD163+ monocytes		cell type frequency	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 2 (ISGlow) vs healthy	33	Adults (53-104)	Basal & Liestal, Switzerland				33033248	2020	Fig 3c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig3/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani	19th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		CD3+ T cells, CD68+ monocytes, CD163+ monocytes, CD8+ T cells		cell type frequency	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 2 (ISGlow) vs cluster 1 (ISGhigh)	33	Adults (53-96)	Basal, Switzerland				33033248	2020	Fig 3c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig3/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani	19th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		CD4+ T cells, CD20+ B cells, CD8+ PD1+ T cells		cell type frequency	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 2 (ISGlow) vs cluster 1 (ISGhigh)	33	Adults (53-96)	Basal, Switzerland				33033248	2020	Fig 4a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig4/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani	19th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		Tumor Necrosis Factor (TNF), Interleukin-1B (IL-1B), interleukin 6 (IL6), IFNA17, IFNB1, CCL2, CXCL9, CXCL10, CXCL11		cytokines/protein levels	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 1 (ISGhigh) vs cluster 2 (ISGlow)	31	Adults (53-96)	Basal, Switzerland				33033248	2020	Fig 5a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig5/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani	19th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		CD8+ T cell signature		cell activation state	negatively correlated					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 autopsy cluster 1 (ISGhigh) negatively correlated with viral load	31	COVID-19 autopsy cluster 1 (ISGhigh) (53-96)	Basal, Switzerland				33033248	2020	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig5/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani	19th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		CD38 CD8+ T cell, GZMA CD8+ T cell, GZMB CD8+ T cell, CCR5 CD8+ T cell		cytokines/protein levels	negatively correlated					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 autopsy cluster 1 (ISGhigh) negatively correlated with viral load	31	COVID-19 autopsy cluster 1 (ISGhigh) (53-96)	Basal, Switzerland				33033248	2020	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig5/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani	19th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		C1QA, C1QB		gene expression	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 2 (ISGlow) vs cluster 1 (ISGhigh)	31	Adults (53-96)	Basal, Switzerland				33033248	2020	Fig 6b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig6/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani	19th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		Ki67, p53		cytokines/protein levels	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 2 (ISGlow) vs cluster 1 (ISGhigh)	31	Adults (53-96)	Basal, Switzerland				33033248	2020	Fig 6a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/figure/Fig6/	-also 2nd sentence under "The ISGlow lung profile shows..."  "ISGlow lung samples expressed elevated p53 and Ki67"				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546638/					
	Amani 	15th of Feb 2021.	8hrs total			Peripheral Blood Mononuclear Cells (PBMCs)		plasmablasts of CD45 cells, effector CD8 T cells of CD8 T cells		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)					161	161	161	161	2697049	infected vs healthy	140	Adults (18-94)	Atlanta, Hong Kong				32788292	2020	Fig 1b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pDC (plasmacytoid dendritic cells) CD45 cells		cell type frequency	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)					161	161	161	161	2697049	infected vs healthy	140	Adults (18-94)	Atlanta, Hong Kong				32788292	2020	Fig 1c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pS6 (mTOR) in pDCs (plasmacytoid dendritic cells)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	infected vs healthy	140	Adults (18-94)	Atlanta, Hong Kong				32788292	2020	Fig 1d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IKBalpha in mDCs		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	infected vs healthy	140	Adults (18-94)	Atlanta, Hong Kong				32788292	2020	Fig 1e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F1/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pDCs Interferon-alpha (IFN-a), pDCs tumor necrosis factor-alpha (TNF-a), pDCs interferon-alpha and tumor necrosis factor-alpha (IFN-a + TNF-a)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	infected donors in response to viral cocktail (polyIC + R848) vs healthy donors in response to viral cocktail (polyIC + R848)	31	Adults (23-94)	Atlanta				32788292	2020	Fig 2a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F2/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		mDCs Interleukin-6 (IL-6), mDCs tumor necrosis factor-alpha (TNF-a), mDCs interleukin-6 and tumor necrosis factor-alpha (IL-6 + TNF-a)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	infected without stimulation vs healthy without stimulation	31	Adults (23-94)	Atlanta				32788292	2020	Fig 2b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F2/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		mDCs Interleukin-6 (IL-6), mDCs tumor necrosis factor-alpha (TNF-a), mDCs interleukin-6 and tumor necrosis factor-alpha (IL-6 + TNF-a)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	infected donors in response to bacterial cocktail (Pam3CSK4, LPS, & Flagellin) vs healthy donors in response to bacterial cocktail (Pam3CSK4, LPS, & Flagellin)	31	Adults (23-94)	Atlanta				32788292	2020	Fig 2b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F2/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		mDCs Interleukin-6 (IL-6), mDCs tumor necrosis factor-alpha (TNF-a), mDCs interleukin-6 and tumor necrosis factor-alpha (IL-6 + TNF-a)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	infected donors in response to viral cocktail (polyIC + R848) vs healthy donors in response to viral cocktail (polyIC + R848)	31	Adults (23-94)	Atlanta				32788292	2020	Fig 2b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F2/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		p65 (Ser529) in mDCs		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	infected donors in response to bacterial cocktail (Pam3CSK4, LPS, & Flagellin) vs healthy donors in response to bacterial cocktail (Pam3CSK4, LPS, & Flagellin)	31	Adults (23-94)	Atlanta				32788292	2020	Fig 2c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F2/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma Interleukin-6 (IL-6), plasma tumor necrosis factor-alpha (TNF-a), plasma OSM, plasma TNFSF14		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs healthy 	52	Adults (23-94)	Atlanta				32788292	2020	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F3/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma OSM, plasma TNFSF14, plasma EN-RAGE		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs moderate  	52	Adults (23-94)	Atlanta				32788292	2020	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F3/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma OSM, plasma interleukin-6 (IL-6)		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU vs severe   	52	Adults (23-94)	Atlanta				32788292	2020	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F3/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma OSM, plasma interleukin-6 (IL-6), plasma TNFSF14, plasma EN-RAGE, plasma MCP-3		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU vs moderate   	52	Adults (23-94)	Atlanta				32788292	2020	Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F3/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		innate antiviral response (M150); type I interferon response (M127); enriched in activated dendritic cells (II) (M165); antiviral IFN signature (M75); cell cycle and transcription (M4.0); enriched in T cells (I) (M7.0); MHC-TLR7-TLR8 cluster (M146); enriched in antigen presentation (II) (M95.0); immune activation - generic cluster (M37.0); TLR and inflammatory signaling (M16); activated dendritic cells (M67); RIG-1 like receptor signaling (M68); viral sensing & immunity; IRF2 targets network (I) (M111.0); viral sensing & immunity; IRF2 targets network (II) (M111.1); T cell activation and signaling (M5.1); T cell activation (I) (M7.1); cell adhesion (lymphocyte homing) (M21); T cell differentiation (Th2) (M19); Activated (LPS) dendritic cell surface signature (S11); T cell surface, activation (M36); integrins and cell adhesion (M84); T cell differentiation via ITK and PKC (M18); T cell activation (III) (M7.4); T cell signaling and costimulation (M44); regulatory electron transport chain (mitochondrion) (M238); transcription regulation in cell development (M49); putative targets of PAX3 (M89.0); chaperonin mediated protein folding (II) (M204.1); chaperonin mediated protein folding (I) (M204.0); enriched in monocytes (II) (M11.0)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Fig S13	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shorter version of same data in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		Monocyte surface signature (S4); regulation of antigen presentation and immune response (M5.0); enriched in antigen presentation (I) (M71); antigen processing and presentation (M200); platelet activation (I) (M32.0); platelet activation (II) (M32.1); myeloid, dendritic cell activation via NFkB (II) (M43.1); inflammasome receptors and signaling (M53); putative targets of PAX3 (M89.1); GF induced, enriched in nuclear receptor subfamily 4 (M94); inflammatory response (M33); suppression of MAPK signaling (M56); enriched in antigen presentation (III) (M95.1); translation initiation factor 3 complex (M245); cytoskeletal remodeling (enriched for SRF targets) (M34); cell movement, Adhesion & Platelet activation (M30); enriched in myeloid cells and monocytes (M81); cell adhesion (M51); chaperonin mediated protein folding (II) (M204.1); chaperonin mediated protein folding (I) (M204.0); chemokines and inflammatory molecules in myeloid cells (M86.0); signaling in T cells (I) (M35.0); leukocyte differentiation (M160); AP-1 transcription factor network (M20); cell cycle and growth arrest (M31); enriched in NK cells (I) (M7.2); enriched in monocytes (II) (M11.0)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Fig S13	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in monocytes (II) (M11.0), cell cycle and transcription (M4.0), type I interferon response (M127), enriched in activated dendritic cells (II) (M165); innate antiviral response (M150), immune activation - generic cluster (M37.0), TLR and inflammatory signaling (M16), antiviral IFN signature (M75), regulation of antigen presentation and immune response (M5.0), monocyte surface signature (S4)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	C MONO_IFN cluster/cluster 11 from COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		platelet activation - actin binding (M196); cell adhesion (M51); chemokines and inflammatory molecules in myeloid cells (M86.0); enriched in myeloid cells and monocytes (M81); cell movement, Adhesion & Platelet activation (M30); signaling in T cells (I) (M35.0); cytoskeletal remodeling (enriched for SRF targets) (M34); putative targets of PAX3 (M89.0)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	C MONO_IFN cluster/cluster 11 from COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		type I interferon response (M127), enriched in T cells (I) (M7.0), T cell activation and signaling (M5.1), T cell activation (I) (M7.1), innate antiviral response (M150), T cell differentiation (Th2) (M19), enriched in antigen presentation (II) (M95.0), cell adhesion (lymphocyte homing) (M21)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	T cluster/cluster 23 from COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in NK cells (I) (M7.2), cell cycle and growth arrest (M31), regulation of antigen presentation and immune response (M5.0), AP-1 transcription factor network (M20), signaling in T cells (I) (M35.0), enriched in NK cells (II) (M61.0), leukocyte differentation (M160), chemokines and inflammatory molecules in myeloid cells (M86.0), T cell activation (II) (M7.3)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	T cluster/cluster 23 from COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		type I interferon response (M127); innate antiviral response (M150); enriched in activated dendritic cells (II) (M165); enriched in T cells (I) (M7.0); T cell activation and signaling (M5.1); antiviral IFN signature (M75); cell cycle and transcription (M4.0); T cell surface, activation (M36); activated dendritic cells (M67)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Cl21 cluster/cluster 21 from COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in monocytes (II) (M11.0); antigen processing and presentation (M200); enriched in antigen presentation (II) (M95.0); blood coagulation (M11.1); inflammatory response (M33); innate activation by cytosolic DNA sensing (M13); proinflammatory dendritic cell, myeloid cell response (M86.1); regulation of antigen presentation and immune response (M5.0); monocyte surface signature (S4)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Cl21 cluster/cluster 21 from COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		type I interferon response (M127); innate antiviral response (M150); enriched in activated dendritic cells (II) (M165); antiviral IFN signature (M75); cell cycle and transcription (M4.0); activated dendritic cells (M67); MHC-TLR7-TLR8 cluster (M146); RIG-1 like receptor signaling (M68); immune activation - generic cluster (M37.0)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	HSC cluster/cluster 19 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		cell cycle and growth arrest (M31); putative targets of PAX3 (M89.1); growth factor induced, enriched in nuclear receptor subfamily 4 (M94); AP-1 transcription factor network (M20); signaling in T cells (I) (M35.0); chemokines and inflammatory molecules in myeloid cells (M86.0); inflammatory response (M33); inflammasome receptors and signaling (M53); suppression of MAPK signaling (M56); myeloid, dendritic cell activation via NFkB (II) (M43.1)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	HSC cluster/cluster 19 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		type I interferon response (M127), respiratory electron transport chain (mitochondrion) (M238), RIG-1 like receptor signaling (M68), integrins and cell adhesion (M84), cytoskeletal remodeling (M32.8)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	PB_1 cluster/cluster 13 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		chaperonin mediated protein folding (I) (M204.0), chaperonin mediated protein folding (II) (M204.1), platelet activation (I) (M32.0), enriched in antigen presentation (I) (M71), MHC-TLR7-TLR8 cluster (M146), Ran mediated mitosis (M15), regulation of antigen presentation and immune response (M5.0), platelet activation (II) (M32.1), lysosomal/endosomal proteins (M139)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	PB_1 cluster/cluster 13 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in monocytes (II) (M11.0), innate antiviral response (M150), putative targets of PAX3 (M89.0), cell cycle and transcription (M4.0), enriched in activated dendritic cells (II) (M165), type I interferon response (M127), immune activation - generic cluster (M37.0), antiviral IFN signature (M75), Activated (LPS) dendritic cell surface signature (S11), formyl peptide receptor mediated neutrophil response (M11.2)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	C MONO_1 cluster/cluster 3 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in antigen presentation (II) (M95.0), antigen processing and presentation (M200), MHC-TLR7-TLR8 cluster (M146), monocyte surface signature (S4), antigen presentation (lipids and proteins) (M28), translation initiation factor 3 complex (M245), regulation of antigen presentation and immune response (M5.0)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	C MONO_1 cluster/cluster 3 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		innate antiviral response (M150), cell cycle and transcription (M4.0), antiviral IFN signature (M75), cell cycle (I) (M4.1), enriched in activated dendritic cells (II) (M165), mitotic cell cycle in stimulated CD4 T cells (M4.5), enriched in monocytes (II) (M11.0), lysosome (M209), transcription regulation in cell development (M49), type I interferon response (M127)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	BASO cluster/cluster 20 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in T cells (I) (M7.0), enriched in T cells (II) (M223), enriched in NK cells (III) (M157), enriched in NK cells (I) (M7.2) 		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	BASO cluster/cluster 20 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		type I interferon response (M127); MHC-TLR7-TLR8 cluster (M146); innate antiviral response (M150); enriched in activated dendritic cells (II) (M165); viral sensing & immunity; IRF2 targets network (I) (M111.0); viral sensing & immunity; IRF2 targets network (II) (M111.1); activated dendritic cells (M67); antiviral IFN signature (M75); regulation of antigen presentation and immune response (M5.0); enriched in monocytes (II) (M11.0)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	PDC cluster/cluster 10 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		Monocyte surface signature (S4), enriched in NK cells (I) (M7.2), T cell activation and signaling (M5.1)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	PDC cluster/cluster 10 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		innate antiviral response (M150), enriched in T cells (I) (M7.0), type I interferon response (M127), enriched in NK cells (I) (M7.2), enriched in activated dendritic cells (II) (M165), putative targets of PAX3 (M89.0), chemokines and inflammatory molecules in myeloid cells (M86.0), cell cycle and transcription (M4.0), activated dendritic cells (M67)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	C MONO_2 cluster/cluster 16 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in monocytes (II) (M11.0), antigen processing and presentation (M200), enriched in antigen presentation (I) (M71), MHC-TLR7-TLR8 cluster (M146), enriched in antigen presentation (II) (M95.0), regulation of antigen presentation and immune response (M5.0), cell cycle and growth arrest (M31), enriched in antigen presentation (III) (M95.1), enriched in monocytes (surface) (M118.1)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	C MONO_2 cluster/cluster 16 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in T cells (I) (M7.0); enriched in NK cells (I) (M7.2); innate antiviral response (M150); type I interferon response (M127); enriched in antigen presentation (II) (M95.0); viral sensing & immunity; IRF2 targets network (I) (M111.0); cell adhesion (lymphocyte homing) (M21); RIG-1 like receptor signaling (M68); T cell signaling and costimulation (M44)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CD8 cluster/cluster 2 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		cell cycle and growth arrest (M31), AP-1 transcription factor network (M20), signaling in T cells (I) (M35.0), chemokines and inflammatory molecules in myeloid cells (M86.0), inflammasome receptors and signaling (M53), suppression of MAPK signaling (M56), myeloid, dendritic cell activation via NFkB (II) (M43.1), leukocyte differentiation (M160), regulation of antigen presentation and immune response (M5.0)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CD8 cluster/cluster 2 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in antigen presentation (I) (M71), enriched in antigen presentation (II) (M95.0), type I interferon response (M127), enriched in antigen presentation (III) (M95.1), innate antiviral response (M150), MHC-TLR7-TLR8 cluster (M146), regulation of antigen presentation and immune response (M5.0), RIG-1 like receptor signaling (M68), enriched in activated dendritic cells (II) (M165), activated dendritic cells (M67)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CDC1 cluster/cluster 24 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		antigen processing and presentation (M200)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CDC1 cluster/cluster 24 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		type I interferon response (M127); innate antiviral response (M150); enriched in NK cells (I) (M7.2); enriched in T cells (I) (M7.0); MHC-TLR7-TLR8 cluster (M146); viral sensing & immunity; IRF2 targets network (I) (M111.0); viral sensing & immunity; IRF2 targets network (II) (M111.1); enriched in antigen presentation (I) (M71); enriched in antigen presentation (II) (M95.0); RIG-1 like receptor signaling (M68)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	NK cluster/cluster 1 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		AP-1 transcription factor network (M20), signaling in T cells (I) (M35.0)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	NK cluster/cluster 1 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		RIG-1 like receptor signaling (M68); innate antiviral response (M150); transcription elongation, RNA polymerase II (M234); respiratory electron transport chain (mitochondrion) (M238); respiratory electron transport chain (mitochondrion) (M219); Activated (LPS) dendritic cell surface signature (S11)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	GRAN cluster/cluster 9 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in monocytes (II) (M11.0), enriched in antigen presentation (II) (M95.0), cell cycle and transcription (M4.0), regulation of antigen presentation and immune response (M5.0), enriched in monocytes (IV) (M118.0), inflammatory response (M33), translation initiation factor 3 complex (M245), suppression of MAPK signaling (M56), enriched in antigen presentation (III) (M95.1), Monocyte surface signature (S4)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	GRAN cluster/cluster 9 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		type I interferon response (M127); innate antiviral response (M150); enriched in activated dendritic cells (II) (M165); AP-1 transcription factor network (M20); signaling in T cells (I) (M35.0); MHC-TLR7-TLR8 cluster (M146); viral sensing & immunity; IRF2 targets network (I) (M111.0); platelet activation (I) (M32.0); antiviral IFN signature (M75)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CDC2 cluster/cluster 5 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		antigen processing and presentation (M200), translation initiation factor 3 complex (M245), enriched in antigen presentation (I) (M71), enriched in dendritic cells (M168), Monocyte surface signature (S4)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CDC2 cluster/cluster 5 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IL2, IL7, TCR network (M65); T cell activation (I) (M7.1); chaperonin mediated protein folding (II) (M204.1); chaperonin mediated protein folding (I) (M204.0); T cell differentiation via ITK and PKC (M18); T cell activation (III) (M7.4); cell adhesion (lymphocyte homing) (M21); T cell signaling and costimulation (M44)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	T_IFN cluster/cluster 18 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in T cells (I) (M7.0); cell cycle and growth arrest (M31); viral sensing & immunity; IRF2 targets network (II) (M111.1); translation initiation factor 3 complex (M245); type I interferon response (M127); enriched in antigen presentation (I) (M71); MHC-TLR7-TLR8 cluster (M146); enriched in NK cells (I) (M7.2); platelet activation (II) (M32.1); platelet activation (I) (M32.0)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	T_IFN cluster/cluster 18 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		heme biosynthesis (I) (M171), enriched in cell cycle (M167), enriched in membrane proteins (M124), transcription regulation in cell development (M49), erythrocyte differentiation (M173)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	RBC cluster/cluster 17 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		AP-1 transcription factor network (M20), signaling in T cells (I) (M35.0)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	RBC cluster/cluster 17 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in B cells (I) (M47.0); MHC-TLR7-TLR8 cluster (M146); enriched in antigen presentation (II) (M95.0); innate antiviral response (M150); regulation of antigen presentation and immune response (M5.0); myeloid, dendritic cell activation via NFkB (II) (M43.1); enriched in B cells (VI) (M69); plasma cells & B cells, immunoglobulins (M156.0); RIG-1 like receptor signaling (M68); integrins and cell adhesion (M84)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	B cluster/cluster 7 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		antigen processing and presentation (M200), enriched in antigen presentation (I) (M71), T cell activation (I) (M7.1), enriched in T cells (I) (M7.0)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	B cluster/cluster 7 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		RIG-1 like receptor signaling (M68); Activated (LPS) dendritic cell surface signature (S11); signaling in T cells (I) (M35.0); complement activation (I) (M112.0); chemokines and inflammatory molecules in myeloid cells (M86.0); TLR and inflammatory signaling (M16); cell cycle and transcription (M4.0); T cell surface, activation (M36)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	NC MONO cluster/cluster 4 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		antigen processing and presentation (M200), regulation of antigen presentation and immune response (M5.0), enriched in monocytes (II) (M11.0), enriched in antigen presentation (I) (M71), MHC-TLR7-TLR8 cluster (M146), enriched in antigen presentation (II) (M95.0), immune activation - generic cluster (M37.0), enriched in NK cells (I) (M7.2), B cell surface signature (S2)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	NC MONO cluster/cluster 4 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		receptors, cell migration (M109); enriched in T cells (I) (M7.0); T cell activation (I) (M7.1); cell adhesion (lymphocyte homing) (M21); integrins and cell adhesion (M84); integrin mediated leukocyte migration (M39); T cell differentiation via ITK and PKC (M18); T cell activation (III) (M7.4); T cell differentiation (Th2) (M19); enriched in antigen presentation (II) (M95.0)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CD4 cluster/cluster 0 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		chemokines and inflammatory molecules in myeloid cells (M86.0), cell cycle and growth arrest (M31), inflammasome receptors and signaling (M53)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CD4 cluster/cluster 0 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		Activated (LPS) dendritic cell surface signature (S11)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	PLATE_1 cluster/cluster 6 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		cell movement, Adhesion & Platelet activation (M30); chemokine cluster (I) (M27.0); cytoskeletal remodeling (enriched for SRF targets) (M34); G protein mediated calcium signaling (M159); cell adhesion (M51); enriched in myeloid cells and monocytes (M81); platelet activation & blood coagulation (M199)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	PLATE_1 cluster/cluster 6 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		enriched in NK cells (I) (M7.2); regulation of transcription, transcription factors (M213)		pathway enrichment	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	EOS cluster/cluster 12 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		cell cycle and growth arrest (M31); growth factor induced, enriched in nuclear receptor subfamily 4 (M94); AP-1 transcription factor network (M20); signaling in T cells (I) (M35.0); leukocyte differentiation (M160); putative targets of PAX3 (M89.1); suppression of MAPK signaling (M56); chemokines and inflammatory molecules in myeloid cells (M86.0); regulation of antigen presentation and immune response (M5.0)		pathway enrichment	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	EOS cluster/cluster 12 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 'btm_enrichment_analysis' tab	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-same as above, annotation system for this & row above is BTM				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IL7R, LTB, TRAC, LDHB, CD3E, CD3D, NOSIP, TCF7, MAL, TRBC2, CD3G, PIK3IP1, TRBC1, RCAN3, TRAT1, LEF1, CCR7, CD69, SARAF, EEF1B2, TPT1, ETS1, NOP53, EEF1A1, IL32, BCL2, CD27, LEPROTL1, OXNAD1, NPM1, TOMM7, AQP3, TRABD2A, CAMK4, C12orf57, INPP4B, BTG1, SPOCK2, TSHZ2, LCK, EIF3E, GIMAP7, BCL11B, DNAJB1, PBXIP1, JUNB, FOXP1, SH3YL1, CD2, ARID5B, MYC, SNHG8, EEF1D, AES, RACK1		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 0 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		CAPNS1, MOB1A, REL, PIK3AP1, LGALS9, XAF1, GNAI2, ZYX, BID, ITGAX, RTN3, OAS1, IFNGR1, CNPY3, FOSB, DUSP1, SEC61B, RHOB, ARF1, AGTRAP, ETFA, CMC1, CMIP, CD83, CD300A, AKIRIN2, PRKCB, AHNAK, IFI27L2, OGFRL1, CD99, WARS, RAB31, ALDH2, LY86, JAML, HSBP1, BST2, KCTD12, RRBP1, RAB11A, RGS10, GNAS, ABHD17A, GPX4		gene expression	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 0 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		GNLY, NKG7, PRF1, FGFBP2, SPON2, CCL4, KLRF1, KLRD1, GZMA, CD247, GZMB, KLRB1, CTSW, CLIC3, HOPX, PTGDS, CD7, TRDC, GZMM, IL2RB, MATK, ABHD17A, CST7, IGFBP7, GZMH, CD160, ADGRG1, AKR1C3, PYHIN1, SAMD3, EFHD2, HCST, TTC38, CMC1, APMAP, NCR3, KLRC1, PTGDR, ARL4C, FCGR3A, PRSS23, RARRES3, TXK, APOBEC3G, CX3CR1, CEP78, XCL2, JAK1, GNPTAB, RUNX3, MYBL1, TBX21, CCL5, S1PR5, C1orf21, PTPN4, GNG2, CHST2, FCRL6, SYNE1, ZAP70, IFITM2, LITAF, ARPC5L, METRNL, DHRS7, CD81, EVL, ARHGAP9, ITGB2, CCL3, SKAP1, DDIT4, MBP, CHST12, SYNE2, CALM1, GIMAP7, PLAC8, PLEKHF1, PRKCH, TXNIP, SEPT.7, DENND2D, ASCL2, TBC1D10C, SH2D1B, CXXC5, IL2RG, STK17A, RAC2, RASSF1, OSTF1, SYTL3, TFDP2, AES, CD300A, ID2, SLFN5, CD63		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 1 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		GZMH, IL32, TRGC2, NKG7, CD3D, GZMK, CCL5, GZMA, CD3G, CD8A, KLRG1, CD8B, CD3E, CD2, FGFBP2, GZMM, GNLY, TRAC, TRBC2, CCL4, LYAR, DUSP2, HOPX, KLRD1, HCST, LCK, CTSW, LINC01871, PPP2R5C, CD52, TRBC1, SAMD3, CMC1, RARRES3, SYNE2, HLA-C, CD81, RORA, APOBEC3G, CLEC2D, FCRL6, MYBL1, ARL4C, CALM1, CST7, PRF1, LITAF, ABHD17A, IL2RG, MATK, PYHIN1, SKAP1, B2M, ANXA6, PAXX, ADGRG1, SYNE1, MALAT1, AES, CD6, C1orf21, IL7R		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 2 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		AC007952.4 H2AFY TNFSF10 SYK SELL C1orf162 HCK CD55 LMO2 GPR183 CTSH CTSB HLA-DMB MAR.1 FOS RAB11FIP1 FKBP1A BLVRB CLEC12A DAPP1 PECAM1 JAML NFKBIZ CAPG LYL1 RNF130 POU2F2 CAPZA2 GSTO1 SNAP23 VIM LAMTOR1 HLA-DRB5 ARPC1B S100A11 CALM3 NT5C3A VCL		gene expression	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 2 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		LYZVCANS100A9CXCL8FCN1S100A8CD14MNDACTSSS100A12NEAT1MS4A6AIL1BAC020656.1LGALS2CSTACEBPDATP2B1-AS1TKTCYBBTSPOTYROBPIER3CSF3RFGL2RGS2KLF4S100A6NCF2NCF1FOSNAMPTAIF1BRI3TYMPCD36APLP2DUSP6CFDCCL3S100A11GRNPLBD1LGALS3FTLG0S2CLEC7AFOSBEREGNFKBIABLVRBAP1S2RBP7PSAPKCTD12MPEG1CLEC12AFCGRTTNFAIP2FPR1DUSP1CPVLSERPINA1AC007952.4SLC11A1MCL1PLAURIGSF6ANXA1TNFSF13BTMEM176BCDANUP214CST3GCALRRK2JAMLVIMDMXL2RNF130S100A10EGR1CFPKLF6S100A4SDCBPTREM1PYCARDASGR1AC020916.1C5AR1MEGF9LGALS1SPI1CLEC4ECD302OGFRL1RETNNLRP3IER2		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 3 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		CDKN1CLST1FCGR3AMS4A7AIF1CFDSMIM25LYPD2SERPINA1COTL1SAT1FCER1GPSAPLYNFTLTCF7L2CTSSTNFRSF1BSPI1NFKBIZCSF1RC1QAPECAM1LILRB2PILRALRRC25MAFBS100A11WARSTYROBPMARCKSC5AR1POU2F2HMOX1FTH1NEAT1RHOCFGL2BCL2A1BRI3CEBPBHCKHES4NAMPTCD68BIDRRASCST3LYSTCSTBSIGLEC10IFI30STXBP2VASPIFITM2SLC7A7S100A4NPC2CYBBMBD2LMO2CLEC7AVSIRLILRA5CFPATP2B1-AS1TYMPAPOBEC3AS100A6ASAH1PTPN6TKTLILRB1LGALS3CLEC12AANXA5PYCARDCPPED1SLC2A6ZFAND5CTSLDUSP6FCN1TMEM176BFGRNAAAPRELID1C19orf38GPBAR1KLF4DUSP1RNASET2CKBRGS19ABI3CASP1G0S2HLA-DPA1ADGRE2PLAUR		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 4 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		FCER1AHLA-DRAHLA-DQA1HLA-DPB1HLA-DPA1HLA-DQB1HLA-DRB1HLA-DRB5CLEC10ACD74CST3CD1CHLA-DMAHLA-DQA2CPVLGPR183LGALS2HLA-DMBENHOPHACTR1LYZVIMANXA2ALDH2RGS1CTSZJAMLIGSF6GSTP1S100A10CAPGCFPCTSHID2MS4A6ACEBPDBASP1KLF4LY86LMNAFCGRTLGALS1COTL1C1orf162AREGSAMHD1CCDC88AH2AFYAP1S2GRNSPI1PAK1IFI30GADD45BCIITAANXA1NR4A2IL13RA1MNDACSTAFOSRNH1PPA1SLC25A5FGL2ANXA5RNF130CD33CHMP1BGDI2IL1BCSTBCLEC4AMAP3K8NDRG2IL18CD1DGAPDHID1BHLHE40EIF3LTIPARPLSP1GSNTMEM14CSLC25A6ACTG1TYMPCASP1TUBA1AAC020656.1GLIPR1GRASPSGK1LGALS3OGFRL1PRCPPGLSRBPJPYCARD		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 5 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		NRGNPPBPCAVIN2PF4HIST1H2ACTUBB1GNG11TSC22D1RGS18CLUGP9MYL9ACRBPCMTM5MAP3K7CLTREML1PTCRATUBA4ASPARCTMEM40RUFY1LIMS1C2orf88RGS10HIST1H3HNCOA4PGRMC1CD9PRKAR2BHIST1H2BJMMDF13A1MPP1GRAP2TPM4ODC1CTSABEX3TLN1VCL02-MarFERMT3CLDN5TMEM140KIF2ACLEC1BTAGLN2TGFB1NT5C3AYWHAHCALM3OAZ1OST4TIMP1RAB27BAP003068.2CTTNAP001189.1ESAMPDLIM1ITGA2BMAXNEXNTPM1RAP1BCCL5RAB32GSTO1ILKPARVBGPX4PRDX6SMIM5IFI27DAB2SMOXSNNMYLKMPIG6BGMPRRSU1CDKN2DSNCAENKURPTGS1SNAP23ACTN1ITM2BARHGAP18H3F3ALAMTOR1PKMPDZK1IP1TLK1GAS2L1SLC40A1AC147651.1EIF2AK1DAPP1SH3BGRL3		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 6 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		CD79AMS4A1IGHDIGHMCD79BRALGPS2BANK1TCL1ACD37LINC00926TNFRSF13CCD74VPREB3HLA-DQA1HLA-DQB1HLA-DRB1FCER2MEF2CHLA-DRACD22AFF3SWAP70P2RX5BLKFCRL1LTBBIRC3HVCN1ADAM28PLPP5CD69CXCR4IL4RHLA-DPB1CD24HLA-DMBFCRLAHLA-DMATSC22D3ARHGAP24CD40STRBPFAM129CIFT57BCL11ABTG1PAX5FCMRHLA-DPA1HLA-DOBFAM30ACD72STX7SNX201-MarTXNIPSPIBEZRFCRL5CYB561A3FCRL2ZCCHC7FOXP1CXXC5ISG20CD19BCL7ATMEM156LINC02397CD52EAF2GNG7CDCA7LTPD52COBLL1PPM1KIRF8CLEC2DCAMK2DPRDM2NFKBIDIKZF3RELSEC62NCF1BLNKSMIM14LAPTM5TCF4QRSL1SMAP2ARID5BBASP1ADKGAPTGABPB1-AS1CD83JUNDKLF2RHOB		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 7 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		LYZ, IGHG1, S100A9, S100A8, IGKC, CTSS, FCN1, AC020656.1, VCAN, NEAT1, MNDA, AIF1, IGHA1, PSAP, KLF4, EHBP1L1, SPI1, S100A12, SAT1, SERPINA1, LCP1, TKT, PARP14, TYMP, LST1, FGL2, SLC38A2, CFD, NAMPT, CYBB, S100A11		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 9 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		ARL4C, CD3E, CCL5, OST4, TGFB1, KIF2A, RGS10, BTG1, CD52, TUBA4A, LTB, CD7, TRBC2, TAGLN2, NT5C3A, TRAC, CTSW, YWHAH, CST7, TLN1, LIMS1, MARCH2, RUFY1, IGLC3, NKG7, TRBC1, IL7R, IL32		gene expression	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 9 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		TCF4IRF8PPP1R14BIRF7CCDC50PTGDSITM2CPLD4TPM2LILRA4UGCGSERPINF1GZMBIL3RATCL1ABCL11AALOX5APSPIBTSPAN13TXNSMPD3CYB561A3SEC61BSCTPLAC8CLEC4CAPPGPR183DNASE1L3SOX4C12orf75STMN1NPC2MAPKAPK2GAPTCLIC3RNASE6SPCS1CD74IRF4SELENOSHERPUD1DERL3CCDC88ARGS1FAM129CLAMP5LINC00996VEGFBPLP2TRAF4RUNX2UNC93B1CCDC186CD2APFCHSD2ZFATSLC15A4OFD1AC119428.2RNASET2TGFBIMZB1LILRB4IDH3ALGMNMYBL2COBLL1NUCB2GAS6BLNKP2RY14MAP1ARRBP1MPEG1CD4JCHAINCIB2ERP29C12orf45HIGD1ARGS2VAMP8CTSZZDHHC17PHBST6GALNAC4RAB11FIP1PARK7CTSCPACSIN1HLA-DMASCARB2PPM1KRASD1CLN8PTMSPTPRESMC6B4GALT1		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 10 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFI27S100A8S100A12S100A9IFITM3PLBD1RNASE2IFI6CD14ISG15VCANAPOBEC3ARETNMNDATYMPIFI44LAC020656.1CTSDGRNAPLP2MX1LYZS100A11FCN1FPR1SERPINA1PLAC8NAMPTMX2IFIT1LY6ELGALS1TNFSF13BIFIT3CTSBS100A6CTSSACSL1PLSCR1NCF2IFI44SELLXAF1TNFSF10CYBBCEBPDBLVRBMAFBFTLIFITM2CYP1B1EPSTI1LILRB2OAS1LILRA5RSAD2TYROBPS100A10MGST1AIF1CD163KCTD12SPI1ANXA2OAS3GCAFGL2CREG1MEGF9MS4A4AOAS2GLULITGB2NEAT1IGSF6CEBPBNAIPSIGLEC1BLVRAC5AR1FCGR1ACD63SLC11A1TSPOCAPGS100A4CSTA01-MarCLEC12ASULT1A1SPTLC2CD36SRGNPSAPLAP3CR1LGALS9SERPINB1DUSP6CDA		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 11 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		SYNE2MALAT1RNF213SYNE1MACF1NKTRXISTSLFN12LPRRC2CUTRNRORAZAP70DDX17ATMANKRD11RBM39PTPRCSRRM2ARGLU1ATRXETS1GOLGA4SMCHD1ARAP2AAK1CLEC2DPCSK7ASH1LIKZF3PLCG2ANKRD12DIP2AAHNAKHNRNPH1SAMD3PRPF4BAKNAPRF1TUT4PNISRAKAP13MYO1FACAP1AKAP9PPP2R5CZNF292EVLCCNL1BPTFTCF25N4BP2L2ZFP36L2OGADDX24MBNL1LUC7L3FUSSMG1SRSF11KLRD1DDX3XRSRP1EML4PNNSONARL4CIKZF1KMT2APCM1ATF7IPITGALANKRD44KIAA1551USP34SLFN5VPS13CNEMFBDP1POLR2J3.1CDK13EPB41SNRNP70GOLGB1OGTYIPF4INTS6AFF4PARP8SREK1GPBP1SP100YME1L1RBM26CASP8ZNF207HECTD1TNRC6BIRF3TRA2BUSP15		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 12 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IGLC2IGHA1IGLC3IGKCJCHAINIGHG1IGHG3MZB1IGHG4IGHA2IGHG2HSP90B1SEC11CITM2CPPIBTNFRSF17MYDGFXBP1FKBP11CD38LMAN1DERL3PDIA4HSPA5SSR3RRBP1PDIA6SPCS3SUB1CD27SDF2L1SSR4ISG20SPCS2IGHGPERLEC1RPN2UBE2J1CALRPRDX4MAN1A1ELL2TXNDC11MANFPOU2AF1FKBP2NCOA3SEC61BP4HBEAF2HM13SELENOSSEL1L3SPCS1DDOSTTENT5CHDLBPAQP3RABAC1CRELD2LMAN2KDELR2SEC61GTP53INP1ZBP1PIM2TNFRSF13BOSTCSLAMF7PRDM1TMED10TMED9TMEM258DERL1TPD52FNDC3BDNAJB11RPN1PLPP5GOLGB1SPATS2CPEB4CANXSEC61A1CD79ATMEM208TRAM1FCRL5COBLL1HERPUD1NUCB2MLECIDH2FAM30ATXNDC15SRPRBALG5ARF4SSR1IGHM		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 13 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		HBG2ITGA2BPPBPPF4CLEC1BPRKAR2BGNG11CLUTREML1TUBB1YWHAHGP9TLN1CST7NRGNMYL9RGS18RUFY1SNCAHIST1H2ACPDLIM1ACRBPBEX302-MarF13A1E2F1PGRMC1CTSATPM4VCLCMTM5GAS2L1CAVIN2CD9MPP1MMDTSC22D1TMEM40SPARCTIMP1CA2TPM1TAGLN2TGFB1FLNAOAZ1RSU1EIF2AK1ETFARGS10KIF2ATUBA4ARAB32ARHGAP18NAP1L1GRAP2MPIG6BFERMT3OST4MMRN1GPX4ACTN1ARPC1BSOD2MGLLLIMS1SELPPTGS1STOMLCN2ILKANKRD9TSPAN33CALM3CTTNMYL6GMPRNCOA4SH3BGRL2PRKAR1BH3F3AFAXDC2MGAT4BPTCRAPKMITM2BANO6ITGB3ENDOD1NT5MWDR1PROS1AC147651.1LAMTOR1ITGB1ARHGAP6TFPINORADRAB11ADAP		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 14 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IGHG1IGKCIGLC3IGLC2IGHA1JCHAINMZB1IGHG4IGHG3HSP90B1IGHA2SEC11CIGHG2PPIBMYDGFLMAN1XBP1HSPA5TNFRSF17SSR3SUB1PDIA6FKBP11SDF2L1PDIA4ITM2CHIST1H1BCD38SPCS3CALRMANFRRBP1SPCS2MKI67DERL3UBE2J1ELL2SEC61BPOU2AF1KDELR2P4HBHIST1H1DSEC61GRPN2ERLEC1SMC4RRM2PRDX4TMEM258MAN1A1TXNDC11ISG20HDLBPAQP3HSPD1FKBP2EAF2OSTCCRELD2CD27CCND2HM13CANXSSR4LMAN2MYBL2TMED9IGHGPSRMSELENOSMLECDERL1SSR1SPCS1CENPFTYMSPTTG1DNAJB11RPN1HIST1H2AHPCLAFFABP5HIST1H3GTMED10LRRC59SEC61A1ASPMPSME2TMEM208TOP2APIM2TNFRSF13BPRDX1DDOSTNCOA3H2AFZHMGB2HIST1H1EHIST1H4CIGHM		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 15 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		S100A9, LYZ, VCAN, FCN1, S100A8, CXCL8, CD14, MNDA, CTSS, AC020656.1, LGALS2, NEAT1, S100A12, MS4A6A, TSPO, CSTA, CEBPD, ATP2B1-AS1, CCL3, CSF3R, TKT, DUSP6, NCF1, S100A6, FOSB, RGS2, FGL2, NCF2, CYBB, KLF4, AC007952.4, FPR1, RBP7, IER3, CD36, APLP2, RETN, LGALS3, NAMPT, AIF1, BLVRB, PLBD1, SLC11A1, CFD, GRN, KCTD12, CLEC7A, GCA, TYMP, TYROBP, FOS, FTL, S100A11, ZFP36L1, MCL1, DUSP1, IL1B, S100A4, KLF6, IER2, NFKBIA		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 15 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		NRGN, RGS18, CST7, MPP1, IGKC, CCL5, JCHAIN, IGLC3, IGLC2, CLU, VCL, LIMS1, TPM4, PPDPF, TGFB1, IGHA1, TLN1, MARCH2, RGS10, RUFY1		gene expression	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 16 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		EPB41, RBM38, BAG1, UBB, HAGH, HBB HBA2 HBA1 HBD HBM SLC25A37 ALAS2 AHSP SLC25A39 SNCA GYPC CA1 YBX3 FAM210B GUK1 BNIP3L MXI1 SLC4A1 DCAF12 SELENBP1 FBXO7 FKBP8 RNF10 BPGM ADIPOR1 HBQ1 STRADB KRT1 FECH HEMGN BCL2L1 SMIM1 EPB42 08-Mar DMTN MYL4 GYPB TRIM58 NFIX IFI27 GSPT1 MKRN1 GLRX5 TENT5C BLVRB		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 17 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		EIF3JRASSF1NCOA3PTPRASEMA4DKLF10PARP8ARL4AANXA7RAB4A, CPNE1 CAMLG TMED5 TMEM14C PRDM2 PABPC4 XPO1 DYNLT1 ANKRD13D USP8 HOOK3 IL16 SSH2 ZC3H13 IDI1 CEBPZ CCDC107 MAP3K1 CTDSP1 HELZ INTS6 TSC22D4 UBE2R2, SLIRP EIF6 SNF8 NDUFS2 PSMB7 CYBC1 ETFB LSM10 KDELR1 SAT2 PRMT1 CNOT2 RBBP4 PABPN1 SHKBP1 ARHGAP4 IFNAR1		gene expression	down	cluster 18 (COVID-19 patients)			time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 18 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		ZFP36L2, SMCHD1 TRBC1 SAMD9 ARID5B, GIMAP7 CLEC2D NOSIP, IL7R IFI44L ISG15 LTB TRAC XAF1 MX1 CD3E IFIT3 LEF1 CD3G CD3D TCF7 IL32 MYC RCAN3 ETS1 CCR7 IFITM1 IFI6 SARAF TRAT1 PIK3IP1 EIF2AK2 MALAT1 RSAD2 CAMK4 ISG20 CD69 MAL LDHB IFIT1 SOCS3 LY6E ITK HERC5 TRBC2 TXNIP BCL2 MX2 CD2 OXNAD1 SPOCK2 SP100 TMEM123 CDC14A EPSTI1 EIF4A2 LCK STAT1 DGKA IFI44 ITM2A SELL DDX60 PIM1 PDE3B LEPROTL1 AAK1		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 18 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		MARCH1, CYBA SKAP2 ACTG1 PTPRE MAP3K8 HLA-DMB MYO1F CTSH AP2S1 SERF2 PTPN12 GLUL TNFSF13B ARPC5 POU2F2 FCGRT RAC1 CTSB TNFRSF1B TUBA1B PTPN18 FKBP1A SERPINB1 PLEKHO1 TPST2 ATP2B1-AS1 ILK C12orf75 IFI27 GPX4 PKM NAP1L1		gene expression	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 18 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		SOX4, LMO4AREGJUND,  SPINK2 CDK6 AC084033.3 FAM30A PRSS57 ZFAS1 NPM1 STMN1 SNHG7 ANKRD28 CYTL1 HSP90AB1 LAPTM4B EBPL NUCB2 NRIP1 HNRNPA1 MSI2 EGFL7 SMIM24 DDAH2 CRHBP CD34 MYB IMPDH2 NPR3 HMGA1 RACK1 GATA2 FAM117A IGFBP7 BTF3 ARMH1 MDK IL18 SYPL1 SSBP2 AL157895.1 BEX2 CLEC11A ALDH1A1 PDZD8 ATP8B4 FHL1 HPGDS HEMGN PTMS TCEAL4 MYL6B MSRB3 EREG TFDP2 H1F0 HINT1 EIF3E H2AFY SNHG8 EPB41L4A-AS1 APEX1 ANP32B LDHB TXN SERPINB1 C6orf48 CAT EEF1B2 EEF2 HIST1H1E HSPD1 ST13 HIST1H1D PNN TUBA1A YBX3 ID1		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 19 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		FAM107B, UPP1, TXNIP, MARCH1, REEP5, KLF2, CAST, AGTRAP, SMAP2, LITAF, MYO1F, PTP4A2, VSIR, GADD45B, CEBPB, GPR183, CLEC2D, IFI27L2, WDR1, SYNE1, HLA-DRB1		gene expression	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 19 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		STMN1HMGB2MKI67TUBA1BTYMSHIST1H1BTUBBPCNADUTH2AFZPCLAFHMGN2CENPFTOP2ASMC4GZMANUSAP1MCM7NASPRRM2RANCLSPNFABP5DEKTK1PTTG1HMGB1H2AFVHELLSASPMRANBP1ANP32ESMC2HSP90AA1ATAD2MCM5CENPMBIRC5DNMT1TPX2NUCKS1MCM4MCM3RPA3CENPUCARHSP1SNRPBDNAJC9HNRNPABLMNB1GINS2PRF1CKS1BSLBPDDX39AZWINTDHFRUBE2CHNRNPA2B1FEN1EBPNUDT1CDKN3USP1EZH2ATAD5PTMARRM1CCDC167HIST1H2AHPPIASNRPD1SMC3PFN1ANP32BGAPDHCACYBPLDHAHIST1H1DTMPOHIST1H4CJPT1ENO1SNRPGPA2G4UBE2SPSME2HNRNPFSLC25A5HOPXGZMBNKG7HIST1H1EHSPD1GNLYCTSWHSPA8HSPE1HIST1H1CIL32		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 20 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		CD79A, MS4A1, IGHD, CD79B, HLA-DQA1, RALGPS2, BANK1, IRF8, HLA-DQB1, TCF4, TCL1A, TNFRSF13C, CYB561A3, IGHM, CD74, CCDC50, HLA-DRA, HLA-DPB1, HLA-DMA, HLA-DPA1, HLA-DRB1, CD37		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 21 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		MZB1, IGKC, IGHG3, IGLC3, IGLC2, JCHAIN, IGHG1, ITM2B, SH3BGRL3, RUFY1, IGHA1, VCL, NCOA4		gene expression	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 21 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		S100A8 S100A12 S100A9 RETN AC020656.1 LYZ LGALS1 CD14 RNASE2 CXCL8 NAMPT VCAN CTSD PLBD1 CD36 TSPO MNDA FPR1 MAFB ACSL1 HIF1A PTAFR CSTA AGFG1 CTSB APLP2 MS4A6A SLC2A3 LTA4H MCEMP1 SLC11A1 NAIP THBS1 CKAP4 BCL2A1 CYP1B1 AHR SAMSN1 SGK1 GPCPD1 CAPG PGD ETS2 ANKRD28 KCTD12 MGST1 GCA CD163 MEGF9 ASGR2 RBM47 EAF1 BCL6 ITGAM CD93 CCR1 IL17RA CLEC7A SERPINB1 S100A6 SERPINA1 PLAUR CD63 NCF2 DUSP6 GRN CEBPD BRI3 CDC42EP3 CD55 VIM CYBB ATP2B1 METTL9 ENO1 S100A10 CTNNB1 SPI1 GAPDH FCN1 MCL1 CXCL2 ANXA2 CD44 SRGN IQGAP1 PGAM1 MYADM ATP6V0B RAB11FIP1 ANXA1 NEAT1 S100A4 ZEB2 G0S2 TKT ACTR2 CTSS EREG HMGN2 		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 22 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IL7R, GZMA, NKG7, GZMH, GNLY, CD3G, IL32, CD3E, CAVIN2 PPBP PF4 TUBB1 GNG11 MYL9 SPARC TREML1 CMTM5 NRGN CLU MAP3K7CL PRKAR2B CD9 F13A1 RGS18 CCL5 TUBA4A LIMS1 NCOA4 ODC1 CD3D		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 23 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		HLA-DRA, TSPOS100A10COTL1, LYN LGALS1 BLVRB FOS NPC2 APLP2 S100A11 MCL1 HLA-DPB1 ATP2B1-AS1 ANXA5 PSAP S100A8 NEAT1 S100A6, FGL2 LYZ FCGRT KLF4 NAMPT HLA-DPA1 NCF1 CFP CCDC88A BRI3 HLA-DMB RGS2 CTSB CAPG POU2F2 TKT TNFSF13B HLA-DRB5 JAML CEBPD TYROBP LGALS3 TYMP HLA-DQA1 RAB11FIP1 VIM S100A9 ANXA2 CYBB CD74 HLA-DRB1 MNDA SPI1 CTSZ 01-Mar LST1 CTSS FCN1 MPEG1 NCF2 HLA-DQB1 GRN IGSF6 HLA-DMA CTSH RNF130 AIF1 PYCARD SERPINA1 CFD		gene expression	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 23 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		CPVLC1orf54CLEC9AIRF8BASP1IDO1WDFY4SHTN1DNASE1L3BATF3CLNKFLT3CADM1NDRG2CCND1CCSER1HLA-DOBXCR1DSTSERPINF1ADAM28TLR10NET1CLIC2HLA-DQA1REPIN1HLA-DQB1CPNE3CAMK2DCSRP1HDAC9LGALS2KCNK6SLAMF7HSDL2HLA-DPA1HLA-DRAHLA-DPB1HLA-DMACD74HLA-DRB1CST3CIITAC20orf27HLA-DMBHMGA1SNX3GSTP1PPT1CSF2RARAB32HLA-DQA2CTSZPPA1ALDH2S100BASAP1FABP5LY86CCDC88AVIMRGCCDPYSL2CCDC6FCGRTS100A10FGL2ID2ACTG1FNBP1PTPREHLA-DRB5C1orf162PPP1R14BMARCKSL1H2AFYRNH1NAAAACTBRGS1NDUFV2LSM6GDI2BIDCOX5AC1QBPSUB1SPI1CD83LYZSLC25A6EEF1B2GRNSLC25A3LSP1UCP2SLC25A5PGLSSAMHD1TXN		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	cluster 24 (from COVID-19 patients) vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 1: top100genesPerCluster	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		RETN, IFITM3, LY6E, IFI6, NKG7, MT-DN2, LINC00937, SMIM5, CD226, LINC00877, RAP1B, LDLRAP1, TPT1, RPL26, CALM3, ZNF185, A1BG BTG1, SSX2IPPLA2G12AJUNBIFIH1BRK1ALOX5APSPATS2LALDH1A1CENPTLAMTOR1RPL35ASVIPPIK3AP1MGST1ENDOD1GM2ATSTFPR1S100A12PPP1R14AHIST1H3HAC020916.1FERMT3PFDN5B2MDDX60JUNCCL4COX6CRPS12RPS23TMSB10HLA-CCYBARNF11TMEM140FLNAAL360012.1VCANNFKBIZANXA4ENO1MNDAHLA-DPB1TUBA1CRPL21LRBAMT-CYBRPL18DOK2C12orf57PTBP3MGST3CFL1SAMSN1TOMM7TUBB4BMAFBCDKN2DZCCHC17HLA-DQB1RPL5IFNGR201-MarDDX60LCD164RAB32RPL19SDHDSNNRPA1HSPA6C12orf75EEF1A1NAIPTTC39CLARP7DDX58PPIBAC020656.1CNIH4RPS11SP110PSMB3ACTR2ANP32ASULF2LUCAT1LMNB1SNX2TMEM91DDOSTNMITNFRAB5IFCHMP5GBP1ZCCHC2AP000547.3ATOX1PTPRCLILRB2TMED9PTGS2RPL15ST14IRF1POMPUBE2L6PSMA4TMBIM6ABTB1IFIT2RDH11FAM110AZDHHC1VPS29DAB2AGPAT1H1FXERV3-1HMOX1YPEL5YWHAHLAMP2EEF2RPS7ABCC3S100A6SMAP2RPL7APIM1PMLTCN2ARHGAP18UBBSHTN1ATF3STAT2MCUR1H2AFJSTK17BLAP3PSMA3ACTN1DRAP1VIM-AS1B4GALT5FRMD4BF5BCL2L1PSMA7CAMTA1LGALS3BPDDX3XSUSD3TAGAPPSMB6ERO1ASAP30HIST1H1CUNC93B1NR4A2ARF6TXNVNN1WBP2EEF1DPTENSERPING1SLFN5SAMD4AHLXRPL23ANO6CD4EIF1BRPS29HNMTLMAN2SRIARHGAP21EZRPRDX3GIMAP4DUSP2ITGB1HLA-DMBSAMHD1HELZ2SH3GLB1CALRGNSMYL12ACTSLTNFSF10FLT3MT-ATP6ITGB7RRBP1NT5C2CD163EGR1PGAM1KDM6BUTYROMO1C9orf16MRPS18CMTPNRPLP0AQP9AC007952.4HLA-EORAI1KLF6THAP2NDUFA12LAPTM4AANXA5POLR2LHSP90AA1CAPN2NDUFB3BADNCKAP1LMAP2K1FAM20APRDX6ANXA6DECR1RPN2VDAC3RGS2LITAFCOX7BPAG1RPL7EIF5AMEF2AIFNGR1EFHD2MYL12BTNFSF13BHLA-DPA1RRAGAPDIA6FCGR1ASPI1CCR1ITGA1CCDC92TNFAIP2VEGFACAPGPLEKHO1KIAA1958ATP5F1CGSTP1ZNF638SMIM15TPST2SERPINA1BTG2SCN1BMETTL7BFLVCR2MYOFZFP36L2TCF4PDE4BACSL4SWI5GUSBPSMC2CES1CR1SCPEP1GMPRATP5MFWASRPL3FDFT1ATP5PDKCNE1STAB1IDH1PAK2CCDC88AIMPA2TRIM14VPS28BLVRBSNRPB2HPDAPP1UPP1STAC3ETFBDYSFSOCS3CNSTHACD4NUDT16RNASE1SEC61GTLR8FABP5MAP2K6CD37EEF1B2HMGN2CASP1CYB5R3LLPHPEPDSIGLEC14ANKFY1TMEM107PRDX1ORAI2ASGR2MAP4SENCRRPL35RAC2MT-CO2TMEM126BFGD4NRIP1MSRB1APBB1IPLEPROTL1AREGSEM1PANK2P4HBUBL4AMAP3K8SAV1RPL4MTRNR2L8SLIRPAP1S2ADMNDUFA3RB1SCAF11INF2SF3B6HCAR3OGFRL1ARID5BLY96RUNX1TMEM165LAIR1CXCL2RHOGDDAH2CAPZA1SMCHD1ISCUUBE2E3FGD2LRPAP1ZNFX1RIN2NDUFB9PSME2FESMYD88ID2MBNL1IVNS1ABPIFIT5SLC16A7SCARB2CTNNA1PIP4K2ALTA4HKLF9CPNE8CCNL1CD300ASASH3MT-ATP8ASPHFBXO6CBX6CD58COX8AUQCR10CPT1AIQGAP1CDC40MDH1BRI3EMC3ATP5MDKTN1CTSZKLF10DNAJC13GSRNENFPTPN6ERP44C3AR1CCNYSPNS1AC245014.3GLIPR2SLC25A36CARHSP1RGCCUBE2L3RPS2TRMT6CLEC12ACST7CPVLSLC39A3SQLEUSF2URI1MT1XRTCBMYO1GEHD4PSMA1PLXNC1MTHFD2TMEM14CN4BP1FKBP15XRN1SPINT2RRP7ASQORSLC9A3R1UBE2MTLR4JMJD1CCD14ZDHHC20PATL1MTFR1LFKBP1ATHBS1RAB4ARAB8BRAB10VAMP5MAP2K2LILRB3SMIM3SPPL2AMEGF9MOB2TLE3CRYL1AMD1TACC3ABCF1RBM3EMC7G0S2HSH2DGLAPCGF5EIF3FMS4A6ATMPORHOQTLK1YWHAZJOSD2CFPTNFAIP3SELENOFCATSPER1SDHBPPP4CPSMB2TMA7BACH1WIPF1PPIAPSMB1HSPA8NQO2NLRP3ZNF148LILRA6FPR2KLF7PLD3CATSKAP2SLC25A5MACF1DCTN2CCDC6SORL1SRRM1MIR29B2CHGCCNG1TMEM33HEXBANP32EPPDPFCSTBYPEL3LILRB1PMAIP1ARPC5LITGAMPLEKHB2RASA3ADIPOR1UBAC2ZBTB43CTSANAPRTEIF4ETBK1CD44BIN2CSF3RAPOL6TSPAN14HSP90B1DPYDSYNGR2ANAPC5SLATCF7L2GYPCLYL1TALDO1ALDH2ITGA4NDUFC2RAB11ADENND3EIF3LFCGRTKCTD20NORADEIF4BU2SURPCAPN1FCARIRAK3BASP1STX11PRNPMETTL7AMDM1CD79BPRRC2CCKAP4VDAC1CCDC186EIF2AK1AGTPBP1C1orf162POU2F2FKBP8SNRPBKIDINS220DNASE2IL17RACOQ7PPIP5K2HSPA1AMFSD1UBXN11ZNF281VMP1CDV3SLC25A37OGFRSTEAP4LINC01003AP2S1PDIA3ID1DNAJB6MAPK14ST8SIA4NFKB2SPG11AKR7A2TBPL1MDM2STK24WDR74ETS2FAM198BGLULUCP2CDC37LYPLAL1PYCR2GADD45ACYP1B1CARD19DGAT1RBM38PGPTMEM170BCLEC4AAC103591.3PLEKATP2C1ARHGAP45SOS2EVLNDUFAF3ATP2A3CMPK1MAP2K3RPS27LMPSTVNN2CYTORH1F0XPNPEP1NFE2PGLSLEPROTPCMTD1CDKN1AWDR1MAPRE2NDE1DNAJC4PTPN18MKRN1ETFAEMDIL13RA1STOMUBE2HAKIRIN2FFAR2EREGGSTO1RHOBSIN3BNEXNFAM118AHDAC5TIMP1GOLGA2DAAM1BLOC1S6SMARCA2,  TSPOAP1-AS1 TMEM176B PABPC1 GAS2L1 MLH3, MPP1 SNAP23, NFKBIA, TMSB4X, IER2, SOD2, CD151, PTGS1, ESAM, ODC1, CCL3, FOS, PGRMC1, NAP1L1, TGFB1 FOSB, CTDSPL, H3F3A, GNAS, NRGN, RPS14, LAT, NT5M, KLF4, PNRC1, GPX4, RPS3A DUSP1, SLC40A1, DYNLL1 RPL6,  RPS4X,  FAXDC2, PPP1R15A, RPL10, NCOA4, F13A1, RPS27A, SNRPN, RAB37, RPL13, ATP2B1-AS1, OAZ1,  RGS1,  RPS8,  MAX,  MGLL, SMOX Z93241.1 INAFM2 RPLP1 ILK CDIP1,  CYP27A1,  MGAT4B,  CD83 TPM4,  TLN1,  TAGLN2, FTH1 MT-ND1 LIMS1 SNCA, MARCH2,  EGFL7 IL1B RUFY1 KIF2A,  VCL MT-ND3, MAP3K7CL, RGS18, CXCL8, MMD, STON2, TSC22D1, HIST1H2AC MT-CO3 MT-CO1 HIST1H2BJ RGS10, ANKRD9, TPM1, OST4 CD9 SLA2 EIF1 NCK2 LTBP1 PARVB MEIS1 ITGB5 TUBA4A PDLIM1 FHL1 JUND C19orf33 GUCY1B1 SYTL4 TRIM58 SELP IER3 MYLK, AC147651.1 PDZK1IP1 CALD1 CLDN5 TREML1 MPIG6B HGD GP9 TUBB1 AP001189.1 HLA-DRB5 PTCRA CTTN TMEM40 CAVIN2 GNAZ C2orf88 CMTM5 MFAP3L AQP10 GRAP2 GNG11 ITGA2B MMRN1 AC090409.1 LGALSL RAB27B TMEM158 CCL5 PF4 MYL9 TSPAN33 PPBP SH3BGRL2 CLEC1B DMTN TNFSF4 XIST GP1BA CA2 AP003068.2 PRKAR2B ASAP2 GFI1B MTURN DNM3 PDE5A ITGB3 ENKUR ARHGAP6 SPARC TNNC2 TAL1 ACRBP PDGFA TGFB1I1 ELOVL7 BEX3, KLF2 ITM2B,  IFI35, USP18 TNNT1 H2AFY CSGALNACT2 RPS26 RPS4Y1 ISG20 PLIN2 SP100 PHF11 DBI STAT1 CTSB BLOC1S1 NOP10 AGFG1 HLA-A LILRA5,  MS4A4A HMGB2 APOBEC3A ADAR IRF7 SAMD9 S100A11 S100A10 ACSL1 S100A9 CREG1 HERC5 HIST1H1D SULT1A1 IFITM1 S100A8 APLP2 PARP14 LILRB4 SHISA5 DDIT4 PPA1 LDHA LGALS9 SSB DTX3L PARP9 CUL1 BLVRA,  PLAC8 IFI44L IFITM2 ISG15 MX1 IFI27 SELL XAF1 EPSTI1 MX2 IFI44 IFIT3 OAS2 RNASE2 LGALS1 OAS3 HIST1H1E EIF2AK2 BST2 CD63 IFIT1 PLSCR1 TYMP SIGLEC1 PLBD1 MT2A CTSD IFI16 RSAD2 FKBP5 OASL OAS1 JCHAIN CMPK2 HLA-B SPTLC2 TRIM22 LCP1 ANXA2 GRN ITGB2 SAMD9L TMEM123 CD53 RNF213		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	C MONO_IFN cluster/cluster 11 from COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFI27IFITM3JCHAINMT-CYBIFI6IFI44LMT-CO1MT-CO2JUNDMT-ATP6MT-ND3KLF2DUSP1MT-CO3MT-ND1S100A8JUNFOSMT-ND4IER2NCOA4TXNIPRPS14PDZK1IP1IER5JUNBEIF2AK2TIMP1SERTAD1ISG15ARL4CNR4A2RPL3XAF1MX1AC147651.1FOSBNFKBIAS100A9LY6EEPSTI1IFI44ITM2BHOPXNCR3HBG2ETS1MIR4435-2HGIRF7ACTG1RGCCSIVA1HBBHMGA1HLA-ESP100GNASTSPAN33CST3OAZ1DYNLL1IRF1MATKLYPLAL1RPL28CD81STAT1ATP5MPLATP2A3HSPA8CST7CD247PLSCR1SOCS3RPL10HIST1H2ACDDX6ANO6RPL36TNFAIP3HTATIP2N4BP2L1VIM-AS1MX2C4orf48TMEM123RPS21RPS3ARPL13ASELLMYCCLIC3KLF13ISG20GRK2ATMCYTORFCGR3AUQCR11SAMD9ANKRD44TRA2BMORF4L1PPM1KRARRES3BEX3SAMHD1DNAJC4FGFBP2MYADMTAGLN2CD5KLRB1NPM1HSP90AB1RPS26HMGB2USP16AP001189.1AIF1MALARHGAP9SP110CD3DRNF145ATF7IP2CD3GCCL5ITGB2ATP5MDSMAP2NKG7PAG1SLC40A1CYLDBAZ1ARPL36ADOK2SRRM2HIST1H1CHIST1H3HRBMXDDX21SETXPTGS1CYTIPCELF2PCM1MSL3FTH1PFDN1KLF6TMEM91FYNHSP90B1APPDDX60CD300ABCL2TRAT1JAM3MAZSTAT3NDUFA3NOP58IDSRRASHDDC2CRYBG1CBX5TUBA1BOGACMC1OXNAD1MTDHCREBRFKLF9ANP32ETOMM5NUB1YPEL5IL32FCER1GCCL4HCLS1SLC9A3R1IL7RGADD45BMYCBP2PPP1R10TBX21PRDM1PPP1R15ACD3ENT5CAPMAPITGA2BTUBB4BMED30EFHD2DTX3LTUBA4APAXXFNBP4EZRITGA6FGRCITED2GZMAGTF3AIFI16IL2RBTREML1ASH1LPPP1R12ATSHZ2FKBP11MT2AYPEL3SSR2SAMD9LANP32AIL6STARID5BZFP36GPRIN3STK17BTRDCERV3-1UTRNBLOC1S1RSU1FLNAMMDSPON2TYROBPSWI5EIF2AK1PDE3BRNPEPL1CAVIN2RNF126MAPRE2MYBL1GCC2DUSP2CCSER2CTSWHNRNPMTPM1PDLIM1UBE2STYMPRNMTTRIM22MGAT4BHLA-DRB1LEF1EXOSC6CCR7NUMA1EIF3AITGB5GYPCSUPT5HSELPHSPD1TUBA1CPOLR2J3.1R3HDM2MGAT4ABOD1L1ADARUIMC1IFITM1MSI2CXCR4ODC1AC044849.1PARP9BLOC1S6SERPINB1SLC4A7OSTF1TMEM140PIK3IP1DMTNNDUFB7HIST1H1DHIST1H1EPYHIN1SEC62CWF19L2		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	T cluster/cluster 23 from COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFI44LIFI27XAF1HLA-DRB5MT-ND3LY6EEPSTI1MT-ND1IFI44MX1RPS11RPS14RPL27AISG15SELLEIF2AK2RPL13AIFI6HIST1H1EHLA-ARPS20MT-ND2CDKN1CHLA-DQA2TOMM7RPL23RPS18FCGR3ARSAD2MBD2ISG20PLSCR1SP100MS4A7NR4A2TMEM123ADARTRA2BIFIT1IFITM1HIST1H1CSAMD9LMT2ALST1H1FXTXNIPIER5NDUFA3EIF5AHLA-DPB1RNF213HERC5HLA-DPA1JCHAINSTAT1SMIM25SAMD9FOSBCSF1RTRIM22IFI16HIST1H1DSOD2CD63MX2HLA-DRB1OAS2FTH1IFI35BST2TNFRSF1BCXCL8SAT1IRF7HMGB2PPA1IL1BIFITM3IER3PARP9TCF7L2AIF1PIM3NAP1L1TMEM156IFIT3IER2PRPF4BNPC2BRI3HIF1ACCND3FGL2FCHSD2CFDFCER1GFKBP5COTL1PECAM1IL32LDHBFTLDDIT4ARID5BPLAC8HSPA5CD3GAC020656.1BASP1CD3DIL2RGCCL4ETS1LGMNCTSDCD3EMTRNR2L8IL4RPPP1R14BTYMPLILRB4LGALS1APOBEC3A		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Cl21 cluster/cluster 21 from COVID-19 patients vs healthy   	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		TYROBP, RPL10IFI44LRPS14MX1IFITM3HIST1H1ELY6EIFI6XAF1RPL19RPL3BST2EPSTI1HIST1H1DRPS3ARPL36ANXA5JUNDISG15HIST1H1CEIF2AK2IFI44YBX3PLSCR1RPS11SAMD9LPARP9RPS10PRKG1FOSBIFIT1HLA-DRB1AVPAREGIFIT3RPL13ARSAD2OAS1MSRB3IFI16SP100RPL36AEEF1B2GNASATP8B4IFIH1TPM4TYMPJCHAINTCEAL4FOSH1F0YWHAEDDX60CEBPZEGFL7PROM1HSPB1STAT1MAP2K2TFPIIRF7ZFP36STOMMMRN1APPATP5MEMTRNR2L12MDKNUCB2SNHG25MT2AOAS2HBBADARNPDC1RNF213SPTLC2HNRNPDLTRIM22MIR181A1HGS100A8MX2SELLANKRD28HLA-AHLA-BSAMD9CD44APLP2IER5LAPTM4BRGS1PTMSMT-ND4LKTN1RPS17ZFP36L2MSI2S100A9PPP1R15APOLR2J3.1HSP90B1DUSP1KIF2ACD99MAZPPDPFH3F3BMLLT3GLIPR1SERTAD1IQGAP2CLUH1FXCDK6CST7FHL1SOD2CD9CNRIP1HSPD1SOCS2PRSS57HIST1H2ACIER2HLA-DQB1BCL11ANCOA7MGST1NEAT1SEC11ANR4A2CD7PRDX1PIM1NPR3MTURNBTG1IRF1JUNBCXCL8EREGGADD45BBEX1NFKBIACEBPBHPGDSYPEL5EVLARL4CTIPARPHPGDLTBCRHBPTNFAIP3FCER1GLST1AC044849.1VIM		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	HSC cluster/cluster 19 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		RNF213IFI6MTRNR2L12XRN1DDX24MX1ENTPD1TXNDC11IRF7TXNDC15ISG15TRAM1TP53INP1CSDE1GOLGA4ATRXADARSMCHD1PTPN2NCOA3ANKRD12SIL1SAMD9LHNRNPH1YWHAEIFI35SRP54PRDM1ROMO1RFC1MAN1A1CPEB4SCARB2AKAP9OGTSEC14L1SEC13MIFSLAMF7FNDC3ACLINT1ARGLU1FCRL5CNPY2MIR4435-2HGTYMPCD38GLSMYCBP2ATP5MEEIF4G2STAT1NDUFB6ST6GAL1ELL2SERBP1MSI2SP100NKTRGRB2MZT2BEIF5BSTK17BATOX1HERC2FBXW7C4orf3MDM4SYNE2NSD1SEC31APET10002-SepSCFD1SSR1GOLGB1MEF2CNDUFA3DSTNCASP3PLCG2DNAJC3MT-ND4LFKBP8COPANDUFB9FKBP2IFI27BCAP31TRA2ANDUFA11CAPZA1TMEM50APAPOLAMAGT1HNRNPDLEIF4G1SEL1L3WIPF1ICAM3SLC38A2CFLARMT-ND6KLF13TMEM256TCEA1VAPAEDEM2MED13LN4BP2L2NCF1TMC6ITGB7ACBD3RBX1IFI27L2METTL7APNISRPRKCSHPIM2AP2M1ACO2COPZ1SPTY2D1SRSF11TLK1ASCC3IFI16USP34PJA2MAP1LC3BLUC7L3UGGT1SEC24AKMT2CVPS13CNXPE3LILRB4JAK1IKZF3FMNL1UBR5CHPFCKLFTTC3VPS36TXNDC5BCL2L11ACTR2RBM39CBWD1PPP2R5CMDM2AC012368.1FUBP1COX7A2LPPA1EIF1AXATMRTF1AC007952.4PDK1ILF3HIPK2PPM1KTMEM156RPL17MARK3RBM26COBLL1PTPN1TCF4FAM133BGOLGA3CD2BP2BIRC6MBNL2SMAP2SPTBN1ASH1LBTN3A2ATP2A3ATP2A2TRAF3IP3IBTKFBH1SDF4CYLDGOSR2TPP2EBPLPCBP1PARP14ADAM10TMEM259CASP10CREB3L2CHMP4AUBA1SETBP1SQSTM1PLD3TNFSF10STAT2UQCC2LIMS1RSL24D1OS9RPL22L1HIBCHGCC2PSMD14APOL2RPS17TRIP12HSPB11SUZ12NCKAP1LZNF292ITPR2UPF2POLR2BAFTPHDUSP22ATP6V0A1XISTCHMP4BLSM14AARIH2TMEM87ACCDC32OTULINIRF4CEP128LMBRD1ARSAGOLGA2SGK1HDAC7IFI44AUP1EPB41CNPPDCD4EBAG9SELPLGPPIP5K2EML4ITSN2TRIP11RPL38ABI1WAPLHERC5ANKRD36BRIPOR2RBM5CTSATROVE2ZNF92NUGGCNAA20MON2PIM1MRPS34RNPS1CPSF6ARID4BSNHG25RPL27APDIA4ERP44LMO4OXR1TMEM208BLOC1S6CDC16NEMFB4GALT1AP3D1CTSDSPENMALAT1FKBP1AMT-ND3UBE2L3SOD1AC016745.2MRPL22SRSF7ACAA1MTRNR2L8CTSHTMED3RPS10BMS1APOL1PNKDKMT2ASRPRBNDUFS8THOC2ARID5BC1orf43DLG1TLN1APOL6GON4LSRA1CEBPZMCL1SF3B2PIGTTRANK1RASA2C19orf53UAP1GSDMDARHGAP15CLPTM1ARPP19TFRCTAP1NDUFA9SEMA4ATMCO1AP1G1MRPL57UQCRC1EMC3PAICSS100A11MSL3CRIP1PSMD2ZNF37ADAPP1VSIRSDHBTIMM17BLLPHCLIP1CTSSRABGAP1LITGB1ZDHHC12CCT5PRMT1NOL8VPS4BCHST2IFI44LFDPSHLA-AVDAC3MFFCCT8ETFATRAPPC1TMEM14BYWHAQCDK17UQCRC2MAP3K2MRPS11ARPC5LPSMC4IFITM1DBIPTK2BPMPCBHNRNPH3MRPS7RAB14TARSL2CLEC2DATP5F1EXRN2DAZAP2POLR2KNINPSMA4CHMP2ACHCHD1WDR83OSMRPL55OXA1LBUD31RAD21ANAPC11LAMTOR5PSMA7GLO1IMMTCALRRPL8NPC2GTF3C6PSMD4DPM2AC103591.3DUSP5MUC20-OT1MPC1LDHBTHOC7ARL6IP5CCT7MRPL40PHF3VAMP8MEF2AMAPRE1CCT4PTGES3SNRPCGLRX5NUDT22CLPPPOLR1DSNRPBRPL13GMPPBTSEN15BAK1HLA-CDDTEMC4YBX3CD47C19orf24C1DRAC1NDUFV2NUDCRBMXRAP1BFAM173AUBE2ICCDC167SRIHNRNPFIRF1ALKBH7PRDX2HADHAPUM1PSMA1TMEM30AACADMDECR1HSPD1SSBP1TNFRSF13BRANMRPL12SNRPENUCB2SAP18TKTIFNG-AS1DESI1GNB2ATP5POPLP2BLOC1S1SRSF9TRIREZRSUCLG1ERAP2DNAJC4SF3B6XAF1FUCA2MT-ND2ZBTB8OSSLC25A4CIRBPSMC1AHNRNPABRPL7ASRSF3BRK1PSMB6SLC38A5RPS27RPS26PTP4A2HARSMRPS23SARSRNF114LGALS1ECH1B3GAT3LITAFGNAI2RPS21TMED2UBN1ECHS1MRPL3GRK6CYB561D2ATF4HIST1H1ESLC25A5ISOC2CCT3GABARAPL2SNRPGATF5KRASRNASEH1PSMB3TMPOMRPL43SH3BGRL3SLC1A4ALG14SPTLC1NUDT5NT5CEIF5AMIA2HSP90AA1CD79ARPL37AZMYND8TUBA4ASIVA1PKMVPS51JTBRPL19MRPL37S100A8ENO1MAF1BANF1GLIPR1RALAPOLR2C09-SepHSPE1ITGAECYCSFLNAMRPL51ATP5MC1ANKRD39ATXN10FAM177A1H1FXCASP7PBX2ZMPSTE24PDCD10AP2S1HIST1H4CCKS2RANBP1MRPL4AP3S1ATF6LGALS3CNIH1HIST1H1DBABAM1RAB7ASLC25A39SMIM12ACTR10CANXRPS29NAA15LSM4ARHGDIBEFHD2HMGB2POLE4CHMP2BH2AFZCD99RPS14PPP6R3RASAL3ANXA11RPS27AZBTB20SNRPA1ATG4AFAM96APOP4HLA-DRAAPIPRPL18ASPAG7POLR2GCEP63NAMPTAIFM2ATICCDC25BNUDT1LYZNFYCDNAJC2SLC25A3FABP5JUNDUBE2SCFL1ATP5F1AMMP24OSHDGFPSMG2EIF3KSUMO2RPS12DAPK3SBDSRPL32CTBP1MCRIP2DUS1LARL14EPHMGN2ALDH3A2UBE2MPTMAELAC2HLA-DQA1RPS5ECI1RPS3APSME2DNAJC19COA6CSRP1GAPDHSTX11OSTM1TINF2G6PDTUBA1BLINC01480DFFAADKNUDT16L1RPS2B4GALT7VPS4AUBE2E1PITPNARPS3ABHD14BSTK38LSOD2KPNA2SHLD2KIAA1143APOBEC3GTACC1PFDN2CLNS1ATSPOFTLCD74TPI1SNHG15RAB27AS100A10NIFKMDFICFGD5-AS1APRTNFKBIASRSF8MYBL2GSTP1SRMGSTZ1CMTM6LDHAIFRD2RHOQKLF6PPOXHLA-DPB1TIMM50PRPSAP1ACTBPPP1R18EDF1NEDD9STX10STK25DDAH2BTF3CALM1RPL29RPL18TNFAIP3EEF2RPL30CEBPGSRGNCYBBRPS23MYO1FRPL15EIF1RPS4Y1UBE2J1RPL6HSPA8MBD2DAD1ADSSRACK1FAUGLUD1ACTG1DEDD2RPS13COTL1ATP5MC3HLA-DPA1		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	PB_1 cluster/cluster 13 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFI27IFITM3IFI44LJCHAINLY6ECLUIFI6SIGLEC1TYMPRPS3ARPLP1EPSTI1TMEM176BMT-ND3TPT1RPL10IFITM2RPL7RPS24RPL23EEF1A1LMNAHIST1H1ERPL9IFI44TMEM176ARPL21RPS27RPL27AAPOBEC3ARPL5RPS14RPL15PLAC8MT2ACD63MX1RPL13RPL29RPS27ARNASE2UBA52RPS11RPL6ACTBRPS2HLA-CXISTISG15EMP1TIMP1RPL23ARPS8HIF1AID2RPS13SH3BGRL3TNNT1EEF1B2RPL7ARPS26RPL13ABRI3CTSDCFL1CFDSELLOAS3HBEGFRPS4Y1HIST1H1DRPL3OASLMIDNXAF1RPL38MT-ND2MAP3K8TOMM7SPI1DUSP2RPS6IRF7RPL4HLA-DPB1RPS20PSME2ZBTB43RPL27NKG7ZFAS1EEF2KLF10TPM3GRNCD14RNF213S100A10MAFBMTRNR2L1DDX3YEIF2AK2RPL10APPDPFTXNIPSTAT1HLA-DQA2EIF3LRPLP0NAMPTHIST1H1CGBP1TLE3IFIT3PLAURDNTTIP2NAPAEAF1BLVRANAP1L1CYP27A1MIR22HGLGALS1AC020656.1AC007952.4RGCCG0S2EIF3EPKMEIF4BJAMLGRASPPLSCR1EMP3ID1LILRB2S100A8PARP14TPM4SAMD9LCBX6SLC11A1BST2FCGR1AMBOAT7SEC11AMT-ND4LHLA-DPA1UBE2L6EGR1GIMAP7ADARSECTM1KLF4SPAG9FMNL1AFF4RBP7CEBPBCSRNP1H2AFJCTNNB1UPP1MXD1EIF5ATRA2BOAS1P2RY13SAMSN1RSRC2KCTD12H1FXCCR2CR1SNHG8MX2ACSL1FRAT2CYP1B1TRIM22CD36ETS2S100A9ALDH1A1HLA-DRAHNMTIL13RA1LSM6SLC25A37NR4A1CD300EIER3WARSLGALS2AC103591.3CXCL2KIAA1551CCL3SGK1RETN		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	C MONO_1 cluster/cluster 3 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		MX1RPL10IFI44HIST1H1EIFI44LMIR4435-2HGEPSTI1IFI6EIF2AK2RPLP1XAF1SMCHD1RPS27ASP100YWHAEOAS1RPS14HNRNPUMT-ND3PAXBP1IFITM3HBBOAS3SPATS2LHERC5KLF2STAT1RPL23AIFI27USP18TYMPHIST1H1CMX2IRF7SMC1APRPF4BPLSCR1CCZ1ISG15ADARRRBP1HSPD1HIST1H1DLAP3ACADVLRPL13ALGALS1DDX11IFIT3HIST2H2ACEIF5AZFC3H1IFITM1HIST1H1BMCM4ANKRD36CLY6EKLRB1DDX21XISTFBXO5RNF213CTSBKNL1N4BP2ARL4CTPRNRGNSAMD9LTIMP1SELLSFPQHCSTBST2CD160MAFFHOPXRPL27AJUNBHIST1H2ACSRRM2TYMSMKI67LAIR2MBPCD81ISG20H1FXMYOM2AREGCTSZCMC1HLA-DPB1CCL4GIMAP7PLCG2AKR1C3MT2APMAIP1MATKS100A8HLA-DRB1ZNF22FCGR3ATOP2AASPMPDCD4FGFBP2GRNPRSS23CLIC3PSMB8-AS1DOK2TSTD1TRAF3IP3RPS4Y1GZMMAPLP2ZFAS1		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	BASO cluster/cluster 20 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFI44LLY6EISG15XAF1MX1IFI27PIM3EPSTI1ISG20EIF2AK2IFI44B2MHLA-DQA2STAT1BST2MT-ND3USP18HLA-BHLA-ASAMD9LPARP14PPP1R14BRPLP0RPS11ZFP36L2PLSCR1HLA-DRB5MT-ND1VIMMX2OAS2SP110IFI16HLA-DRB1COX5AUBE2L6TYMPNPC2LGALS9RPS14PTMAADARMT-CO1RPS18HLA-CMNDAHLA-EHSH2DHERC5TCL1AANXA5FCHSD2HIST1H1EPARP9TNFSF10LAP3FCER1GOAS1CAPN2IFITM2PLA2G16H3F3BBRI3DDX60GNASHESX1UBE2E3C12orf75TRIM22CD38CCDC50SP100JUNDIFI6SEC61BMS4A6AIFI35RPL23VEGFBSRGNPYCARDS100A8HIST1H1CPHF11CLIC3SPATS2LNT5C3AS100A9RPS20SAMD9HLA-FC19orf66DRAP1LGMNMYADMTXNIPGALNT2FXYD5HIST1H2ACNAPAHIST1H1DSTAT2GZMBDDIT4GLULSELLMIF4GDTAGLN2PLXNA4TAP1CLEC2BSH3BGRLNMIDUSP22PTCRAARL4CSLC20A1AC020916.1PDIA6TSC22D1PSMB9CD4RGS1CTSHTBC1D4ZNRF2IDSDUSP5CUEDC1PTPREDNAJC15MYBL2GUK1CYP46A1MGLLPMEPA1FCGRTGLRXSOX4XRN1RASD1CRYMCDK2AP2TMEM8BC12orf45SLC1A5ALCAMHLA-DQA1KDM6BDRD4C12orf57S100A10CD63H1FXRUBCNGADD45BSCTTSPYL2AL355075.4ID1CD52		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	PDC cluster/cluster 10 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFI27IFITM3JCHAINIFI44LCLULY6ETPT1MT-ND3SIGLEC1IFI6HIST1H1EEPSTI1RPL27ATYMPRPS3ARPL21RPL23RPL7IFI44HLA-CRPL10RPLP1MX1HIST1H1CRPS27OASLAPOBEC3ARPL38MT2ATMEM176BRPL9RPL23ARPS26HIF1AXAF1RPL34RPL13ARPL37RPL6RPL26ISG15CD63RPS11TMEM176ATOMM7RPL15RPS27ARPL5ACTBRPL3EEF1A1LGALS1SAMSN1EEF1B2DNTTIP2PDE4DRPS20IFITM2RNASE2PFN1TNNT1RPS2RPL24SH3BGRL3G0S2HIST1H1DRNF213RPS29RPS14IFIT3NAPARPL37APSME2XISTCFL1PPDPFTPM3HLA-DQA2RPS6BCLAF1RSAD2RPS4Y1PSMB10RPL10ALMNAPKMIRF7RNF19APSMB3LST1HBEGFID2RPL4DUSP1SMCHD1RPL31MTRNR2L1CTSDSYNE2BRI3RRBP1SP100STAT1SLC11A1CEMIP2BST2EIF2AK2MAP3K8TIMP1JUNBFCGR1ASERP1MIR22HGIFITM1GAPDHAC007952.4PLSCR1LDHATPM4EML4SLC25A36IL32DYNC1H1GIMAP7DDX3YAFF4SMIM25FGL2ETS2IER2H1FXLGALS2UPP1PIK3R1S100A10MXD1TLE3ZEB2DDX21EIF3LCYP27A1EMP3PNPLA8KLF4S100A8ZBTB43RHOGSELLPLAURGIMAP1PDE4BSUPT16HEZRLGALS9RHOBGPRIN3ALDH1A1LTA4HRPL36ACTNNB1CXCL2PARP14CEBPBTUBA1ARBP7HNMTLILRA5BCL2A1GBP1AC245014.3PLAC8ZFP36L1ETS1TRA2BAREGNCF1CFDHLA-DPB1MTRNR2L8KCTD12MAFBTRGC2DUSP2HLA-DRB1NAMPTGZMHCD14HLA-DRAVAMP5HLA-DMBS100A9IER3PTGDSNKG7AC103591.3CTSWCCL5CD3GGZMBKLRB1HLA-DPA1		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	C MONO_2 cluster/cluster 16 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		JCHAINRPS3RPS2RPL13RPS3ARPL10RPL3RPS27ARPS18RPS14MT-ND1RPS12RPL29RPL21RPL19IFI44LTXNIPXAF1RPS9RPS19TPT1RPL23ARPS23RPS7RPL7ARPL34RPL18MX1RPLP2RPL11MT-CYBRPS6RPL26MT-ATP6RPL10ARPL13AEEF1B2EEF1A1IFI6RPL9MT-ND3EIF2AK2RPS8RPL18ARPL27ARPL7NACAMT-ND2RPS20HIST1H1ERPLP1RPS11UBA52MT-ND4IER5RPL4RNF213MT2ASP100NFKBIAETS1TOMM7MT-CO1DUSP1FOSOAS1ISG15JUNBJUNDIRF7SYNE2RPS5EPSTI1PIK3R1SMCHD1ISG20HLA-DRB1MBNL1LY6ESAMD9LRPLP0IL32DDX6RPS4Y1PRPF4BSAMSN1PLSCR1PARP9CLEC2DUTRNSTAT1ADARSAMD9RIPOR2JUNIER2IFI16SYTL3HNRNPUDDX24LCP1SERTAD1MYBL1SAMHD1RPL23TRIM22MX2SRRM2RNF125VPS13CSF3B1SAMD3GZMBBTN3A2RBM39HCLS1RGCCSLFN5HIST1H1CUSP15HOPXHNRNPA3DTX3LIFITM2ATMTRGC2ITGA4SP110PRF1KIAA1551ALOX5APMACF1PLAC8SYTL2CEBPZXCL2AKAP13HNRNPH1XISTCTSWARID5BSYNE1FLNAPRRC2CWIPF1BZW1PARP8IRF9BTG2MYADMHIST1H1DIFITM1GNLYPDE3BSLFN12LOASLNDUFA13PYHIN1PDE4DZBP1TNFAIP3PTPN4EPB41DOCK8IQGAP2TYMPDDX17KTN1CAPN2RPS26ELF1MYO1FSH2D2ATRBC1PARP14TMEM123ATG2AOGABST2KIAA1109CD2SELLDOCK10ATF7IPCEMIP2MTRNR2L8GADD45BPHF11AKNAMYH9ARAP2APOL6EML4N4BP1IFI35KLF3S100A11LTBH1FXIL7RIFNGKLRB1KLRD1GZMK		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CD8 cluster/cluster 2 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFITM3IFI44LLY6EJCHAINMX1XAF1ISG15IFI44RPS14RPS11IFI27IFI6RPLP1HLA-DRB5RPS18ISG20EPSTI1RPS12IFITM2STAT1RPS3ARPL13RPL29RPL23AIRF7RPS23RPL10RPL18AHIST1H1EHLA-DQA2SP110RPL27ARPS20RPS6EIF2AK2COX5APARP9RPL7ARPL13AUSP18HLA-DRB1OAS2HLA-DPA1B2MRPL23UBE2L6RPS7KLF10RPS2PPA1RPS25SAMD9LRPL3RPL24BST2MX2LAP3RPLP0BRI3CAP1TYMPRPL27RPL7PIM3HLA-DPB1RPL35EEF1B2MCL1GMPRPPP1R14BPARP14LCP1TXNIPPLAC8ADARMAP2K2HLA-BPHF11HNRNPA2B1SMCHD1CD164RPL31TPM3IFIH1PRPF4BDRAP1H3F3BSHTN1DDX21TPM4IFI16NAPAPLEKHIST1H1DMTRNR2L1DDIT4CNDP2PTPRCSRP14MBD2CALRHSP90B1HLA-DQA1HLA-ASEPHS2HIST1H1CHSDL2PSME2PDIA3IFI27L2TRIM22PLSCR1IFI35EFHD206-SepHSH2DFCHSD2HNRNPUNAMPTHSPA5MEF2AHNRNPCSUB1SPAG7CHMP5IRF8RPL38FNBP1IDH3ASAMD9SSBWASRHOASPATS2LCACYBPCD53HCLS1IER5PSMA3RPS26CCDC6DNAJA1CAPN2CDV3SP100TRA2BNOP53BIDCNN2YWHAEHSP90AA1VMP1DEKHMOX1STK17BNDUFV2C6orf48C1orf21EZRFABP5SELLMNDASRP72YBX3TSPAN33HDAC9SRSF7CEBPDDDX3XS100A11TSC22D3XISTMTRNR2L8BTG1ZFP36GPR183		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CDC1 cluster/cluster 24 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFI44LIFITM3JCHAINMT-ND3MX1IFI6XAF1HIST1H1ERPL27AMT-ATP6MT-CYBRPL13ARPL10EPSTI1MT-ND2ALOX5APRPS3ARPL3HIST1H1CGZMBRPL21IFI44MT-ND1HLA-CRPS14EIF2AK2OAS1MT-ND4RPS27RPS6LY6ERPL13TPT1IFITM1IRF7RPS20ISG15CEMIP2MX2MT-CO1MT2ARPS18ISG20RPL23AAREGHLA-DRB1RPL7PDE4DGIMAP7SYTL3RPL38RPL9IL32HIST1H1DRPLP2RPL37ASTAT1RPL27TYMPRPS11LAIR2PRF1SAMD9LXISTPLSCR1HLA-DPA1KLRB1EEF1B2MT-ND5GAPDHPIK3R1OAS2ATG2ARNF213LGALS1PARP9SMCHD1KLRC1SP100CTSWIRF9CD52BST2ADARRPS9PRKXMTRNR2L8LGALS9SLA2GNLYETS1SH2D2AH1FXCD38MYOM2PSME2CD74IFITM2SEC14L1ITGA4FOSBCD79BTCIRG1SP110CREMTRIM22MIR4435-2HGSAMD9HLA-DPB1MAP3K8ZBP1RPS4Y1PRPF4BFBXO7PSMB10TOMM7CAPN2USP15SYAP1SYNE2IFI35TXNIPUTRNFLNAHNRNPUS100A10RAB5IFPTGDSFXYD5ARID5BUBE2L6DDX6GNASSTAT3EML4CCL4TGFB1TAP1JUNBSRRM2TMEM123PPDPFOGARPL23DTX3LTRA2BSELLTSPYL2ZBTB1HSH2DSETXCEBPBHSPA5CLIC3ATF7IPHMGB2CD160SFPQGZMHMT-ND4LCCND2TNFAIP3PARP14IFI16S100A11PTGDRTUBA1BPMAIP1CALRZFP36LYZIER5PLEKHF1BAXCOQ7NFKBIA		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	NK cluster/cluster 1 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		JCHAINIFI27RPL10HLA-DPA1HLA-DPB1TPT1IFITM3MZB1RPS27RPS2HSP90B1RPL21RPS3ARPS24CST3EEF1A1RPL30RPS27ARPL13RPL26RPL11HLA-DRB5RPL34RPS14RPS20RPS18RPL29PFDN5RPS9HIF1AUBA52CD63RPL24RPL37MT-ND3RPL23ARPS12RPL5TOMM7NACARPL12RPL19RPL9RGS2RPL38RPS6MALAT1APOBEC3ARPL37ATMEM154RPL13ARPL27RPL4RPS16LY6ECDKN1CRPL6FCGR3ACALM2RPS29RPL14RPL8EEF1B2FGL2SMIM25SUB1TMA7HMGB2JUNBHLA-DRAAIF1TYROBPISG15RPL10ASNHG25RPS23IFI6RPL23SELLRPL18NAP1L1C1orf162SNHG8MAP3K8CTSSCTSDPER1COMMD6RPL22WASF2MT2AGLRXRPS3DUSP6RPL27ANDUFB2CPVLFOSBNAMPTATF4RPL3CXCL8P4HBCARD16CASP1XISTRPL31HSPA5CSF1RUBALD2CYBBBTG1HMGN1TNFRSF1BIL1BXAF1ZBTB7AARRB2PLAC8UQCRHLDHALYSTRNF213TRABDEIF3HC5AR1PPIBCALM3SDCBPFCGR2AIFNGR1ANXA1OSBPL8LIMD2EVI2BAHNAKSRSF10PLCG2SLC25A6SF3B1IRF7SPCS1GPX4CLEC7AM6PRPOLR2J3.1KLF4SPCS3CD164HNRNPH3MS4A7PSMB1MYL12BFMNL1LGALS3SKAP2RAC1NAGKPSME2ARF6HSPA8OGTH2AFZTUBA1BCXCR4MTDHSSR4AC103591.3USP3LTA4HLAP3LGALS1EIF3ESEC61GEIF3LGLULUQCRQCDKN2DSPNS100A9SELPLGARF1TYMPS100A8		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	GRAN cluster/cluster 9 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFI27, IFITM3, IFI44L, IFI6, LY6E, RPS3A, RPL3, RPS18, RPS14, RPL13, RPLP1, RPS2, EEF1B2, TPT1, RPL9, EEF1A1, RPS6, RPS27A, RPL13A, RPL10, RPS11, RPS8, MX1, RPL27A, RPL23A, TYMP, RPL23, RPL7, RPS24, RPL7A, JCHAIN, IFITM2, RPL21, XAF1, RPL18A, RPLP0, EPSTI1, RPS16, RPS20, RPS23, RPL29, RPL6, RPL15, RPL10A, RPL5, RPS7, IFITM1, IFI44, RPS3, RPS12, ISG15, TOMM7, MT2A, RPL24, RPS26, HLA-DRB1, PLSCR1, IRF7, HLA-DQA2, RPL27, RPL37A, HLA-A, EIF2AK2, ACTB, RPS5, RPS27, PFN1, HIST1H1E, KLF10, RPS4Y1, EIF3L, IFIT3, RPL38, HLA-DPB1, MTRNR2L8, TPM3, SELL, RNF213, UBE2L6, ARPC1B, OAS2, RPL31, STAT1, MT-ND3, MX2, SAMD9L, CLEC10A, OAS3, HIF1A, BST2, HNRNPU, XIST, PARP9, SEC11A, PARP14, PSME2, NOP53, PDIA3, PPDPF, NAMPT, EIF3F, NAPA, RBM39, CUL1, EIF3E, AC020656.1, DDX3Y, PKM, LST1, CMPK2, LGALS9, PIM3, BRI3, CCND3, ZFAS1, MBOAT7, TRA2B, RHOG, SP110, LAP3, EIF5A, STK17B, CALR, HIST1H1D, HLA-DPA1, HIST1H1C, GLIPR2, ISG20, IFI35, TOB1, BATF3, PTP4A2, SAMHD1, HLA-DRB5, CCL3L1, SNHG8, CLK1, PSMB9, ADAR, HSP90B1, ZYX, JUN, ZFP36, MS4A6A, CD63, TIMP1, SAMD9, OAS1, SNHG15, SH3BP5, CTSD, DDIT4, FOS, GBP1, TPM4, H1FX, RNASE2, FCER1A, NEU1, HLA-DQA1, CFD, MAP3K8, HSPA5, ATF3, YBX3, AREG, GRASP, NEAT1, IER2, EREG, DUSP1, CCL3, S100A9, S100A8		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CDC2 cluster/cluster 5 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		RPS14, MT-CYB, RPL4, GBP4, RPL10, RPL3, IFI44L, NIFK-AS1, RPL7A, RPS27A, TPT1, JCHAIN, RPLP2, RPS3A, MALAT1, MTRNR2L12, RPS8, MBD2, AC133644.2, CCDC167, EXOSC6, YIPF6, RPL13A, MT-ND3, HAPLN3, ANXA1, HSP90AB1, OAZ2, RPL19, CNBD2, MKRN2, ACTR6, SIAH2, GTF2B, RPS2, RPS20, CYSLTR1, SRSF5, MT-CO1, PTMA, LRRC59, CCND3, IFIH1, RPS6, RGS1, LPAR6, IFI27, DDX5, EEF1D, FAM50A, PFDN5, RPS3, GBP5, OASL, RNGTT, TRA2B, ST8SIA4, RPL10A, ADAR, RPL21, HNRNPDL, ACAP1, RIPOR2, PPCS, SH3YL1, TAP1, XAF1, HIGD2A, H3F3A, MOB4, RPS11, CCT4, RPS4X, BCL2, IFITM1, FOXO1, RPS18, KLF2, FTL, TXNIP, ARGLU1, H3F3B, CYTOR, MRPL21, CTDNEP1, PYCR2, ARL4C, ATP5MG, ATP2B1, SMAD3, RPL27, PSMB9, UBTF, PAK2, METTL26, LAMTOR5, RGCC, DECR1, S100A9, DCPS, TXN, ILF3-DT, SELL, NDUFS6, SLTM, SH3BGRL3, SELENOT, RPL5, BRD7, PRKCSH, UBA52, SVIP, SRGN, TMEM123, IDH2, ATP5PF, NCBP2-AS2, C11orf58, ACYP2, UXT, KLF6, HINT1, WASHC1, CDC42EP3, HMGN1, TNFAIP3, SRRM2, SDHC, IFIT2, GLRX3, ORAI1, STAT3, JUN, C19orf24, MYC, CEBPZ, FAS, ZCCHC7, IFITM3, PLGRKT, RNF114, GZMA, EIF3H, DUSP1, GBP2, TPP2, GNB1, YME1L1, HNRNPUL1, CDC26, EIF4A2, FAAP20, HLA-DPB1, SFXN1, SNHG25, TOMM7, SLC25A6, KLF9, PIM1, PPP1R2, RPL36A, RASGRP2, PNISR, SOCS3, GBP1, GLIPR1, TSPO, BTN3A3, CWF19L2, LRPAP1, EIF3F, CASP4, CD3D, CHD2, IDS, LAPTM5, SPCS3, COX5B, SEPT7, PRDM2, FAM133B, ITM2A, PSMA3-AS1, ARHGAP15, CD82, CDKN2D, ATP5MPL, SDAD1, RAP1A, ANP32A, ACTG1, RPL27A, EPB41, NDUFA6, MDM4, SMG1, KRTCAP2, HSPE1, VSIR, IL7R, CD99, SATB1, NAE1, RBMX, STAU1, HNRNPH1, HNRNPH3, CDC25B, ARHGAP9, SLC4A1AP, RNASEH2C, DYNLL2, TRIR, SSU72, PCM1, NIPSNAP2, ZC3H7A, COMMD6, CD63, IFRD1, HNRNPL, ACTN4, NDUFA13, SUN2, KIF2A, PDE3B, ARPC2, HIST1H1E, PIK3IP1, BSG, ZFAND5, PFN1, TTC37, MAP3K1, YIPF4, TRIM44, PPP1R18, KMT2E, LAT, RAB8B, DNAJB1, PRMT2, CFDP1, TCF7, RORA, COL4A3BP, NMT1, PPP1R15A, MIF, SNRPA1, R3HDM2, ISG15, LAP3, TMEM173, ILF3, POLR2J, MZT2B, STK38, STK17B, RAB8A		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	T_IFN cluster/cluster 18 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		HBA1, HBA2, HBB, ALAS2, AHSP, IFI27, SLC4A1, GABARAPL2, ATP5F1E, HBD, GUK1, GSPT1, UBB, GLRX5, MPP1, GMPR, ADIPOR1, WNK1, SELENBP1, RNF10, ISCU, NCOA4, ANP32B, FTH1, YPEL3, BCL2L1, HBM, R3HDM4, OST4, FIS1, SIAH2, GYPB, DMTN, HAGH, CCNDBP1, TRIM58, PRDX2, HBQ1, EIF2AK1, RBM38, BLVRB, MAP1LC3B, SKP1, DCAF12, BSG, TERF2IP, EPB42, TALDO1, PRDX6, MARK3, PPP1CB, PIM1, TMOD1, MXI1, ODC1, SEC14L1, SNCA, HPS1, YBX3, CA1, PA2G4, FKBP8, KRT1, MAP2K3, WASF2, FOSB, POLR1D, EIF1B, CHPT1, MARCH8, RPIA, MICAL2, METTL9, NFE2, WDR45, FOS, ISCA1, MKRN1, FECH, RBX1, TESC, RAD23A, LPIN2, FAM210B, OAZ1, STMP1, HK1, CDC34, ASCC2, S100A9, JCHAIN, ANKRD9, SMIM1, MTRNR2L12, SMOX, SELENOK, PNP, VTI1B, SLC25A37, DCUN1D1, NPRL3, ANK1, H2AFJ, S100A8, TUBB2A, EMC3, CDKN2D, ACP1, UBXN6, UQCR11, TOP1, ARF1, UBA52, DDX5, HIST1H1C, ELOB, MARCH2, RPL29, LYL1, RPL36AL, SH3BGRL3, SLC25A39, PCGF5, PCBP2, RPL21, IFIT1B, OSBP2, KLF3, EEF1A1, RPL10, NEAT1, RPS28, RPS9, TSC22D3, RPL13, PABPC1, RPS3A, RPL12, UBC		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	RBC cluster/cluster 17 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		HLA-DRB5, TXNIP, MT-ND3, ABCA6, MT-CO1, MT-CYB, MT-ATP6, RPS14, MT-CO3, HLA-DPA1, JCHAIN, IFI44L, BTG1, CD27, CCDC88A, MT-ND4, RPS7, MT-ND1, ACTG1, RPL6, RHOC, MT-ND2, XAF1, HLA-DRB1, HLA-A, TRAC, HSPA8, TSC22D3, MTRNR2L8, MX1, TRIM22, RGS1, HLA-DPB1, RPL4, EPSTI1, IFIT3, EIF2AK2, RGS10, SP100, UBE2M, EEF2, VOPP1, MBD2, ARL4C, IFI6, HLA-DQB1, MTRNR2L12, RAB11FIP1, LY6E, BIRC3, S100A4, RPS10, LINC00926, S100A6, DDX5, CYBB, TMEM123, TRA2B, TNFRSF13B, YPEL5, SRGN, HLA-C, ZFP36L2, GNAS, ISG15, ANXA2, TOMM7, BRK1, SMAP2, AHNAK, SMARCB1, LITAF, EIF3L, ISG20, AC007952.4, GABARAPL2, BANK1, ANXA11, MT-ATP8, GPR183, CLIC1, SMCHD1, RGS2, CLEC2D, RNH1, COTL1, RNF213, DYNLL1, SAMD9L, DDX24, MEF2C, AC245014.3, CXCR4, CCNL1, LGALS1, HIST1H1E, H3F3B, CYB561A3, GAPDH, STAT1, H1FX, LTB, HIST1H1C, HIST1H2AC, RHOB, PARP14, SRRM2, ADAR, PRPF4B, VIM, IFITM2, APLP2, S100A8, RIPOR2, MDM4, IRF7, MYC, TAPT1, MX2, FCHSD2, DDX21, MBNL1, UTRN, BCL7A, ETS1, REL, SP110, SAMD9, HIF1A, TCOF1, DDX6, HNRNPH1, COL19A1, TMEM156, IRF8, S100A9, P2RX5, ITPR1, SF3B1, CSNK1G3, ITGA4, EIF5A, USP15, PIK3IP1, SRSF10, TP53INP1, EIF1B, VPS13C, ILF3-DT, CD22, PPM1K, ATF7IP, BST2, SNHG9, SP140L, SELL, TYMP, ELF1, CNOT1, DUSP22, AFF3, TRA2A, PLCG2, MACF1, IL4R, LYST, IFI16, HSH2D, STK17A, ATP2B1, SNX29, ZNF92, ADAM28, JUN, COBLL1, NFKB2, CEMIP2, ASH1L, PAX5, CD69, CLK1, CDK12, MZB1, FOS		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	B cluster/cluster 7 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFI27, JCHAIN, IFITM3, RPL10, RPS27, RPL9, RPS2, TPT1, RPS18, RPS3A, TMSB10, RPS6, TMEM176B, HLA-DRB5, RPL27A, RPL13A, RPL13, RPL23A, EEF1B2, EEF1A1, RPL15, RPL3, HLA-DQA2, CD63, RPL10A, RPL21, RPL27, RPL18A, RPL23, RPS20, HIST1H1E, RPL34, MIDN, LY6E, RPL5, RPS9, HLA-DPB1, RPL7, RPS4X, RPL12, TNNT1, FMNL1, LILRB2, RPS11, HES4, NAMPT, RPL6, ELL2, RPL29, TMEM176A, TOMM7, APOBEC3A, KLF10, RPLP1, RPLP0, RPL4, PPDPF, FTH1, RPL38, RPS3, NEAT1, TPM3, RPS5, RPL35, MT2A, BLOC1S1, ZBTB7A, RPL37A, HLA-DPA1, IFITM1, IFI44L, MT-ND3, PIM3, HIST1H1D, ADM, MALAT1, CFD, GRASP, CYP4F22, LILRB1, SNHG15, GIMAP7, IFI6, ARF5, CDKN1A, MYO9B, ULK1, NFKBIA, ANXA4, CD48, TCIRG1, RPL31, TIMP1, S100A9, MTRNR2L1, CTSH, CCNL1, TRA2B, CTNNB1, AC020916.1, IFI30, NKG7, POLR2J3.1, MAP1LC3B, SLC43A2, MDM2, AFF4, LENG8, EPSTI1, SNHG8, FUS, EIF4G2, LSM6, CDKN2D, MAP3K8, FOXO3, ISG15, P2RY13, DYNLL1, EP300, ATF3, CCDC85B, RNF144B, CSRNP1, NFKBIZ, MIR22HG, BCLAF1, CSTB, TUBA1B, HLA-DRA, ANPEP, CTSD, KLF6, RSRC2, AC020656.1, TMC6, FAM45A, MNDA, CLK1, ZFP36, PIK3AP1, CXCL16, ATG2A, CREBRF, TACC1, CALM3, ADAM10, CPVL, RHOC, G0S2, SCGB3A1, C1QB, GLUL, CD300E, LILRA1, H1FX, XAF1, TNF, RPS27L, GNLY, ID2, JUN, C1QA, LYPD2, IL1B		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	NC MONO cluster/cluster 4 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		JCHAIN, TPT1, MT-ND1, MT-ATP6, MT-ND3, RPL13A, TOMM7, IFI44L, MT-CYB, MT-ND2, RPS11, RPS20, ETS1, RPL27A, TXNIP, ANXA1, DUSP1, RIPOR2, MBNL1, RPS4Y1, IER5, HIST1H1E, BCL2, DDX6, SOCS3, RGCC, XIST, RPS26, TNFAIP3, RNF213, STK17B, SELL, XAF1, MYC, HNRNPU, TXK, TRA2B, SMCHD1, IL32, PRMT2, DDX24, EPB41, SFPQ, ARGLU1, CXCR4, SRRM2, PRRC2C, ARID5B, HNRNPH1, MTRNR2L12, STAT3, PIM1, ITGA4, ATM, PRPF4B, OXNAD1, MX1, PIK3IP1, LY6E, PDE3B, DDX21, NORAD, S100A4, IKZF1, IL6ST, LEF1, SATB1, SRGN, CYLD, NKTR, SAMHD1, NFKBIA, NFKBIZ, EIF2AK2, TNRC6B, MDM4, GPRIN3, CHD2, SYNE2, TRAT1, MTRNR2L8, LGALS1		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	CD4 cluster/cluster 0 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IFI27, IFITM3, CST7, JCHAIN, NCOA4, IFI6, PDZK1IP1, GNAS, TSPAN33, PTMA, LY6E, AC147651.1, TUBA4A, ITM2B, TMSB4X, MT-CO3, S100A8, DYNLL1, MYL12A, S100A9, CMPK2, ODC1, HCST, TAGLN2, IFI27L2, PF4, CAVIN2, AQP10, FTH1, GAPDH, HLA-E, NCK2, CA2, LGALSL, MT-CYB, PRKAR2B, ANAPC5, TMEM91, HEMGN, EVA1B, PDLIM1, OAZ1, HGD, VIM-AS1, EPSTI1, CDKN2D, TMEM158, KIFAP3, ACTG1, FTL, TIMP1, MLH3, PPBP, GNG11, CCDC88C, ARHGDIB, FHL1, HTATIP2, MMD, GP9, ILK, MYL6, IFITM2, RHOC, MIR4435-2HG, MT-ATP6, SMIM5, AMD1, PABPC1, MGAT4B, HIST1H1C, TPM1, C19orf33, TUBA1B, TMEM140, ITGB5, HIST1H2AC, CCL5, MT-ND1, ACTB, EIF1, CTDSPL, CFLAR, AP001189.1, TMSB10, RPS26, EIF2AK1, YPEL3, GPX4, PCMT1, RPS27, RPS18, ACTN1, BEX3, TUBA1C, RPS28, LIMS1, CST3, SUB1, CD99, HIST1H3H, RPL37, ZCCHC17, MPST, PTCRA, ADI1, CD9, UBXN11, PAIP2, EMC3, RPL36, MT-ND2, RPS24, ATP5MPL, GRAP2, HIST1H2BJ, SERF2, CLDN5, LY6G6F, MAP3K7CL, ATP2A3, DAPP1, RPS29, SLC40A1, UIMC1, RNF11, CAPN2, RPL41, CALD1, ISCU, UQCRH, RPL23A, SET, UQCR11, SQSTM1, TST, SEPT11, RPL37A, TSC22D3, TMEM50A, FCER1G, RPL39, JAK1, TACC3, RPS2, SVIP, MTPN, MTRNR2L8, MT-ND3, UBE2J1, UBC, CERS2, CYB5R3, AC090409.1, HSPB1, RPS19, RPL34, EPB41, ATP5F1E, C12orf76, CNPY3, SELP, CTSD, SMIM10L1, RPL15, RPL26, RPL28, CMIP, YBX3, FRMD3, GNAZ, NAP1L4, PLEK, AKIRIN2, ADD3, SPINT2, SRGN, CCDC92, RSU1, ARHGEF12, PLEKHO1, RPS13, YWHAH, RPL36AL, CD68, ANO6, RPS7, USF2, EGFL7, RPS8, NDUFB4, LCN2, GMFG, PARVB, STON2, RIOK3, RPS23, RPL10, INAFM2, GSN, RPS16, RPA1, SH3BGRL, RPL32, UCP2, UBE2B, STRAP, DERA, APP, PRDX5, SCN1B, RPL7A, H2AFJ, UXS1, MFSD1, RACK1, CENPT, RPL18A, ABTB1, PYCR2, RDH11, EID1, CXCL5, FHL2, RPL30, GAS2L1, RAB8A, NDUFA4, NENF, UBE2F, G3BP2, MORF4L1, HIST1H2AG, CRBN, HMG20B, DOK2, RPL8, MT-ATP8, ANKRD9, SEC14L1, RPS19BP1, VAPA, KCTD20, AP2S1, YBX1, TNNC2, UBE2E3, TXNIP, RAB4A, MYLK, PCP2, RPS25, YWHAE, CAMTA1, NDUFA5, HDGF, DAD1, RAB37, TAF10, UBAC2, ANP32B, VSIR, LYPLAL1, PDGFA, PTPN18, WASF2, FOS, TNFSF4, MAGED2, ENKUR, TAL1, RBM38, NT5M, RTN4, BCL2L1, RHEB		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	PLATE_1 cluster/cluster 6 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th of Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		JCHAIN, FOSB, IFI44L, MT-CYB, MT-ND3, MT-ND1, RPS18, RPL13, SP100, HIST1H1E, RPL13A, KLF6, RPS27A, IER5, RPL21, MT-ND2, XAF1, FOS, RPS3, RPL10, RPL27A, RNF213, JUN, RPS3A, NOP53, RPL9, UTRN, SYNE2, TOMM7, RPS6, TPT1, RACK1, MACF1, RPL32, RPS12, RPS26, RPS27, RPS8, RPS2, IER2, SAT1, RPL3, RPL4, RPL38, RPS19, PRRC2C, RPS9, MTRNR2L12, TXNIP, RPL6, SMCHD1, RPS23, XIST, IFI16, JUND, SUB1, RPS11, RPL11, GIMAP7, RPL12, BTG2, SMG1, RPL19, DUSP1, PRPF4B, RPS20, RPL27, GNLY, NR4A2, TRIM22, S100A6, PLCG2, VPS13C, SYNE1, EEF1B2, IDS, COX4I1, ADAR, RPL37A, ANKRD11, RPL23A, SRSF7, CD74, PPP1R15A, RPL29, EEF1D, GADD45B, RPL18A, UPF2, MYCBP2, USP15, DDX24, BIRC6, YWHAZ, ZFAND5, CCDC12, PARP14, ARAP2, DDX21, SCAF11, KLF2, SRRM1, CEMIP2, AC044849.1, NFKBIA, POLR2J3.1, CEP350, MYO1F, RPS14, RBBP6, KIAA1109, SLFN12L, ANKRD36C, USP34, TGOLN2, ITGAL, TAPBP, IQGAP2, AKAP9, CD69, ZNF292, SERBP1, YME1L1, ASH1L, INTS6, GZMB, SETX, TUT4, MTRNR2L8, MYBL1, DNAJA1, DIP2A, ACIN1, NPM1, GOLGA4, CNTRL, PIK3R1, KMT2C, ZFC3H1, TUBA1A, PARP8, BDP1, CYLD		gene expression	enriched				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	EOS cluster/cluster 12 from COVID-19 patients vs healthy	12	Adults (23-94)	Atlanta				32788292	2020	Table S4 Tab 2: DEG_healthy_vs_covid-19.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-shortened version in Fig 4c				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th Feb 2021.	8hrs total			Peripheral Blood Mononuclear Cells (PBMCs)		plasmablasts of CD45 cells, effector CD8 T cells of CD8 T cells		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with IFN-B1 vs healthy 		Adults (21-80)	Hong Kong				32788292	2020	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	15th Feb 2021.	8hrs total			Peripheral Blood Mononuclear Cells (PBMCs)		plasmablasts of CD45 cells, effector CD8 T cells of CD8 T cells		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without IFN-B1 vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.	7hrs total			Peripheral Blood Mononuclear Cells (PBMCs)		plasmablasts of CD45 cells, effector CD8 T cells of CD8 T cells		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with corticosteriod vs healthy 		Adults (21-80)	Hong Kong				32788292	2020	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasmablasts of CD45 cells, effector CD8 T cells of CD8 T cells		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with corticosteriod vs COVID-19 patients without corticosteriod		Adults (21-80)	Hong Kong				32788292	2020	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasmablasts of CD45 cells, effector CD8 T cells of CD8 T cells		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without corticosteriod vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasmablasts of CD45 cells, effector CD8 T cells of CD8 T cells		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with antiviral treatment vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		effector CD8 T cells of CD8 T cells		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with antiviral treatment vs COVID-19 patients without antiviral treatment		Adults (21-80)	Hong Kong				32788292	2020	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasmablasts of CD45 cells, effector CD8 T cells of CD8 T cells		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without antiviral treatment vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S3.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with IFN-B1 vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without IFN-B1 vs healthy 		Adults (21-80)	Hong Kong				32788292	2020	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients treated with corticosteriod vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with corticosteriod vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without corticosteriod vs healthy 		Adults (21-80)	Hong Kong				32788292	2020	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with antiviral treatment vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pDCs (plasmacytoid dendritic cells) of CD45 cells		cell type frequency	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without antiviral vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pS6 (mTOR) in pDCs (plasmacytoid dendritic cells)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with IFN-B1 vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pS6 (mTOR) in pDCs (plasmacytoid dendritic cells)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without IFN-B1 vs healthy 		Adults (21-80)	Hong Kong				32788292	2020	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pS6 (mTOR) in pDCs (plasmacytoid dendritic cells)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with corticosteriod vs healthy 		Adults (21-80)	Hong Kong				32788292	2020	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pS6 (mTOR) in pDCs (plasmacytoid dendritic cells)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without corticosteriod vs healthy 		Adults (21-80)	Hong Kong				32788292	2020	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pS6 (mTOR) in pDCs (plasmacytoid dendritic cells)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with antiviral treatment vs healthy 		Adults (21-80)	Hong Kong				32788292	2020	Fig S4b.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pS6 (mTOR) in pDCs (plasmacytoid dendritic cells)		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without antiviral treatment vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		pS6 (mTOR) in pDCs (plasmacytoid dendritic cells)		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without antiviral treamtnet vs COVID-19 patients with antiviral treatment		Adults (21-80)	Hong Kong				32788292	2020	Fig S4b	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IKBalpha in mDCs		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with antiviral treatment vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IKBalpha in mDCs		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without antiviral treatment vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IKBalpha in mDCs		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients treated with corticosteriod vs healthy 		Adults (21-80)	Hong Kong				32788292	2020	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IKBalpha in mDCs		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without corticosteriod vs healthy 		Adults (21-80)	Hong Kong				32788292	2020	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IKBalpha in mDCs		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients with IFN-B1 treatment vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		IKBalpha in mDCs		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	COVID-19 patients without IFN-B1 vs healthy		Adults (21-80)	Hong Kong				32788292	2020	Fig S4c.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		Interleukin-1B (IL-1B) CD14+ monocytes, tumor necrosis factor-alpha (TNF-a) CD14+ monocytes, interleukin-6 (IL-6) CD14+ monocytes, interleukin-6-positive and tumor necrosis factor-positive (IL-6+ TNF+) CD14+ monocytes		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	infected patients in response to bacterial cocktail (Pam3CSK14, LPS,  & Flagellin) vs healthy in response to bacterial cocktail (Pam3CSK4, LPS, & Flagellin)	31	Adults (23-94)	Atlanta				32788292	2020	Fig S5.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		Interleukin-1B (IL-1B) CD14+ monocytes, tumor necrosis factor-alpha (TNF-a) CD14+ monocytes, interleukin-6 (IL-6) CD14+ monocytes, interleukin-6-positive and tumor necrosis factor-positive (IL-6+ TNF+) CD14+ monocytes, interleukin-6 (IL-6) CD14+ monocytes, MCP-1 CD14+ monocytes		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	infected patients in response to viral cocktail (polyIC + R848) vs healthy in response to viral cocktail (polyIC + R848).	31	Adults (23-94)	Atlanta				32788292	2020	Fig S5.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma HGF		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU vs severe   	30	Adults (23-94)	Atlanta				32788292	2020	Fig S6b.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care." 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma HGF, plasma 4E-BP1		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU vs moderate   	16	Adults (23-94)	Atlanta				32788292	2020	Fig S6b.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care." 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma HGF, plasma 4E-BP1, plasma CXCL10, plasma CXCL5		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs healthy 	22	Adults (23-94)	Atlanta				32788292	2020	Fig S6b.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma EN-RAGE, plasma OSM, plasma TNFSF14		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU vs severe   	37	Adults (23-94)	Atlanta				32788292	2020	Fig S7a.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care." 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma EN-RAGE, plasma OSM, plasma TNFSF14		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU vs moderate   	37	Adults (23-94)	Atlanta				32788292	2020	Fig S7a.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma EN-RAGE, plasma OSM		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe vs moderate 	37	Adults (23-94)	Atlanta				32788292	2020	Fig S7a.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.				Peripheral Blood Mononuclear Cells (PBMCs)		plasma OSM		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate vs healthy 	55	Adults (23-94)	Atlanta				32788292	2020	Fig S7a.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD4, CD28		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0, 10-11, 16, 18, 21, 23		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD4, CD28		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 1-9, 12-15, 17, 19-20, 22, 24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD19, CD20		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 7, 9, 21		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD19, CD20		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-6, 10-20, 22-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD8, CD56		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 2, 7, 9, 16		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD8, CD56		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-1, 3-6, 10-15, 17-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD69, CD95		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 3, 6, 11, 14, 16		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD69, CD95		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-2, 4-5, 7-10, 12-13, 15, 17-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD3, CD94, CD127, CD197, CD45RA		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0, 2, 12, 16, 18, 20-23		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD3, CD94, CD127, CD197, CD45RA		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 1, 3-11, 13-15, 17, 19, 24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD34, TCRa7		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 2, 9, 18-19, 21		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD34, TCRa7		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-1, 2-7, 10-17, 20, 22-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD33, CD86, CD11c		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 3-5, 11, 16, 21		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD33, CD86, CD11c		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-2, 6-10, 12-15, 17-20, 22-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CDC1c-BDCA1, FCER1a		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 5, 7, 14, 17, 21-22		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CDC1c-BDCA1, FCER1a		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-4, 6, 9-13, 15-16, 19-20, 23-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						isotype 2, isotype 3, isotype 4		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0, 2-4, 9, 14, 22		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						isotype 2, isotype 3, isotype 4		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 1, 5-7, 10-13, 15-21, 23-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD25, CD45RO		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0, 3, 11, 16		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD25, CD45RO		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 1-2, 4-10, 12-15, 17-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						isotype 1, anti		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0, 2, 9, 14, 17, 22		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						isotype 1, anti		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 1, 3-7, 10-13, 15-16, 18-21, 23-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						HLA		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 3-5, 7, 10, 15-16, 21		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						HLA		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-2, 6, 9, 11-14, 17-20, 22-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD14		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 3, 11, 16, 22		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD14		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-2, 4-10, 12-15, 17-21, 23-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD16		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 1, 4, 21		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD16		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0, 2-3, 5-20, 22-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						TCRgd, CD274-PD		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 9, 14, 17, 22		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						TCRgd, CD274-PD		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-8, 10-13, 15-16, 18-21, 23-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD25, CD163		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 11, 22		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD25, CD163		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-10, 12-21, 23-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD370-CLEC9A		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 18, 21		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD370-CLEC9A		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0-17, 19-20, 22-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD38		antibody response 	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 1, 11, 13, 15-16, 20		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						CD38		antibody response 	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Clusters 0, 2-10, 12, 14, 17-19, 21-24		uncertain	uncertain				32788292	2020	Fig S11.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". convalescent defined as "more than 4 weeks since symptom onset and currently asymptomatic. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases [ICU] were organ failure necessitating intensive care unit (ICU) care. Patients with RSV and influenza were defined as acute hospitalized patients with confirmed diagnoses by BioFire FilmArray of nasopharyngeal and oropharyngeal swabs. RSV and Flu patients were classified as moderate if not requiring oxygen, severe if requiring oxygen, and critical if requiring ICU level care." from Supplemental				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, LGALS9, OGFR, SELL, TRIM25, VCPIP1, ANKFY1, ABTB2, TRIM14, FAM111A, GBP4, GCH1, GBP2, CASP4, TRAFD1, CXCL10, NMI, RTP4, PHF11, TRIM21, GBP3, PSME2, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, TAP1, PARP12, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, XRN1, HSH2D, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, CCRL2,EHD4, IL1RN, CCNYL1, HK2, TMEM140, CLIC4, CD86, PIK3AP1, TIPARP, TLK2, ATP10A, SLFN5, NLRC5, PPA1		gene expression	up		5	days	time of symptoms	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Severe 5d vs Severe 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs.Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						RBM43, CD274, P2RY14, BBX, AIDA, PCGF5, PYHIN1, GBP5, DCK, SLFN5, TLK2, NR4A3, CD69, TMEM140, MAX, NAMPT, CCRL2		gene expression	down		5	days	time of symptoms	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Severe 5d vs Severe 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs.Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, LGALS9, OGFR, TRIM25, VCPIP1, ANKFY1, TRIM14, FAM111A, GBP4, GCH1, GBP2, CASP4, TRAFD1, CXCL10, NMI, RTP4, PHF11, TRIM21, GBP3, PSME2, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, TAP1, PARP12, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, XRN1, HSH2D, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, CCRL2, EHD4, IL1RN, TMEM140, TLK2, ATP10A, NLRC5, PPA1, MAX, CD69, NR4A3, TLK2, BBX, AIDA, PCGF5, PYHIN1, GBP5		gene expression	up		10	days	time of symptoms	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Moderate 10d vs Moderate 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						RBM43, P2RY14, DCK, NAMPT, CCRL2, HK2, CCNYL1, CLIC4, CD86, PIK3AP1, TIPARP		gene expression	down		10	days	time of symptoms	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Moderate 10d vs Moderate 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						PARP14, BST2, IFITM3, OAS2, PARP9, CNP, IFI35, IRF7, PLSCR1, FAM111A, GCH1, GBP2, CASP4, CXCL10, NMI, RTP4, PHF11, TRIM21, GBP3, PSME2, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, TAP1, PARP12, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, XRN1, HSH2D, RNF213, SMCHD1, ZCCHC2, SLFN5, PPA1, MAX, CD69, BBX, PYHIN1, GBP5, DCK, RBM43, P2RY14		gene expression	up		5	days	time of symptoms	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Moderate 5d vs Moderate 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						NAMPT, CCRL2, HK2, CCNYL1, CLIC4, CD86, PIK3AP1, TIPARP, DTX3L, STAT2, ADAR, OAS3, CNP, PML, IL15RA, PLSCR1, LGALS9, OGFR, SELL, TRIM25, VCPIP1, ANKFY1, TRIM14, GCH1, GBP2, CASP4, TRAFD1, UBE2L6, USP25, ZNFX1, CCRL2, EHD4, IL1RN, TMEM140, NR4A3, TLK2, ATP10A, NLRC5, CD69, AIDA, PCGF5		gene expression	down		5	days	time of symptoms	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Moderate 5d vs Moderate 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, LGALS9, OGFR, SELL, TRIM25, VCPIP1, ANKFY1, ABTB2, TRIM14, TRAFD1, CXCL10, NMI, RTP4, PHF11, TRIM21, GBP3, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PARP12, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, XRN1, HSH2D, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, CCRL2, EHD4, IL1RN, CCNYL1, HK2, TMEM140, CD86, TIPARP, TLK2, ATP10A, PPA1, NAMPT, CCRL2, MAX, NR4A3, FAM111A, GBP4, GCH1, GBP2, CASP4		gene expression	down		15	days	time of symptoms	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Severe 15d vs Severe 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						RBM43, CD274, P2RY14, BBX, AIDA, PCGF5, PYHIN1, GBP5, DCK, SLFN5, TLK2, NR4A3, CD69, MAX, VCPIP1, FAM111A, GBP4, GCH1, GBP2, CASP4, PHF11, PSME2, TAP1, PPM1K, ISG20, ZBP1, IRF9, XRN1, HSH2D, RNF213, USP25, CLIC4, PIK3AP1, TIPARP, CD69, ATP10A, NLRC5, SLFN5, PPA1		gene expression	up		15	days	time of symptoms	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Severe 15d vs Severe 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						RBM43, CD274, BBX, AIDA, PCGF5, PYHIN1, GBP5, DCK, SLFN5, TLK2, NR4A3, CD69, FAM111A, GBP4, GCH1, PHF11, PSME2, TAP1, PPM1K, ISG20, ZBP1, XRN1, HSH2D, USP25, PIK3AP1, TIPARP, ATP10A, NLRC5, PPA2, PARP12, NAMPT, CCNYL1, CD86		gene expression	up		10	days	time of symptoms	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Severe 10d vs Severe 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	16th Feb 2021.						PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, LGALS9, OGFR, SELL, TRIM25, VCPIP1, ANKFY1, TRIM14, TRAFD1, CXCL10, NMI, RTP4, PHF11, TRIM21, ABTB2, FAM111A, GBP4, GBP3, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, CCRL2, EHD4, IL1RN, HK2, TMEM140, TIPARP, PPA1, NAMPT, MAX, GCH1, GBP2, CASP4, PSME2, CLIC4, P2RY14, RBM43		gene expression	down		10	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Severe 10d vs Severe 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						PYHIN1, DCK, NR4A3, CD69, PIK3AP1, TIPARP, PPA2, NAMPT, CCNYL1, CD86, LGALS9, VCPIP1, ABTB2, TRIM14, CCRL2, EHD4, IL1RN, HK2 		gene expression	up		20	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Severe 20d vs Severe 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, OGFR, SELL, TRIM25, ANKFY1, TRAFD1, CXCL10, NMI, RTP4, PHF11, TRIM21, FAM111A, GBP4, GBP3, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, TMEM140, PPA1, MAX, GCH1, GBP2, CASP4, PSME2, CLIC4, P2RY14, RBM43, TAP1, PARP12, XRN1, HSH2D, TLK2, ATP10A, NLRC5, SLFN5, PCGF5, GBP5, AIDA, BBX, P2RY14, CD274		gene expression	down		20	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Severe 20d vs Severe 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.	2.5 hrs total					PYHIN1, DCK, PPA2, FAM111A, GBP4, GBP2, GCH1, CASP4, TRAFD1, RTP4, PHF11, TRIM21, GPB3, MAX, TMEM140, TLK2, SLFN5, GBP5, AIDA, PPA1, CD274, RBM43		gene expression	up		20	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU 20d vs ICU 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, OGFR, SELL, TRIM25, ANKFY1, CXCL10, NMI, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, PSME2, CLIC4, P2RY14, TAP1, PARP12, XRN1, HSH2D, ATP10A, NLRC5, PCGF5, BBX, P2RY14, LGALS9, VCPIP1, ABTB2, TRIM14, CCNYL1, CD86, EHD4, IL1RN, HK2, NR4A3, CD69, PIK3AP1, TIPARP		gene expression	down		20	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU 20d vs ICU 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						PYHIN1, DCK, NR4A3, CD69, PIK3AP1, TIPARP, PPA2, NAMPT, CCNYL1, CD86, CCRL2, EHD4, IL1RN, HK2, GCH1, XRN1, ZCCHC2, ZNFX1		gene expression	up		15	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Moderate 15d vs Moderate 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, PLSCR1, OGFR, SELL, TRIM25, ANKFY1, CXCL10, NMI, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PNPT1, SP110, IRF9, SMCHD1, MOV10, TMEM140, PPA1, MAX, PSME2, CLIC4, P2RY14, RBM43, TAP1, PARP12, TLK2, ATP10A, NLRC5, SLFN5, PCGF5, GBP5, AIDA, BBX, P2RY14, CD274, LGALS9, VCPIP1, ABTB2, TRIM14, FAM111A, GBP4, GBP2, CASP4, TRAFD1, RTP4, PHF11, TRIM21, GPB3		gene expression	down		15	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Moderate 15d vs Moderate 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						NR4A3, PIK3AP1, TIPARP, PPA2, NAMPT, CCNYL1, CCRL2, EHD4, IL1RN, HK2, PLSCR1, OGFR, SELL, TRIM25, LGALS9, VCPIP1, ABTB2, NAMPT, MAX, CLIC4, PCGF5, CD274, PPA1		gene expression	up		15	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU 15d vs ICU 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						PARP14, DTX3L, STAT2, ADAR, OAS3, BST2, IFITM3, OAS2, PARP9, TDRD7, CNP, PML, IFI35, IRF7, IL15RA, ANKFY1, CXCL10, NMI, DHX58, RSAD2, IFIT2, UBE2L6, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, IFIT3, PNPT1, SP110, PPM1K, ISG20, ZBP1, IRF9, RNF213, SMCHD1, ZCCHC2, USP25, MOV10, ZNFX1, TMEM140, PSME2, CD86, P2RY14, RBM43, TAP1, PARP12, XRN1, HSH2D, ATP10A, NLRC5, SLFN5, GBP5, AIDA, BBX, P2RY14, TRIM14, FAM111A, GBP4, GBP2, TRAFD1, RTP4, PHF11, TRIM21, GPB3, GCH1, PYHIN1, DCK		gene expression	down		15	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU 15d vs ICU 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						PIK3AP1, PPA2, EHD4, HK2, OGFR, TRIM25, LGALS9, ABTB2, NAMPT, MAX, CLIC4, STAT2, ADAR, BST2, IFITM3, IRF7, ANKFY1, GBP2, CASP4, TRAFD1, IRF9, TMEM140, CD86, P2RY14		gene expression	up		10	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU 10d vs ICU 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						PARP14, IFI35, IL15RA, DHX58, RSAD2, IFIT2, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, PNPT1, SP110, PPM1K, ISG20, ZBP1, RNF213, SMCHD1, ZCCHC2, USP25, ZNFX1, PSME2, RBM43, TAP1, PARP12, XRN1, ATP10A, NLRC5, SLFN5, GBP5, AIDA, BBX, PPA1, CD274, TRIM14, FAM111A, PHF11, TRIM21, GPB3, GCH1, PYHIN1, DCK, SELL, VCPIP1, IL1RN, CCNYL1, TIPARP, CD69, NR4A3, TLK2, PCGF5		gene expression	down		10	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU 10d vs ICU 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						PIK3AP1, PPA2, EHD4, HK2, OGFR, TRIM25, LGALS9, TRIM14, NAMPT, CLIC4, ANKFY1, TMEM140, CD86, P2RY14, IL15RA, CCRL2, IL1RN, CCNYL1, HK2, TIPARP, NR4A3		gene expression	up		5	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU 5d vs ICU 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.						PARP14, DTX3L, STAT2, ADAR, OAS2, PARP9, TDRD7, PML, IRF7, IFI35, DHX58, RSAD2, IFIT2, IFI44, EIF2AK2, CMPK2, EPSTI1, LGALS3BP, ISG15, USP18, PARP11, STAT1, DDX60, SAMD9L, DDX58, IFIH1, XAF1, IFIT1, PNPT1, SP110, PPM1K, ISG20, ZBP1, RNF213, SMCHD1, ZCCHC2, USP25, ZNFX1, PSME2, RBM43, TAP1, PARP12, XRN1, NLRC5, SLFN5, GBP5, AIDA, BBX, PPA1, CD274, ABTB2, FAM111A, PHF11, TRIM21, GPB3, GCH1, PYHIN1, DCK, VCPIP1, CD69, TLK2, PCGF5, GBP4, GBP2, CASP4, TRAFD1, CXCL10, NMI, RTP4, UBE2L6, IFIT3, IRF9, HSH2D, MOV10, MAX		gene expression	down		5	days	time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU 5d vs ICU 0d		uncertain	uncertain				32788292	2020	Fig S15a	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.				Peripheral Blood Mononuclear Cells		pDCs (plasmacytoid dendritic cells)		cell type frequency	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU, severe, & moderate 	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using immune cell type frequences..detected in phospho-CyTOF..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.				Peripheral Blood Mononuclear Cells		pDCs (plasmacytoid dendritic cells)		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy, convalescent	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using immune cell type frequences..detected in phospho-CyTOF..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.				Peripheral Blood Mononuclear Cells		plasmablast, Effector_CD8_T_cells		cell type frequency	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU, severe, & moderate 	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using immune cell type frequences..detected in phospho-CyTOF..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.				Peripheral Blood Mononuclear Cells		plasmablast, Effector_CD8_T_cells		cell type frequency	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy, convalescent	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using immune cell type frequences..detected in phospho-CyTOF..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	18th Feb 2021.				Peripheral Blood Mononuclear Cells		pDCs.pS6, mDCs.Ikba		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU, severe, & moderate 	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using signaling molecules..detected in phospho-CyTOF and circulating plasma cytokines..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		pDCs.pS6, mDCs.Ikba		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy, convalescent	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using signaling molecules..detected in phospho-CyTOF and circulating plasma cytokines..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.	1hr total			Peripheral Blood Mononuclear Cells		mDCs.HLA_DR		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU, severe, moderate, convalescent	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using signaling molecules..detected in phospho-CyTOF and circulating plasma cytokines..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		mDCs.HLA_DR		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy, convalescent	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using signaling molecules..detected in phospho-CyTOF and circulating plasma cytokines..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		interleukin6 (IL6), MCP.3		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU, severe, & moderate 	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using signaling molecules..detected in phospho-CyTOF and circulating plasma cytokines..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		interleukin6 (IL6), MCP.3		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy, convalescent	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using signaling molecules..detected in phospho-CyTOF and circulating plasma cytokines..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		EN.RAGE, TNFSF14, OSM		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU & severe 	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using signaling molecules..detected in phospho-CyTOF and circulating plasma cytokines..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		EN.RAGE, TNFSF14, OSM		cytokines/protein levels	down				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy, convalescent, moderate	52	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig S20.	https://science.sciencemag.org/content/suppl/2020/08/11/science.abc6261.DC1	"hierarchical clustering..using signaling molecules..detected in phospho-CyTOF and circulating plasma cytokines..."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		mDC HLA-DR		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy	30	Adults (23-94)	Atlanta				32788292	2020	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		mDC HLA-DR		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy	21	Adults (23-94)	Atlanta				32788292	2020	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		mDC HLA-DR		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate	17	Adults (23-94)	Atlanta				32788292	2020	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs". Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		mDC HLA-DR		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy	40	Adults (21-80)	Hong Kong				32788292	2020	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		mDC HLA-DR		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy	45	Adults (21-80)	Hong Kong				32788292	2020	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		C monocyte (C mono) HLA-DR		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy	30	Adults (23-94)	Atlanta				32788292	2020	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		C monocyte (C mono) HLA-DR		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy	40	Adults (21-80)	Hong Kong				32788292	2020	Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults prior to widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		TNFSF14, tumor necrosis factor (TNF)		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy	15	Adults (23-94)	Atlanta				32788292	2020	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		S100A12		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU	15	Adults (23-94)	Atlanta				32788292	2020	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		TNFSF14, tumor necrosis factor (TNF)		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy	15	Adults (23-94)	Atlanta				32788292	2020	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		S100A12		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe	15	Adults (23-94)	Atlanta				32788292	2020	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		tumor necrosis factor (TNF)		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate	15	Adults (23-94)	Atlanta				32788292	2020	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		S100A12		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe	15	Adults (23-94)	Atlanta				32788292	2020	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		TNFSF14		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	moderate	15	Adults (23-94)	Atlanta				32788292	2020	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		S100A12		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	ICU	15	Adults (23-94)	Atlanta				32788292	2020	Fig 5c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F5/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				plasma		16S (bacterial rRNA gene)		gene expression	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	healthy	69	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig 6a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F6/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen. Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.				Peripheral Blood Mononuclear Cells		plasma LPS 		cytokines/protein levels	up				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe & ICU	69	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig 6b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F6/	-healthy: samples from asymptomatic adults before widespread SARS-CoV-2 circulation in the community. COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Severe cases were defined as requiring supplemental oxygen. Critical cases were organ failure necessitating intensive care unit (ICU) care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 	19th Feb 2021.	1hr total for 19th			Peripheral Blood Mononuclear Cells		plasma Interleukin-6 (IL-6), plasma tumor necrosis factor (TNF), plasma MCP-3, plasma EN-RAGE, plasma OSM, plasma TNFSF14		cytokines/protein levels	positive				time of clinical onset	Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	Moderate, severe, & ICU 	69	Adults (21-94)	Atlanta, Hong Kong				32788292	2020	Fig 6c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/figure/F6/	-COVID-19 patients "according to WHO guidance and positive SARS-CoV-2 RT-PCR testing by nasopharyngeal swabs. Moderate cases were defined as respiratory symptoms with radiological findings of pneumonia. Severe cases were defined as requiring supplemental oxygen. Critical cases were organ failure necessitating ICU care."				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665312/					
	Amani 					Peripheral Blood Mononuclear Cells		CD45+ CD19+ IgD- CD71+ CD38+ CD20- plasmablasts		cell type frequency	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	primary COVID-19 vs healthy 	37	Adults (22-89)	St Louis, Missouri, USA				33187979	2020	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F1/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		CD45+ CD3+ CD8+ T cells, CD45+ CD3+ CD4+ T cells, CD45+ CD3- CD19- CD14++ CD16- classical monocytes, CD45+ CD3- CD19- CD14++ CD16+ intermediate monocytes, CD45+ CD3- CD19- CD14+ CD16+ non-classical monocytes		cell type frequency	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	primary COVID-19 vs healthy 	37	Adults (22-89)	St Louis, Missouri, USA				33187979	2020	Fig 1A & C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F1/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD45+ CD3- CD19- CD14+ CD16+ non-classical monocytes		HLA-DR		cytokines/protein levels	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	primary COVID-19 vs healthy 	37	Adults (22-89)	St Louis, Missouri, USA				33187979	2020	Fig 1D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F1/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		CD45+ CD19+ IgD- CD71+ CD38+ CD20- plasmablasts		cell type frequency	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	influenza vs healthy 	38	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 1B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F1/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		CD45+ CD3+ CD8+ T cells, CD45+ CD3+ CD4+ T cells		cell type frequency	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	influenza vs healthy 	38	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 1A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F1/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		CD45+ CD3- CD19- CD14++ CD16- classical monocytes, CD45+ CD3- CD19- CD14++ CD16+ intermediate monocytes, CD45+ CD3- CD19- CD14+ CD16+ non-classical monocytes		cell type frequency	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	primary COVID-19 vs influenza 	45	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F1/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD45+ CD3+ CD8+ T cells, CD45+ CD3- CD19- CD14++ CD16+ intermediate monocytes		HLA-DR		cytokines/protein levels	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	primary COVID-19 vs influenza 	45	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 1D & E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F1/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD45+ CD3- CD19- CD14++ CD16+ intermediate monocytes		HLA-DR		cytokines/protein levels	down					Occurrence of infectious disease	COVID-19.	severe	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs moderate COVID-19	22	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		IFN-gamma (IFN-y), IL-17a, G-CSF, TNFalpha (TNFa), RANTES, MIP-1beta, MIP-1alpha, MIG, IP-10, IL-9, IL-7, IL-5, IL-4, IL-3, IL-2R, IL-22, IL-2, IL-1Ra, IL-1Beta (IL-1b), IL-1alpha (IL-1a), IL-17f, IL-17a, IL-15, IL-13, IL-12, IL-10, IFN-alpha (IFN-a), GM-CSF, FGF, eotaxin		cytokines/protein levels	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	primary COVID-19 vs influenza 	105	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 2B-C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F2/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		VEGF, MCP1, IP-10, HGH, EGF		cytokines/protein levels	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	primary COVID-19 vs influenza 	105	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 2B-C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F2/					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		IP-10, IL-8, MCP1, HGF (hepatocyte growth factor), MIP-1β 		cytokines/protein levels	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	primary COVID-19 vs healthy 	87	Adults (22-89)	St Louis, Missouri, USA				33187979	2020	2nd paragraph under "Cytokine Associations.." / Paragraph under Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#__sec2title					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		IP-10, IL-8, MCP1, HGF (hepatocyte growth factor), MIP-1β 		cytokines/protein levels	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	influenza vs healthy 	34	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	2nd paragraph under "Cytokine Associations.." / Paragraph under Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#__sec2title					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		GCSF, IFNg, MIG, IL1Ra, IL2R, IL9, IL17a, MIP1a		cytokines/protein levels	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	primary COVID-19 vs influenza	105	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S3-4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		TNFalpha (TNFa), IL-1alpha (IL-1a), IP-10, IL-1β (IL-1beta)		cytokines/protein levels	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	validation COVID-19 vs healthy	97	Adults (22-92)	St Louis, Missouri, USA				33187979	2020	Fig 3B-C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F3					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		IP-10, IL-8		cytokines/protein levels	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	validation COVID-19 vs influenza	115	Adults (18-92)	St Louis, Missouri, USA				33187979	2020	Fig 3B & D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F3					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		IL12, EGF (epidermal growth factor), HGF, IL2, IL8, IP10, MIP1b		cytokines/protein levels	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	validation COVID-19 vs healthy	97	Adults (22-92)	St Louis, Missouri, USA				33187979	2020	Fig S6-7	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		IP10, IL1a, IL1b, IL4, IL9, IL17a, IL17f, MIG, TNFa, FGF, eotaxin, GCSF, IFNg, IL1Ra, IL2R		cytokines/protein levels	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	validation COVID-19 vs influenza	115	Adults (18-92)	St Louis, Missouri, USA				33187979	2020	Fig S6-7	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		HGF, IL1Ra, IL2, IL2R, IL12, IP10, IL17f, MCP1, MIG, MIP1b		cytokines/protein levels	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	influenza vs healthy 	105	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S3-4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		HGF, IL8, IP10, MCP1, MIP1b		cytokines/protein levels	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	primary COVID-19 vs healthy	97	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S3-4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Peripheral Blood Mononuclear Cells		HLA-DRA		cytokines/protein levels	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 5D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F5	-all 3 COVID-19 patients died 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					B Cells		GO_RESPONSE_TO_CORTICOSTERIOD		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F5	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					B Cells, monocytes/macrophages, CD8+ T cells, mixed cytolitic lymphocytes, plasmablasts		HALLMARK_INTERFERON_GAMMA_RESPONSE, HALLMARK_INTERFERON_ALPHA_RESPONSE		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F5	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					monocytes/macrophages		GO_RESPONSE_TO_MINERALOCORTICOID, GO_RESPONSE_TO_CORTICOSTERIOD, HALLMARK_INFLAMMATORY RESPONSE		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F5	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD8+ T Cells		HALLMARK_MTORC1_SIGNALING, GO_CELLULAR_RESPONSE_TO_CORTICOSTERIOD_STIMULUS, HALLMARK_P53_PATHWAY		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F5	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD8+ T Cells		HALLMARK_APOPTOSIS		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F5	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					B cells, monocytes/macrophages, mixed cytolitic lymphocytes		HALLMARK_MTORC1_SIGNALING, GO_CELLULAR_RESPONSE_TO_CORTICOSTERIOD_STIMULUS, GO_RESPONSE_TO_OXIDATIVE_STRESS, HALLMARK_P53_PATHWAY, HALLMARK_APOPTOSIS		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F5	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD8+ T cells, mixed cytolitic lymphocytes		HALLMARK_INFLAMMATORY RESPONSE		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F5	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					plasmablasts		HALLMARK_P53_PATHWAY, HALLMARK_APOPTOSIS		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 5E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F5	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					monocytes/macrophages		STAT1, STAT2, STAT3		cytokines/protein levels	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig 5F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/figure/F5	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					B cells		POSITIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION, REGULATION_OF_TYPE_I_INTERFERON_MEDIATED_SIGNALING_PATHWAY		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					B cells		RESPONSE_TO_INTERFERON_BETA, RESPONSE_TO_TYPE_I_INTERFERON, INTERFERON_GAMMA_MEDIATED_SIGNALING_PATHWAY, RESPONSE_TO_INTERFERON_GAMMA		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD8+ T cells		REGULATION_OF_RESPONSE_TO_INTERFERON_GAMMA, NEGATIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION, TYPE_I_INTERFERON_PRODUCTION, RESPONSE_TO_INTERFERON_ALPHA, RESPONSE_TO_INTERFERON_BETA, RESPONSE_TO_TYPE_I_INTERFERON, INTERFERON_GAMMA_MEDIATED_SIGNALING_PATHWAY, RESPONSE_TO_INTERFERON_GAMMA		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD8+ T cells		INTERFERON_GAMMA_SECRETION, INTERFERON_GAMMA_PRODUCTION		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD84+ T cells		INTERFERON_GAMMA_SECRETION		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD84+ T cells		RESPONSE_TO_INTERFERON_ALPHA, RESPONSE_TO_INTERFERON_BETA, RESPONSE_TO_TYPE_I_INTERFERON, 		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					innate-like T cells		POSITIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION, REGULATION_OF_RESPONSE_TO_INTERFERON_GAMMA, RESPONSE_TO_TYPE_I_INTERFERON, TYPE_I_INTERFERON_PRODUCTION		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					mixed cytolitic lymphocytes		REGULATION_OF_RESPONSE_TO_INTERFERON_GAMMA, INTERFERON_BETA_PRODUCTION, RESPONSE_TO_INTERFERON_ALPHA, CELLULAR_RESPONSE_TO_INTERFERON_BETA, RESPONSE_TO_INTERFERON_BETA, RESPONSE_TO_TYPE_I_INTERFERON, INTERFERON_GAMMA_MEDIATED_SIGNALING_PATHWAY, RESPONSE_TO_INTERFERON_GAMMA		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					mixed cytolitic lymphocytes		INTERFERON_GAMMA_SECRETION, TYPE_I_INTERFERON_PRODUCTION, NEGATIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					monocytes/macrophages		POSITIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION, REGULATION_OF_TYPE_I_INTERFERON_MEDIATED_SIGNALING_PATHWAY, TYPE_I_INTERFERON_PRODUCTION, INTERFERON_ALPHA_PRODUCTION, NEGATIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION, POSITIVE_REGULATION_OF_INTERFERON_ALPHA_PRODUCTION, POSITIVE_REGULATION_OF_INTERFERON_BETA_PRODUCTION, INTERFERON_BETA_PRODUCTION, RESPONSE_TO_INTERFERON_ALPHA, CELLULAR_RESPONSE_TO_INTERFERON_BETA, RESPONSE_TO_INTERFERON_BETA, RESPONSE_TO_TYPE_I_INTERFERON, INTERFERON_GAMMA_MEDIATED_SIGNALING_PATHWAY, RESPONSE_TO_INTERFERON_GAMMA		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					plasmablasts		RESPONSE_TO_TYPE_I_INTERFERON		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					platelets		RESPONSE_TO_TYPE_I_INTERFERON, RESPONSE_TO_INTERFERON_GAMMA		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					platelets		RESPONSE_TO_TYPE_I_INTERFERON_BETA		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					regulatory T cells		RESPONSE_TO_TYPE_I_INTERFERON, RESPONSE_TO_INTERFERON_ALPHA, INTERFERON_GAMMA_MEDIATED_SIGNALING_PATHWAY		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S11	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					B cells		UV_RESPONSE_UP, UNFOLDED_PROTEIN_RESPONSE, TNFA_SIGNALING_VIA_NFKB, PROTEIN_SECRETION, PI3K_AKT_MTOR_SIGNALING, P53_PATHWAY, OXIDATIVE_PHOSPHORYLATION, MYC_TARGETS_V2, MYC_TARGETS_V1, MTORC1_SIGNALING, HYPOXIA, HEME_METABOLISM, GLYCOLYSIS, G2M_CHECKPOINT, FATTY_ACID_METABOLISM, E2F_TARGETS, DNA_REPAIR, APOPTOSIS, ANDROGEN_RESPONSE, ALLOGRAFT_REJECTION, ADIPOGENESIS		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					B cells		INTERFERON_GAMMA_RESPONSE, INTERFERON_ALPHA_RESPONSE, EPITHELIAL_MESENCRYMAL_TRANSITION, COAGULATION, APICAL_JUNCTION		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD4+ T cells		UNFOLDED_PROTEIN_RESPONSE, REACTIVE_OXYGEN_SPECIES_PATHWAY, PROTEIN_SECRETION, OXIDATIVE_PHOSPHORYLATION, MYC_TARGETS_V2, MYC_TARGETS_V1, MTORC1_SIGNALING, IL2_STAT5_SIGNALING, INTERFERON_GAMMA_RESPONSE, INTERFERON_ALPHA_RESPONSE, HEME_METABOLISM, G2M_CHECKPOINT, FATTY_ACID_METABOLISM, E2F_TARGETS, DNA_REPAIR, ANDROGEN_RESPONSE, ALLOGRAFT_REJECTION		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD4+ T cells		TNFA_SIGNALING_VIA_NFKB, MYOGENESIS, KRAS_SIGNALING_DN, INFLAMMATORY_RESPONSE, ESTROGEN_RESPONSE_EARLY, EPITHELIAL_MESENCRYMAL_TRANSITION, COAGULATION, APOPTOSIS, APICAL_JUNCTION, ANGIOGENESIS		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD8+ T cells		XENOBIOTIC_METABOLISM, UNFOLDED_PROTEIN_RESPONSE, REACTIVE_OXYGEN_SPECIES_PATHWAY, PROTEIN_SECRETION, PI3K_AKT_MTOR_SIGNALING, P53_PATHWAY, OXIDATIVE_PHOSPHORYLATION, IL2_STAT5_SIGNALING, GLYCOLYSIS, INTERFERON_GAMMA_RESPONSE, INTERFERON_ALPHA_RESPONSE, HEME_METABOLISM, G2M_CHECKPOINT, FATTY_ACID_METABOLISM, DNA_REPAIR, COMPLEMENT, ANDROGEN_RESPONSE, ALLOGRAFT_REJECTION, ADIPOGENESIS		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD8+ T cells		TNFA_SIGNALING_VIA_NFKB, KRAS_SIGNALING_UP, KRAS_SIGNALING_DN, INTERFERON_GAMMA_RESPONSE, INTERFERON_ALPHA_RESPONS, INFLAMMATORY_RESPONSE, IL6_JAK_STAT3_SIGNALING, EPITHELIAL_MESENCRYMAL_TRANSITION, APOPTOSIS, APICAL_JUNCTION		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					innate T cells		TNFA_SIGNALING_VIA_NFKB, REACTIVE_OXYGEN_SPECIES_PATHWAY, PROTEIN_SECRETION, PI3K_AKT_MTOR_SIGNALING, INTERFERON_GAMMA_RESPONSE, DNA_REPAIR, APOPTOSIS, ANDROGEN_RESPONSE, ALLOGRAFT_REJECTION		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					innate T cells		OXIDATIVE_PHOSPHORYLATION, MYC_TARGETS_V1		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					mixed lymphocytes		WNT_BETA_CATENIN_SIGNALING, UNFOLDED_PROTEIN_RESPONSE, TNFA_SIGNALING_VIA_NFKB, TGF_BETA_SIGNALING, PI3K_AKT_MTOR_SIGNALING, P53_PATHWAY, MYC_TARGETS_V2, MTORC1_SIGNALING, MITOTIC_SPINDLE, KRAS_SIGNALING_DN, APOPTOSIS		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					mixed lymphocytes		ADIPOGENESIS, ALLOGRAFT_REJECTION, APICAL_JUNCTION, EPITHELIAL_MESENCRYMAL_TRANSITION, E2F_TARGETS, DNA_REPAIR, COMPLEMENT, COAGULATION, G2M_CHECKPOINT, FATTY_ACID_METABOLISM, IL6_JAK_STAT3_SIGNALING, INTERFERON_GAMMA_RESPONSE, INTERFERON_ALPHA_RESPONSE, INFLAMMATORY_RESPONSE, MYC_TARGETS_V1, OXIDATIVE_PHOSPHORYLATION, PEROXISOME, PROTEIN_SECRETION, XENOBIOTIC_METABOLISM		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					monocytes		UV_RESPONSE_UP, UNFOLDED_PROTEIN_RESPONSE, TNFA_SIGNALING_VIA_NFKB, REACTIVE_OXYGEN_SPECIES_PATHWAY, PROTEIN_SECRETION, PI3K_AKT_MTOR_SIGNALING, P53_PATHWAY, OXIDATIVE_PHOSPHORYLATION, MYC_TARGETS_V1, MYC_TARGETS_V2, MTORC1_SIGNALING, INFLAMMATORY _RESPONSE, IL2_STAT5_SIGNALING, HYPOXIA, G2M_CHECKPOINT, FATTY_ACID_METABOLISM, E2F_TARGETS, DNA_REPAIR, COMPLEMENT, COAGULATION, CHOLESTEROL_HOMEOSTASIS, APOPTOSIS, ANDROGEN_RESPONSE, ALLOGRAFT_REJECTION, ADIPOGENESIS		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					monocytes		KRAS_SIGNALING_DN, INTERFERON_GAMMA_RESPONSE, INTERFERON_ALPHA_RESPONSE, IL6_JAK_STAT3_SIGNALING		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					platelets		PROTEIN_SECRETION, PI3K_AKT_MTOR_SIGNALING, P53_PATHWAY, OXIDATIVE_PHOSPHORYLATION, MYC_TARGETS_V2, MYC_TARGETS_V1, MTORC1_SIGNALING, INTERFERON_GAMMA_RESPONSE, INTERFERON_ALPHA_RESPONSE, INFLAMMATORY_RESPONSE, COMPLEMENT, ADIPOGENESIS		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					platelets		UV_RESPONSE_DN, TGF_BETA_SIGNALING, MYOGENESIS, HEME_METABOLISM, EPITHELIAL_MESENCRYMAL_TRANSITION, COAGULATION, APOPTOSIS, APICAL_JUNCTION		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Regulatory T cells (Tregs)		REACTIVE_OXYGEN_SPECIES_PATHWAY, OXIDATIVE_PHOSPHORYLATION, MTORC1_SIGNALING, MITOTIC_SPINDLE, HEME_METABOLISM, ALLOGRAFT_REJECTION		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Regulatory T cells (Tregs)		UNFOLDED_PROTEIN_RESPONSE, TNFA_SIGNALING_VIA_NFKB, MYC_TARGETS_V1, INTERFERON_GAMMA_RESPONSE, INTERFERON_ALPHA_RESPONSE, INFLAMMTORY_RESPONSE, HYPOXIA, EPITHELIAL_MESENCRYMAL_TRANSITION		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Red Blood Cells (RBCs)		XENOBIOTIC_METABOLISM, MYC_TARGETS_V2, MTORC1_SIGNALING, HEME_METABOLISM, CHOLESTEROL_HOMEOSTASIS, ALLOGRAFT_REJECTION		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Red Blood Cells (RBCs)		OXIDATIVE_PHOSPHORYLATION, MYC_TARGETS_V1, EPITHELIAL_MESENCRYMAL_TRANSITION, COMPLEMENT, COAGULATION, APICAL_JUNCTION, ANDROGEN_RESPONSE, ADIPOGENESIS		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					PDCs		UV_RESPONSE_UP, TNFA_SIGNALING_VIA_NFKB, OXIDATIVE_PHOSPHORYLATION, MYC_TARGETS_V1		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					PDCs		INTERFERON_GAMMA_RESPONSE, INTERFERON_ALPHA_RESPONSE		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					plasmablasts		UV_RESPONSE_UP, PI3K_AKT_MTOR_SIGNALING, P53_PATHWAY, MYC_TARGETS_V1, INTERFERON_GAMMA_RESPONSE, INTERFERON_ALPHA_RESPONSE, GLYCOLYSIS, G2M_CHECKPOINT, FATTY_ACID_METABOLISM, E2F_TARGETS, COMPLEMENT,  APOPTOSIS		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S12.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	GSEA annotation system				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					B cells		REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_IN_RESPONSE_TO_STRESS, INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, REGULATION_OF_ENDOPLASMIC_RETICULUM_STRESS_INDUCED_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, NEGATIVE_REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, POSITIVE_REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, NEGATIVE_REGULATION_OF_ENDOPLASMIC_RETICULUM_STRESS_INDUCED_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, REGULATION_OF_TRANSLATION_IN_RESPONSE_TO_STRESS, CELLULAR_RESPONSE_TO_CORTICOSTERIOD_STIMULUS, REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, RESPONSE_TO_OXIDATIVE_STRESS, CELLULAR_RESPONSE_TO_CHEMICAL_STRESS, STRESS_GRANULE_ASSEMBLY, RESPONSE_TO_CORTICOSTERIOD		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD8+ T cells		REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_IN_RESPONSE_TO_STRESS, INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, REGULATION_OF_ENDOPLASMIC_RETICULUM_STRESS_INDUCED_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, NEGATIVE_REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, POSITIVE_REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, NEGATIVE_REGULATION_OF_ENDOPLASMIC_RETICULUM_STRESS_INDUCED_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, CELLULAR_RESPONSE_TO_CORTICOSTERIOD_STIMULUS, STRESS_ACTIVATED_PROTEIN_KINASE_SIGNALING_CASCADE, REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, CELLULAR_RESPONSE_TO_OSMOTIC_STRESS, CELLULAR_RESPONSE_TO_CHEMICAL_STRESS		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					CD84+ T cells		REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_IN_RESPONSE_TO_STRESS, INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, REGULATION_OF_ENDOPLASMIC_RETICULUM_STRESS_INDUCED_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, NEGATIVE_REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, POSITIVE_REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, REGULATION_OF_TRANSLATION_IN_RESPONSE_TO_STRESS, REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Innate-like T cells		REGULATION_OF_TRANSLATION_IN_RESPONSE_TO_STRESS, CELLULAR_RESPONSE_TO_OSMOTIC_STRESS, RESPONSE_TO_OSMOTIC_STRESS		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					mixed cytolitic lymphocytes		INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, REGULATION_OF_ENDOPLASMIC_RETICULUM_STRESS_INDUCED_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, NEGATIVE_REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS,  RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, CELLULAR_RESPONSE_TO_CORTICOSTERIOD_STIMULUS, RESPONSE_TO_FLUID_SHEAR_STRESS, STRESS_ACTIVATED_PROTEIN_KINASE_SIGNALING_CASCADE, REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, REGULATION_OF_STRESS_ACTIVATED_PROTEIN_KINASE_SIGNALING_CASCADE, NEGATIVE_REGULATION_OF_STRESS_ACTIVATED_PROTEIN_KINASE_SIGNALING_CASCADE, POSITIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER_IN_RESPONSE_TO_STRESS, POSITIVE_REGULATION_OF_STRESS_FIBER_ASSEMBLY		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					mixed cytolitic lymphocytes		REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_IN_RESPONSE_TO_STRESS, CELLULAR_RESPONSE_TO_CHEMICAL_STRESS		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					monocytes/macrophages		POSITIVE_REGULATION_OF_RESPONSE_TO_OXIDATIVE_STRESS, REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_IN_RESPONSE_TO_STRESS, CELLULAR_RESPONSE_TO_CORTICOSTERIOD_STIMULUS, RESPONSE_TO_FLUID_SHEAR_STRESS, STRESS_ACTIVATED_PROTEIN_KINASE_SIGNALING_CASCADE, RESPONSE_TO_OXIDATIVE_STRESS, RESPONSE_TO_MINERALOCORTICOID, RESPONSE_TO_SALT_STRESS, POSITIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER_IN_RESPONSE_TO_STRESS, RESPONSE_TO_CORTICOSTERIOD, CELLULAR_RESPONSE_TO_CHEMICAL_STRESS		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					monocytes/macrophages		RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS 		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					platelets		NEGATIVE_REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, POSITIVE_REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, STRESS_GRANULE_ASSEMBLY  		pathway enrichment	up					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					platelets		RESPONSE_TO_OXIDATIVE_STRESS, CELLULAR_RESPONSE_TO_CHEMICAL_STRESS  		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					Red Blood Cells		CELL_DEATH_IN_RESPONSE_TO_OXIDATIVE_STRESS		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					
	Amani 					plasmablasts		RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, REGULATION_OF_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 		pathway enrichment	down					Occurrence of infectious disease	COVID-19.	acute	SARS-CoV-2 (COVID-19)									2697049	severe COVID-19 vs severe influenza	6	Adults (18-89)	St Louis, Missouri, USA				33187979	2020	Fig S13.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/#idm140617078275904title	"Preranked Gene Set Enrichment Analysis of Gene Ontology gene sets. Gene Ontology Biological Processes gene sets that passed default GSEA thresholds were tested". GSEA & GO annotation systems				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725462/					